Bicyclic peptide ligands and uses thereof

Bicyclic peptides covalently attached to diverse molecular scaffolds address the limitations of cyclic peptides by enhancing binding affinity and specificity to target proteins, improving therapeutic efficacy against diseases mediated by CAIX, MT1-MMP, CD38, EphA2, or PBP1A.

JP2024156841AInactive Publication Date: 2024-11-06BICYCLETX LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2024125814
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-10-23
Filing Date
2024-08-01
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing cyclic peptides lack diversity in molecular scaffolds, which limits their binding affinity and specificity to targets like CAIX, MT1-MMP, CD38, EphA2, and PBP1A, hindering their effectiveness in therapeutic applications.

Method used

Development of bicyclic peptides covalently attached to diverse molecular scaffolds, forming enclosed peptide loops that enhance binding affinity and specificity by fixing target-specific conformations, using various linkers and conjugates to optimize physicochemical properties.

Benefits of technology

The bicyclic peptides demonstrate improved binding affinity and specificity to target proteins, offering potential therapeutic benefits in treating diseases mediated by CAIX, MT1-MMP, CD38, EphA2, or PBP1A, with enhanced stability, solubility, and selectivity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156841000001
    Figure 2024156841000001
  • Figure 2024156841000002
    Figure 2024156841000002
  • Figure 2024156841000003
    Figure 2024156841000003
Patent Text Reader

Abstract

To provide bicyclic peptide glycans, compositions thereof, and methods of using the same.SOLUTION: In some embodiments, peptide sequences are treated with molecular scaffold reagents to form compounds of the present invention. Compounds of the present invention, and compositions thereof, are useful as inhibitors of CAIX, MT1-MMP, CD38, EphA2, or PBP1A. In some embodiments, a provided compound inhibits CAIX. In some embodiments, a provided compound inhibits MT1-MMP. In some embodiments, a provided compound inhibits CD38. In some embodiments, a provided compound inhibits EphA2. In some embodiments, a provided compound inhibits PBP1A.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CITED RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 749,241, filed October 23, 2018, the entirety of which is incorporated herein by reference.

[0002] The present invention relates to polypeptides covalently attached to a molecular scaffold such that two or more peptide loops are enclosed between the attachment points with the molecular scaffold. In particular, the present invention describes scaffolds useful for the organization and presentation of enclosed peptide loops. The present invention also describes peptides that are high affinity binders of carbonic anhydrase IX (CAIX) or membrane type 1 metalloprotease (MT1-MMP). The present invention also includes pharmaceutical compositions comprising said peptide ligands and the use of said peptide ligands in the prevention, inhibition, or treatment of diseases or disorders mediated by CAIX or MT1-MMP.

[0003] The present invention also describes peptides that are high affinity binders of CD38 (cluster of differentiation 38), a glycoprotein also known as cyclic ADP ribose hydrolase and found on the surface of many immune cells (white blood cells), including CD4+, CD8+, B lymphocytes, and natural killer cells. CD38 also functions in cell adhesion, signal transduction, and calcium signaling. The present invention also describes peptides that are high affinity binders of EphA2 (ephrin type A receptor 2) and PBP1A (penicillin-binding protein 1A). The present invention also includes pharmaceutical compositions comprising the aforementioned peptide ligands and the use of the aforementioned peptide ligands in the prevention, inhibition, or treatment of diseases or disorders mediated by CD38, EphA2, or PBP1A. [Background technology]

[0004] Cyclic peptides can bind to protein targets with high affinity and target specificity, and are therefore an attractive class of molecules for the development of therapeutic drugs. Indeed, some cyclic peptides have already been successfully used in the clinic, for example, the antibacterial peptide vancomycin, the immunosuppressant cyclosporine, or the anticancer drug octreotide (Driggers et al. (2008), Nat Rev Drug Discov 7(7), 608-24). The good binding is due to the relatively large interaction surface formed between the peptide and the target and the low structural flexibility of the cyclic structure. Typically, macrocycles bind to surfaces measuring several hundred square angstroms (e.g., the cyclic peptide CXCR4 antagonist CVX15 (400A2; Wu et al. (2007), Science 330, 1066-71), the cyclic peptide with an Arg-Gly-Asp motif (355A2) that binds to integrin αVb3 (Xiong et al. (2002), Science 296(5565), 151-5), or the cyclic peptide inhibitor upain-1 (603A2; Zhao et al. (2007), J Struct Biol 160(1), 1-10) that binds to urokinase-type lasminogen activator).

[0005] Due to their cyclic configuration, peptide macrocycles are less flexible than linear peptides, which results in less entropy loss upon binding to targets and therefore higher binding affinity. The reduced flexibility also locks in a target-specific conformation, increasing binding specificity compared to linear peptides. An example of this effect is the potent and selective inhibitor of matrix metalloproteinase 8 (MMP-8), which loses selectivity over other MMPs when ring-opened (Cherney et al. (1998), J Med Chem 2003). 41(11), 1749-51). Favorable binding properties achieved by macrocyclization include: This is even more evident in polycyclic peptides, which have more than one peptide ring, such as, for example, vancomycin, nisin, and actinomycin.

[0006] Polypeptides bearing cysteine ​​residues have been tethered to synthetic molecular structures previously by different research teams (Kemp and McNamara (1985), J. Org. Chem; Timmerman et al. (2005), ChemBioChem). Meloen and co-workers used tris(bromomethyl)benzene and related molecules to rapidly and quantitatively cyclize multiple peptide loops onto synthetic scaffolds with the aim of mimicking the structure of protein surfaces (Timmerman et al. (2005), ChemBioChem). Methods for the generation of candidate drug compounds generated by linking cysteine-containing polypeptides to molecular scaffolds such as tris(bromomethyl)benzene are disclosed in WO2004 / 077062 and WO2006 / 078161.

[0007] A phage display-based combinatorial approach has been developed to generate and screen large libraries of bicyclic peptides against targets of interest (Heinis et al. (2009), Nat Chem Biol 5(7), 502-7 and WO2009 / 098450). Briefly, a combinatorial library of linear peptides containing three cysteine ​​residues and two regions consisting of six random amino acids (Cys-(Xaa)6-Cys-(Xaa)6-Cys) was displayed on phage and cyclized by covalent linkage of the cysteine ​​side chain to a small molecule (tris-(bromomethyl)benzene). Such bicyclic constrained peptide binders (Bicycles) have proven to be particularly effective binders for a variety of biological targets. As a result, a range of molecular scaffolds have been developed, from the relatively planar tris-(bromomethyl)benzene to the sp 3 It is necessary to expand to molecular scaffolds with higher Fsp content in small molecules. 3 (In the formula, Fsp 3 =(sp 3 sp defined as hybridized carbon / total carbon number) 3Additional loading has led to higher success rates in clinical development due to improved physicochemical properties such as solubility (Lovering et al. (2009), J. Med. Chem. 52(21), 6752-6756; Lovering (2013), Med. Chem. Commun., 4, 515-519). Without being bound to any particular theory, it is believed that the availability of more diverse molecular scaffolds potentially allows for different representations of the same amino acid sequence, which may offer the advantage of increased selectivity in addition to physicochemical properties. Therefore, it is necessary to develop a greater variety of molecular scaffolds for the preparation of bicyclic constrained peptide binders. [Prior art documents] [Patent documents]

[0008] [Patent Document 1] International Publication No. 2004 / 077062 [Patent Document 2] International Publication No. 2006 / 078161 [Patent Document 3] International Publication No. 2009 / 098450 [Non-patent literature]

[0009] [Non-Patent Document 1] Driggers et al. (2008), Nat Rev Drug Discov 7(7), 608-24 [Non-Patent Document 2] Wu et al.(2007),Science 330,1066-71 [Non-Patent Document 3] Xiong et al.(2002),Science 296(5565),151-5 [Non-Patent Document 4] Zhao et al. (2007), J Struct Biol 160(1), 1-10 [Non-Patent Document 5] Timmerman et al. (2005), ChemBioChem [Non-Patent Document 6] Heinis et al. (2009), Nat Chem Biol 5(7), 502-7 [Non-Patent Document 7] Lovering et al. (2009), J.Med.Chem.52(21), 6752-6756 [Non-Patent Document 8] Lovering(2013),Med.Chem.Commun.,4,515-519 Summary of the Invention [Means for solving the problem]

[0010] It has now been found that compounds of the invention, and pharma- ceutically acceptable compositions thereof, are effective as inhibitors of CAIX, MT1-MMP, CD38, EphA2, or PBP1A. In certain embodiments, the compounds of the invention have Formula I: [ka] or a pharma- ceutically acceptable salt thereof, wherein each variable is defined and described herein. In certain embodiments, the compound of the present invention has formula II: [ka] or a pharma- ceutically acceptable salt thereof, wherein each variable is as defined and described herein. The compounds of the present invention and pharma- ceutically acceptable compositions thereof are useful for treating a variety of diseases, disorders, or conditions associated with CAIX, MT1-MMP, CD38, EphA2, or PBP1A, including those described herein.

[0011] The compounds provided by the present invention are also useful for the study of CAIX, MT1-MMP, CD38, EphA2 or PBP1A enzymes in biological and pathological phenomena; for the study of these enzymes occurring in body tissues; and for the comparative evaluation of novel CAIX, MT1-MMP, CD38, EphA2 or PBP1A inhibitors in vitro or in vivo. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] 1. General Description of Certain Embodiments of the Invention: In some embodiments, peptide sequences are treated with molecular scaffolding reagents to form compounds of the invention.

[0013] The compounds and compositions of the present invention are useful as inhibitors of CAIX, MT1-MMP, CD38, EphA2, or PBP1A. In some embodiments, provided compounds inhibit CAIX. In some embodiments, provided compounds inhibit MT1-MMP. In some embodiments, provided compounds inhibit CD38. In some embodiments, provided compounds inhibit EphA2. In some embodiments, provided compounds inhibit PBP1A.

[0014] In certain embodiments, the present invention provides a compound of formula I: [ka] (In the formula, L 1 , L 2 , and L 3 each independently represents a covalent bond or C 1~8 a divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are -Cy 1-, -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -OC(O)N(R)-, -N( R)C(O)O-, -S(O)-, -S(O)2-, -C(CH3)=NN(R)-, -N(R)N=C(CH3)-, -N(R)CH2C(O)-, -(CH2CH2O) 1~10 -, [ka] are independently replaced as necessary; L 4 is a covalent bond, -O-, -N(R)-, or -N(R)CH2CH2N(R)-; Each R is independently hydrogen or C 1~4 It is aliphatic; -Cy 1 - is each independently selected from phenylene, a 3- to 7-membered saturated or partially unsaturated carbocyclylene, a 4- to 7-membered saturated or partially unsaturated heterocyclylene having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 10- to 12-membered saturated or partially unsaturated bicyclic heterocyclylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 10- to 12-membered saturated or partially unsaturated tricyclic heterocyclylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 10- to 12-membered saturated or partially unsaturated tricyclic heterocyclylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an optionally substituted divalent ring selected from a 0-12 membered partially saturated bicyclic heteroarylene, a 10-12 membered partially saturated tricyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 9-12 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 19-20 membered partially unsaturated tetracyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; The scaffold is a trivalent group that attaches and orients the cyclic peptide; Loop A is L 1 and the amino acid residue linked to L 2 a bivalent natural or non-natural amino acid residue or peptide bound to an amino acid residue linked to Loop B is L 1 and the amino acid residue linked to L 3 a bivalent natural or non-natural amino acid residue or peptide bound to an amino acid residue linked to Spacer 1 is a covalent bond, a natural or unnatural amino acid (wherein the amino group is attached to the C-terminus of the bicycle via an amide bond), or a peptide (wherein the N-terminal amino group of said peptide is attached to the C-terminus of the bicycle via an amide bond); Spacer 2 is a covalent bond, a natural or unnatural amino acid (wherein the acid is attached to the N-terminus of the bicycle via an amide bond), or a peptide (wherein the C-terminal acid of said peptide is attached to the N-terminus of the bicycle via an amide bond); R 1 and R 2 are each independently R, [ka] [ka] or -linker-conjugate; Each linker is independently a covalent bond or 1~8 a divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are -Cy 1-, -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -OC(O)N(R)-, -N( R)C(O)O-, -S(O)-, -S(O)2-, -C(CH3)=NN(R)-, -N(R)N=C(CH3)-, -N(R)CH2C(O)-, -(CH2CH2O) 1~10 -, [ka] are independently replaced as necessary; Each conjugate is independently a half-life extending motif, a solubilizing group, a transporter recognition motif, a cell permeability motif, a drug payload, or a detectable moiety; R 3 Each independently represents hydrogen or C 1~4 It is aliphatic; m is 0 or 1; (n is 0 or 1) or a pharma- ceutically acceptable salt thereof.

[0015] In certain embodiments, the present invention provides a compound of formula II: [ka] (In the formula, L2 and L3 are each, independently, a covalent bond or a C1-8 divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are selected from the group consisting of -Cy1-, -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -OC(O)N(R)-, -N(R)C(O)O-, -S(O)-, -S(O)2-, -C(CH3)=NN(R)-, -N(R)N=C(CH3)-, -N(R)CH2C(O)-, -(CH2CH2O)1-10-, [ka] are independently replaced as necessary; L 4 is a covalent bond, -O-, -N(R)-, or -N(R)CH2CH2N(R)-; Each R is independently hydrogen or C 1~4 It is aliphatic; -Cy 1 - is each independently selected from phenylene, a 3- to 7-membered saturated or partially unsaturated carbocyclylene, a 4- to 7-membered saturated or partially unsaturated heterocyclylene having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 10- to 12-membered saturated or partially unsaturated bicyclic heterocyclylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 10- to 12-membered saturated or partially unsaturated tricyclic heterocyclylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. optionally substituted 10- to 12-membered partially saturated bicyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; 10- to 12-membered partially saturated tricyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; 9- to 12-membered bicyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; 19- to 20-membered partially unsaturated tetracyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or 5- to 6-membered heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. It is a bivalent ring; The scaffold is a trivalent group that attaches and orients the cyclic peptide; Loop C is L 2 and the amino acid residue linked to L 3 a peptide bound to an amino acid residue linked to Spacer 1is a covalent bond, a natural or unnatural amino acid (wherein the amino group is attached to the C-terminus of the bicycle via an amide bond), or a peptide (wherein the N-terminal amino group of said peptide is attached to the C-terminus of the bicycle via an amide bond); Spacer 2 is a covalent bond, a natural or unnatural amino acid (wherein the acid is attached to the N-terminus of the bicycle via an amide bond), or a peptide (wherein the C-terminal acid of said peptide is attached to the N-terminus of the bicycle via an amide bond); R 1 and R 2 are each independently R, [ka] [ka] or -linker-conjugate; Each linker is independently a covalent bond or 1~8 a divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are -Cy 1 -, -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -OC(O)N(R)-, -N( R)C(O)O-, -S(O)-, -S(O)2-, -C(CH3)=NN(R)-, -N(R)N=C(CH3)-, -N(R)CH2C(O)-, -(CH2CH2O) 1~10 -, [ka] are independently replaced as necessary; Each conjugate is independently a half-life extending motif, a solubilizing group, a transporter recognition motif, a cell permeability motif, a drug payload, or a detectable moiety; R 3 Each of 1~4It is aliphatic; R 5 is R 5 Together with the atom to which it is bonded, L 2 and L 3 The peptide forming a moiety that includes a hydrogen bond acceptor (HBA) and / or a hydrogen bond donor (HBD) that forms one or more hydrogen bonds with one or more amino acid residues of; m is 0 or 1; (n is 0 or 1) or a pharma- ceutically acceptable salt thereof. 2. Compounds and definitions: Peptide Ligands

[0016] Peptide ligand, as referred to herein, refers to a peptide covalently bound to a molecular scaffold. In some embodiments, the peptide comprises two or more reactive groups (e.g., cysteine ​​and tyrosine residues) that can form a covalent bond to the scaffold, and a sequence juxtaposed between the reactive groups, referred to as a loop sequence, because it forms a loop when the peptide is bound to the scaffold. In some embodiments, the peptide ligand forms one or more loops through one or more hydrogen bonds to the scaffold. In some embodiments, the peptide comprises two cysteine ​​residues, which form one or more hydrogen bonds to the scaffold, thus forming at least two loops to the scaffold. In some embodiments, the peptide comprises at least three cysteine ​​residues, which form at least two loops to the scaffold. Advantages of peptide ligands

[0017] Certain bicyclic peptides of the present invention have several advantageous properties that allow them to be considered drug-like molecules suitable for injection, inhalation, nasal, ocular, oral, or topical administration. Without being bound to any particular theory, such advantageous properties may include:

[0018] species cross-reactivity, which is a typical requirement for preclinical pharmacodynamic and pharmacokinetic evaluation;

[0019] Protease stability. Bicyclic peptide ligands should ideally demonstrate stability against plasma proteases, epithelial ("membrane-tethered") proteases, gastrointestinal proteases, pulmonary surface proteases, and intracellular proteases. Protease stability should be maintained across different species so that bicyclic lead candidates can be developed in animal models and can be reliably administered to humans;

[0020] A desirable solubility profile, which is a function of the ratio of charged and hydrophilic to hydrophobic residues and intra- / inter-molecular H-bonds, and is important for formulation and absorption;

[0021] Optimal plasma half-life in circulation. Depending on the clinical indication and treatment regimen, it may be necessary to develop bicyclic peptides for short-term exposure in the setting of managing acute disease, or to develop bicyclic peptides that have enhanced retention in the circulation and are therefore optimal for managing more chronic disease states. Other factors driving the desired plasma half-life are necessary for sustained exposure in order to maximize therapeutic efficacy against the concomitant toxicities that result from sustained exposure of the drug; and

[0022] Selectivity. Certain peptide ligands of the invention have demonstrated good selectivity over other carbonic anhydrases and metalloproteases.

[0023] The compounds of the present invention include those generally described herein and are further exemplified by the classes, subclasses and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of the present invention, For purposes of this specification, chemical elements are identified according to the Handbook of Chemistry and Physics, 75th Edition, Periodic Table of the Elements, CAS Edition. In addition, general principles of organic chemistry are described in "Organic Chemistry," 1999, pp. 1171-1175, the entire contents of which are incorporated herein by reference. and March's Advanced Organic Chemistry, 5th ed., eds. Smith, M. B. and March, J., John Wiley & Sons, New York: 2001.

[0024] The term "aliphatic" or "aliphatic group," as used herein, means a linear (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is fully saturated or contains one or more units of unsaturation, or a monocyclic or bicyclic hydrocarbon that is fully saturated or contains one or more units of unsaturation, but is not aromatic (also referred to herein as "carbocyclic," "alicyclic," or "cycloalkyl"), which has one point of attachment to the remainder of the molecule. Unless otherwise specified, an aliphatic group contains 1-6 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1-5 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-4 aliphatic carbon atoms. In still other embodiments, an aliphatic group contains 1-3 aliphatic carbon atoms, and in still other embodiments, an aliphatic group contains 1-2 aliphatic carbon atoms. In some embodiments, "alicyclic" (or "carbocycle" or "cycloalkyl") refers to a monocyclic C3-C6 hydrocarbon that is fully saturated or contains one or more units of unsaturation, but is not aromatic, and which has one point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl groups, alkenyl groups, alkynyl groups, and hybrids thereof, such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl, or (cycloalkyl)alkenyl.

[0025] As used herein, the term "bridged bicyclic" refers to any bicyclic ring system having at least one bridge, i.e., carbocyclic or heterocyclic, saturated or partially unsaturated. As defined by IUPAC, a "bridge" is an unbranched chain of atoms, or an atom or valence bond, connecting two bridgeheads, where a "bridgehead" is any skeletal atom of the ring system that is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, the bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic groups are well known in the art and include the groups shown below, each of which is attached to the remainder of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, bridged bicyclic groups are optionally substituted with one or more substituents as shown for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of the bridged bicyclic group is optionally substituted. Exemplary bridged bicyclic groups include: [ka] [ka]

[0026] The term "lower alkyl" refers to a straight or branched C 1~4 refers to an alkyl group. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0027] The term "lower haloalkyl" refers to a straight or branched C alkyl group substituted with one or more halogen atoms. 1~4 Refers to an alkyl group.

[0028] The term "heteroatom" means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including any oxidized form of nitrogen, sulfur, phosphorus, or silicon, the quaternized form of any basic nitrogen, or a substitutable nitrogen of a heterocyclic ring, such as N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR+ (as in N-substituted pyrrolidinyl)).

[0029] The term "unsaturated," as used herein, means that a moiety has one or more units of unsaturation.

[0030] As used herein, the term "divalent C1-8 (or C1-6) hydrocarbon chain" refers to divalent alkylene chains, alkenylene chains, and alkynylene chains, which are straight or branched, as defined herein.

[0031] The term "alkylene" refers to a divalent alkyl group. An "alkylene chain" is a polymethylene group, i.e., -(CH2) n - and n is a positive integer, preferably 1 to 6, 1 to 4, 1 to 3, 1 to 2 or 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced by a substituent. Suitable substituents include those described below for substituted aliphatic groups.

[0032] The term "alkenylene" refers to a divalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced by a substituent. Suitable substituents include those described below for substituted aliphatic groups.

[0033] As used herein, the term "cyclopropylenyl" refers to a divalent cyclopropyl group, having the following structure: [ka]

[0034] The term "halogen" means F, Cl, Br or I.

[0035] The term "aryl", used alone or as part of a larger moiety such as in "aralkyl", "aralkoxy" or "aryloxyalkyl", refers to a monocyclic or bicyclic ring system having a total of 5 to 14 ring members, in which at least one ring in such systems is aromatic, and in which each ring in such systems contains 3 to 7 ring members. The term "aryl" may be used interchangeably with the term "aryl ring". In certain embodiments of the invention, "aryl" refers to an aromatic ring system, including but not limited to phenyl, biphenyl, naphthyl, anthracyl, and the like, which may bear one or more substituents. Similarly, within the scope of the term "aryl", as used herein, are groups in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthoimidyl, phenanthridinyl, or tetrahydronaphthyl.

[0036] The terms "heteroaryl" and "heteroar-", used alone or as part of a larger moiety such as "heteroaralkyl" or "heteroaralkoxy", refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms, with 6, 10, or 14 pi-electrons shared in the cyclic arrangement, and having 1 to 5 heteroatoms in addition to the carbon atoms. The term "heteroatom" refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, but are not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms "heteroaryl" and "heteroar-" as used herein also include groups in which a heteroaromatic ring is fused to one or more aryl, alicyclic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzothiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one. Heteroaryl groups can be monocyclic or bicyclic. The term "heteroaryl" can be used interchangeably with the terms "heteroaryl ring," "heteroaryl group," or "heteroaromatic," any of which terms include rings that are optionally substituted. The term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl, where the alkyl and heteroaryl portions independently are optionally substituted.

[0037] As used herein, the terms "heterocycle," "heterocyclyl," "heterocyclic radical," and "heterocyclic ring" are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic moiety, either saturated or partially unsaturated, having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" refers to a heterocyclic ring. " includes substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or +NR (as in N-substituted pyrrolidinyl).

[0038] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure, and any of these ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, but are not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms "heterocycle", "heterocyclyl", "heterocyclyl ring", "heterocyclic group", "heterocyclic moiety" and "heterocyclic radical" are used interchangeably herein and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl or alicyclic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl or tetrahydroquinolinyl. Heterocyclyl groups can be monocyclic or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted by a heterocyclyl, where the alkyl and heterocyclyl moieties, independently, are optionally substituted.

[0039] As used herein, the term "partially unsaturated" refers to a ring moiety that contains at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as defined herein.

[0040] As described herein, the compounds of the present invention may contain "optionally substituted" moieties. In general, the term "substituted", whether preceded by the term "optionally" or not, means that one or more hydrogens of the specified moiety are replaced with a suitable substituent. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when one or more positions in any given structure may be substituted with one or more substituents selected from a specified group, the substituents may be the same or different at each position. The combinations of substituents envisioned by the present invention are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable" as used herein refers to a compound that is not substantially altered when subjected to conditions that allow for its production, detection, and, in certain embodiments, its recovery, purification, and use for one or more purposes disclosed herein.

[0041] Suitable monovalent substituents on a substitutable carbon atom of an "optionally substituted" group are independently halogen; -(CH) 0~4 R ○ ;-(CH2) 0~4 OR ○ ;-O(CH2) 0~4 R ○ , -O-(CH2) 0~4 C(O)OR ○ ;-(CH2) 0~4 CH(OR ○ )2;-(CH2) 0~4 S.R. ○ ;-(CH2) 0~4 Ph(R○ Optionally substituted by);-(CH2) 0~4 O(CH2) 0~1 Ph(R ○ -CH=CHPh(R ○ Optionally substituted by);-(CH2) 0~4 O(CH2) 0~1 -Pyridyl (R ○ -NO2; -CN; -N3; ​​-(CH2) 0~4 N(R ○ )2;-(CH2) 0~4 N(R ○ )C(O)R ○ ;-N(R ○ )C(S)R ○ ;-(CH2) 0~4 N(R ○ )C(O)NR ○ 2;-N(R ○ )C(S)NR ○ 2;-N(R ○ )C(NR ○ )N(R ○ )2;-(CH2) 0~4 N(R ○ )C(O)OR ○ ;-N(R ○ )N(R ○ )C(O)R ○ ;-N(R ○ )N(R ○ )C(O)NR ○ 2;-N(R ○ )N(R ○ )C(O)OR ○ ;-(CH2) 0~4 C (O)R ○ ;-C(S)R ○ ;-(CH2) 0~4 C(O)OR ○ ;-(CH2) 0~4 C(O)SR ○ ;-(CH2) 0~4 C(O)OSiR ○ 3;-(CH2) 0~4 O.C.(O)R ○ ;-OC(O)(CH2) 0~4 SR-;-(CH2) 0~4SC(O)R ○ ;-(CH2) 0~4 C(O)NR ○ 2;-C(S)NR ○ 2;-C(S)SR ○ ;-SC(S)SR ○ , -(CH2) 0~4 OC(O)NR ○ 2;-C(O)N(OR ○ )R ○ ;-C(O)C(O)R ○ ;-C(O)CH2C(O)R ○ ;-C(NOR ○ )R ○ ;-(CH2) 0~4 SSR ○ ;-(CH2) 0~4 S(O)2R ○ ;-(CH2) 0~4 S(O)2OR ○ ;-(CH2) 0~4 OS(O)2R ○ ;-S(O)2NR ○ 2;-(CH2) 0~4 S(O)R ○ ;-N(R ○ )S(O)NR ○ 2;-N(R ○ )S(O)2R ○ ;-N(OR ○ )R ○ ;-C(NH)NR ○ 2;-P(O)2R ○ ;-P(O)R ○ 2;-OP(O)R ○ 2;-OP(O)(OR ○ )2;SiR ○ 3;-(C 1~4 Linear or branched alkylene)ON(R ○ )2; or -(C 1~4 Linear or branched alkylene)C(O)ON(R ○ )2, where R ○ are each optionally substituted as defined below and independently represent hydrogen, C 1~6 Aliphatic, -CH2Ph, -O(CH2) 0~1Ph, -CH2- (5-6 membered heteroaryl ring), or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, together with the intervening atom(s), regardless of the above definition, R ○ two independent occurrences of form a 3-12 membered saturated, partially unsaturated or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, which rings may be optionally substituted as defined below.

[0042] R 〇 (or R 〇 Preferred monovalent substituents on the ring formed by two independent occurrences of -(CH) together with their intervening atoms are independently halogen, -(CH) 0~2 R ● , -(Halo R ● ), -(CH2) 0~2 OH, -(CH2) 0~2 OR ● , -(CH2) 0~2 CH(OR ● )2;-O(HaloR ● ), -CN, -N3, -(CH2) 0~2 C(O)R ● , -(CH2) 0~2 C(O)OH, -(CH2) 0~2 C(O)OR ● , -(CH2) 0~2 S.R. ● , -(CH2) 0~2 SH, -(CH2) 0~2 NH2, -(CH2) 0~2 NHR ● , -(CH2) 0~2 NR ● 2, -NO2, -SiR ● 3. -OSiR ● 3. -C(O)SR ● , -(C 1~4 Linear or branched alkylene)C(O)OR ● Or -SSR ● where each R ●is unsubstituted or, if preceded by "halo", is substituted only with one or more halogens; C 1~4 Aliphatic, -CH2Ph, -O(CH2) 0~1 R is independently selected from Ph, or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. 〇 Suitable divalent substituents on a saturated carbon atom of include ═O and ═S.

[0043] Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include the following: =O, =S, =NNR * 2, =NNHC(O)R * , =NNHC(O)OR * , =NNHS(O)2R * , =NR * , =NOR * , -O(C(R * 2)) 2~3 O- or -S(C(R * 2)) 2~3 S-, where R * Each independent occurrence of is selected from hydrogen, C which may be substituted as defined below. 1~6 aliphatic or unsubstituted 5-6 membered saturated, partially unsaturated or aryl rings having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. Preferred divalent substituents attached to the vicinal substitutable carbon of the "optionally substituted" group include -O(CR * 2) 2~3 O-, where R * Each independent occurrence of is selected from hydrogen, C which may be substituted as defined below. 1~6 It is selected from aliphatic or unsubstituted 5-6 membered saturated, partially unsaturated or aryl rings having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0044] R * Suitable substituents on the aliphatic group include halogen, -R ● , -(Halo R ● ), -OH, -OR● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH2, -NHR ● , -NR ● 2 or -NO2, where each R ● is unsubstituted or, if preceded by "halo", is substituted only with one or more halogens, and independently represents C 1~4 Aliphatic, -CH2Ph, -O(CH2) 0~1 Ph, or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0045] Suitable substituents on a substitutable nitrogen atom of an "optionally substituted" group include -R † , -NR † 2. -C(O)R † , -C(O)OR † , -C(O)C(O)R † , -C(O)CH2C(O)R † , -S(O)2R † , -S(O)NR † 2. -C(S)NR † 2. -C(NH)NR † 2 or -N(R † )S(O)2R † and R † are each independently hydrogen, C 1~6 aliphatic (optionally substituted as defined below), unsubstituted -OPh, or an unsubstituted 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or R † two independent occurrences of together with their intervening atom(s) form an unsubstituted 3-12 membered saturated, partially unsaturated or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0046] R †Suitable substituents on the aliphatic groups are independently halogen, -R ● , -(Halo R ● ), -OH, -OR ● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH2, -NHR ● , -NR ● 2 or -NO2, where each R ● is unsubstituted or, if preceded by "halo", is substituted only with one or more halogens, and independently represents C 1~4 Aliphatic, -CH2Ph, -O(CH2) 0~1 Ph, or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0047] As used herein, the term "pharmaceutically acceptable salt" refers to a salt that is suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic reaction, etc., within the scope of sound medical judgment, and is commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, vol. 66, pp. 1-19, 1977, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts of amino groups formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by using other methods used in the art, such as ion exchange. Other pharma- ceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2- Hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate These include phosphates, undecanoates, valerates, and the like.

[0048] Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N+ (C 1~4 Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Additionally, pharma- ceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations, formed where appropriate using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkylsulfonates, and arylsulfonates.

[0049] Unless otherwise indicated, the structures depicted herein are also intended to include all isomers of the structures (e.g., enantiomers, diastereoisomers and geometric (or conformational) isomers), such as the R and S configurations, Z and E double bond isomers, and Z and E conformational isomers for each asymmetric center. Thus, single stereochemical isomers of the compounds, as well as enantiomeric, diastereomeric and geometric (or conformational) isomeric mixtures, are within the scope of the present invention. Unless otherwise indicated, all tautomers of the compounds of the present invention are within the scope of the present invention. Furthermore, unless otherwise indicated, the structures depicted herein are also intended to include compounds that differ only by the presence of one or more isotopically enriched atoms. For example, compounds having the structures depicted herein that include the replacement of hydrogen with deuterium or tritium, or the replacement of carbon with 13C or 14C enriched carbon are within the scope of the present invention. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents according to the present invention. In certain embodiments, Rx of provided compounds comprises one or more deuterium atoms.

[0050] As used herein, the term "inhibitor" is defined as a compound that binds to and / or inhibits CAIX, MT1-MMP, CD38, EphA2 or PBP1A with measurable affinity. In certain embodiments, the inhibitor has an IC50 and / or binding constant of less than about 50 μM, less than about 1 μM, less than about 500 nM, less than about 100 nM, less than about 10 nM or less than about 1 nM.

[0051] The compounds of the present invention may be tethered to a detectable moiety. It is understood that such compounds are useful as imaging agents. Those skilled in the art will recognize that detectable moieties may be attached to the provided compounds via suitable substituents. As used herein, the term "suitable substituents" refers to moieties that can be covalently attached to detectable moieties. Such moieties are well known to those skilled in the art and include groups that include, for example, carboxylate moieties, amino moieties, thiol moieties, or hydroxyl moieties, to name just a few. It is understood that such moieties may be directly attached to the provided compounds or may be attached via a tethering group, such as a bivalent saturated or unsaturated hydrocarbon chain. In some embodiments, such moieties may be attached via click chemistry. In some embodiments, such moieties may be attached via 1,3-cycloaddition of azides with alkynes, optionally in the presence of a copper catalyst. Methods for the use of click chemistry are known in the art and include those described in Rostovtsev et al., Angew. Chem. Int. Ed. 2002, 41, 2596-99 and Sun et al., Bioconjugate Chem., 2006, 17, 52-57.

[0052] As used herein, the term "detectable moiety" is used interchangeably with "label" and refers to any moiety that can be detected (e.g., primary and secondary labels). Radioisotopes (e.g., tritium, 32 P, 33 P, 35 S, or 14 C) Primary labels, such as mass tags and fluorescent labels, are signal generating labels that can be detected without further modification. Detectable moieties also include luminescent and phosphorescent groups.

[0053] The term "secondary label" as used herein refers to moieties such as biotin and various protein antigens that require the presence of a second intermediate to generate a detectable signal. For biotin, the secondary intermediate may include a streptavidin-enzyme conjugate. For antigen labels, the secondary intermediate may include an antibody-enzyme conjugate. Some fluorescent groups act as secondary labels because they transfer energy to another group in a non-radiative fluorescence resonance energy transfer (FRET) process, and the second group generates a signal that is detected.

[0054] As used herein, the terms "fluorescent label", "fluorescent dye", and "fluorophore" refer to a moiety that absorbs light energy at a defined excitation wavelength and emits light energy at a different wavelength. Examples of fluorescent labels include, but are not limited to, the Alexa Fluor dyes (Alexa Fluor 350, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660, and Alexa Fluor 680), AMCA, AMCA-S, the BODIPY dyes (BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY Fluor 660, and BODIPY Fluor 680), and the like. TR, BODIPY530 / 550, BODIPY558 / 568, BODIPY564 / 570, BODIPY576 / 589, BODIPY581 / 591, BODIPY630 / 650, BODIPY650 / 665), carboxyrhodamine 6G, carboxy-X-rhodamine (ROX), cascade blue, cascade yellow, coumarin 343, cyanine dyes (Cy3, Cy5, Cy3.5, Cy5.5), dansyl, dapoxyl, dialkylaminocoumarin, 4',5'-dichloro-2',7'-dimethoxy-fluorescein, DM-NERF, eosin, erythrosine, fluorescein, F AM, Hydroxycoumarin, IRDye (IRD40, IRD700, IRD800), JOE, Lissamine rhodamine B, Marina Blue, Methoxycoumarin, Naphthofluorescein, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, PyMPO, Pyrene, Rhodamine B, Rhodamine 6G, Rhodamine Green, Rhodamine Red, Rhodol Green, 2',4',5',7'-Tetra-bromosulfone-fluorescein, Tetramethyl-rhodamine (TMR), Carboxytetramethylrhodamine (TAMRA), Texas Red, Texas Red-X.

[0055] The term "mass tag" as used herein refers to any moiety that can be uniquely detected by its mass using mass spectrometry (MS) detection technology. Examples of mass tags include electrophoretic release tags such as N-[3-[4'-[(p-methoxytetrafluorobenzyl)oxy]phenyl]-3-methylglyceronyl]isonipecotic acid, 4'-[2,3,5,6-tetrafluoro-4-(pentafluorophenoxyl)]methylacetophenone, and its derivatives. The synthesis and usefulness of these mass tags are described in U.S. Patent Nos. 4,650,750, 4,709,016, 5,360,8191, 5,516,931, 5,602,273, 5,604,104, 5,610,020, and 5,650,270. Other examples of mass tags include, but are not limited to, nucleotides of various lengths and base compositions, dideoxynucleotides, oligonucleotides, oligopeptides of various lengths and monomer compositions, oligosaccharides, and other synthetic polymers. Also, a wide variety of organic molecules (biomolecules or synthetic compounds), both neutral and charged, in the appropriate mass range (100-2000 Daltons) can be used as mass tags.

[0056] The terms "measurable affinity" and "measurably inhibiting" as used herein refer to the ability of a compound of the invention or a composition thereof to inhibit CAIX, MT1-MMP, CD38, E "Measurable changes in the activity of CAIX, MT1-MMP, CD38, EphA2, or PBP1A between a sample containing CAIX, MT1-MMP, CD38, EphA2, or PBP1A and an equivalent sample containing CAIX, MT1-MMP, CD38, EphA2, or PBP1A in the absence of said compound or composition thereof."

[0057] The term "hydrogen bond" as used herein refers to a weak type of force that forms a special type of dipole-dipole attraction that occurs when a hydrogen atom bonded to a more electronegative atom is in the vicinity of another electronegative atom that has a lone pair of electrons. In order for a hydrogen bond to occur, both a hydrogen donor and a hydrogen acceptor must be present. The hydrogen bond donor is the atom to which the hydrogen atom involved in the hydrogen bond is covalently bonded, usually a more electronegative atom such as N, O, or F. The hydrogen acceptor is a nearby electronegative ion or molecule that must have a lone pair of electrons to form a hydrogen bond. 3. Description of Exemplary Embodiments:

[0058] In certain embodiments, the present invention provides a compound of formula I: [ka] (In the formula, L 1 , L 2 , and L 3 each independently represents a covalent bond or C 1~8 a divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are -Cy 1 -, -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -OC(O)N(R)-, -N( R)C(O)O-, -S(O)-, -S(O)2-, -C(CH3)=NN(R)-, -N(R)N=C(CH3)-, -N(R)CH2C(O)-, -(CH2CH2O) 1~10 -, [ka] are independently replaced as necessary; L 4 is a covalent bond, -O-, -N(R)-, or -N(R)CH2CH2N(R)-; Each R is independently hydrogen or C 1~4 It is aliphatic; -Cy 1 Each - is independently phenylene, 3- to 7-membered saturated or partially unsaturated carbocyclylene, 4-7 membered saturated or partially unsaturated heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 10-12 membered saturated or partially unsaturated bicyclic heterocyclylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 10-12 membered saturated or partially unsaturated tricyclic heterocyclylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 10-12 membered partially saturated bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an optionally substituted divalent ring selected from a 10-12 membered partially saturated tricyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 9-12 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 19-20 membered partially unsaturated tetracyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; The scaffold is a trivalent group that attaches and orients the cyclic peptide; Loop A is L 1 and the amino acid residue linked to L 2 a bivalent natural or non-natural amino acid residue or peptide bound to an amino acid residue linked to Loop B is L 1 and the amino acid residue linked to L 3 a bivalent natural or non-natural amino acid residue or peptide bound to an amino acid residue linked to Spacer 1 is a covalent bond, a natural or unnatural amino acid (wherein the amino group is attached to the C-terminus of the bicycle via an amide bond), or a peptide (wherein the N-terminal amino group of said peptide is attached to the C-terminus of the bicycle via an amide bond); Spacer 2 is a covalent bond, a natural or unnatural amino acid (wherein the acid is attached to the N-terminus of the bicycle via an amide bond), or a peptide (wherein the C-terminal acid of said peptide is attached to the N-terminus of the bicycle via an amide bond); R 1 and R 2 are each independently R, [ka] [ka] or -linker-conjugate; Each linker is independently a covalent bond or 1~8 a divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are -Cy 1 -, -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -OC(O)N(R)-, -N( R)C(O)O-, -S(O)-, -S(O)2-, -C(CH3)=NN(R)-, -N(R)N=C(CH3)-, -N(R)CH2C(O)-, -(CH2CH2O) 1~10 -, [ka] are independently replaced as necessary; Each conjugate is independently a half-life extending motif, a solubilizing group, a transporter recognition motif, a cell permeability motif, a drug payload, or a detectable moiety; R 3 Each of 1~4 It is aliphatic; m is 0 or 1; (n is 0 or 1) or a pharma- ceutically acceptable salt thereof.

[0059] As defined herein above, L 1 , L 2 , and L 3 each independently represents a covalent bond or C 1~8 A divalent hydrocarbon chain, in which one, two or three methylene units are -Cy 1 -, -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -OC(O)N(R)-, -N( R)C(O)O-, -S(O)-, -S(O)2-, -C(CH3)=NN(R)-, -N(R)N=C(CH3)-, -N(R)CH2C(O)-, -(CH2CH2O) 1~10 -, [ka] are independently replaced as necessary.

[0060] In some embodiments, L 1 , L 2 , and L 3 Each is a covalent bond. 1 , L 2 , and L 3 Each is -CHS-. In some embodiments, L 1 , L 2 , and L 3 Each is -CHNH-. In some embodiments, L 1 , L 2 , and L 3 Each is -CH2O-. 1 , L 2 , and L 3 Each is -CHCHO-. 1 , L 2 , and L 3 Each is -CHCHCHCHNH-. In some embodiments, L 1 , L 2 , and L 3Each is -CHN(CH)-. In some embodiments, L 1 , L 2 , and L 3 Each is -CHCHCHCHN(CH)-. 1 , L 2 , and L 3 are respectively: [ka] It is.

[0061] In some embodiments, L 1 is a covalent bond. In some embodiments, L 1 In some embodiments, L 1 In some embodiments, L 1 In some embodiments, L 1 In some embodiments, L 1 is -CH2CH2CH2CH2NH-. In some embodiments, L 1 is -CHN(CH)-. In some embodiments, L 1 is -CH2CH2CH2CH2N(CH3)-. In some embodiments, L 1 In some embodiments, L 1 In some embodiments, L 1 In some embodiments, L 1 In some embodiments, L 1 is -CHN(CH)CH-. In some embodiments, L 1 is -CH2CH2CH2CH2NHCH2-. In some embodiments, L 1 is -CH2CH2CH2CH2N(CH3)CH 2-. In some embodiments, L 1 is -CHSCHC(O)NH-. In some embodiments, L 1is -CH2OCH2C(O)NH-. In some embodiments, L 1 is -CH2CH2OCH2C(O)NH-. In some embodiments, L 1 is -CHNHCHC(O)NH-. In some embodiments, L 1 is -CHN(CH)CHC(O)NH-. In some embodiments, L 1 is -CH2CH2CH2CH2NHCH2C(O)NH-. In some embodiments, L 1 is -CH2CH2CH2CH2N(CH3)CH2C(O)NH-. In some embodiments, L 1 is -CHSCHC(O)-. In some embodiments, L 1 is -CH2OCH2C(O)-. In some embodiments, L 1 is -CH2CH2OCH2C(O)-. In some embodiments, L 1 is -CHNHCHC(O)-. In some embodiments, L 1 is -CHN(CH)CHC(O)-. In some embodiments, L 1 is -CH2CH2CH2CH2NHCH2C(O)-. In some embodiments, L 1 is -CH2CH2CH2CH2N(CH3)CH2C(O)-. In some embodiments, L 1 is -CHSCHCHC(O)NH-. In some embodiments, L 1 is -CH2OCH2CH2C(O)NH-. In some embodiments, L 1 is -CH2CH2OCH2CH2C(O)NH-. In some embodiments, L 1 is -CHNHCHCHC(O)NH-. In some embodiments, L 1 is -CHN(CH)CHCHC(O)NH-. In some embodiments, L 1 is -CH2CH2CH2CH2NHCH2CH2C(O)NH-. In some embodiments, L 1 is -CH2CH2CH2CH2N(CH3)CH2CH2C(O)NH-. In some embodiments, L1 is -CHSCHCHC(O)-. In some embodiments, L 1 is -CH2OCH2CH2C(O)-. In some embodiments, L 1 is -CH2CH2OCH2CH2C(O)-. In some embodiments, L 1 is -CHNHCHCHC(O)-. In some embodiments, L 1 is -CHN(CH)CHCHC(O)-. In some embodiments, L 1 is -CH2CH2CH2CH2NHCH2CH2C(O)-. In some embodiments, L 1 is -CH2CH2CH2CH2N(CH3)CH2CH2C(O)-. In some embodiments, L 1 teeth, [ka] In some embodiments, L 1 is selected from those illustrated in Table 1 below.

[0062] In some embodiments, L 2 is a covalent bond. In some embodiments, L 2 In some embodiments, L 2 In some embodiments, L 2 In some embodiments, L 2 In some embodiments, L 2 is -CH2CH2CH2CH2NH-. In some embodiments, L 2 is -CHN(CH)-. In some embodiments, L 2 is -CH2CH2CH2CH2N(CH3)-. In some embodiments, L 2 In some embodiments, L 2 In some embodiments, L 2 In some embodiments, L2 In some embodiments, L 2 is -CHN(CH)CH-. In some embodiments, L 2 is -CH2CH2CH2CH2NHCH2-. In some embodiments, L 2 is -CH2CH2CH2CH2N(CH3)CH2-. In some embodiments, L 2 is -CHSCHC(O)NH-. In some embodiments, L 2 is -CH2OCH2C(O)NH-. In some embodiments, L 2 is -CH2CH2OCH2C(O)NH-. In some embodiments, L 2 is -CHNHCHC(O)NH-. In some embodiments, L 2 is -CH2 N(CH3)CH2C(O)NH-. In some embodiments, L 2 is -CH2CH2CH2CH2NHCH2C(O)NH-. In some embodiments, L 2 is -CH2CH2CH2CH2N(CH3)CH2C(O)NH-. In some embodiments, L 2 is -CHSCHC(O)-. In some embodiments, L 2 is -CH2OCH2C(O)-. In some embodiments, L 2 is -CH2CH2OCH2C(O)-. In some embodiments, L 2 is -CHNHCHC(O)-. In some embodiments, L 2 is -CHN(CH)CHC(O)-. In some embodiments, L 2 is -CH2CH2CH2CH2NHCH2C(O)-. In some embodiments, L 2 is -CH2CH2CH2CH2N(CH3)CH2C(O)-. In some embodiments, L 2 is -CHSCHCHC(O)NH-. In some embodiments, L 2 is -CH2OCH2CH2C(O)NH-. In some embodiments, L 2is -CH2CH2OCH2CH2C(O)NH-. In some embodiments, L 2 is -CHNHCHCHC(O)NH-. In some embodiments, L 2 is -CHN(CH)CHCHC(O)NH-. In some embodiments, L 2 is -CH2CH2CH2CH2NHCH2CH2C(O)NH-. In some embodiments, L 2 is -CH2CH2CH2CH2N(CH3)CH2CH2C(O)NH-. In some embodiments, L 2 is -CHSCHCHC(O)-. In some embodiments, L 2 is -CH2OCH2CH2C(O)-. In some embodiments, L 2 is -CH2CH2OCH2CH2C(O)-. In some embodiments, L 2 is -CHNHCHCHC(O)-. In some embodiments, L 2 is -CHN(CH)CHCHC(O)-. In some embodiments, L 2 is -CH2CH2CH2CH2NHCH2CH2C(O)-. In some embodiments, L 2 is -CH2CH2CH2CH2N(CH3)CH2CH2C(O)-. In some embodiments, L 2 teeth, [ka] In some embodiments, L 2 is selected from those illustrated in Table 1 below.

[0063] In some embodiments, L 3 is a covalent bond. In some embodiments, L 3 In some embodiments, L 3 In some embodiments, L 3 In some embodiments, L 3 In some embodiments, L3 is -CH2CH2CH2CH2NH-. In some embodiments, L 3 is -CHN(CH)-. In some embodiments, L 3 is -CH2CH2CH2CH2N(CH3)-. In some embodiments, L 3 In some embodiments, L 3 In some embodiments, L 3 In some embodiments, L 3 In some embodiments, L 3 is -CHN(CH)CH-. In some embodiments, L 3 is -CH2CH2CH2CH2NHCH2-. In some embodiments, L 3 is -CH2CH2CH2CH2N(CH3)CH2-. In some embodiments, L 3 is -CHSCHC(O)NH-. In some embodiments, L 3 is -CH2OCH2C(O)NH-. In some embodiments, L 3 is -CH2CH2OCH2C(O)NH-. In some embodiments, L 3 is -CHNHCHC(O)NH-. In some embodiments, L 3 is -CHN(CH)CHC(O)NH-. In some embodiments, L 3 is -CH2CH2CH2CH2NHCH2C(O)NH-. In some embodiments, L 3 is -CH2CH2CH2CH2N(CH3)CH2C(O)NH-. In some embodiments, L 3 is -CHSCHC(O)-. In some embodiments, L 3 is -CH2O In some embodiments, L 3 is -CH2CH2OCH2C(O)-. In some embodiments, L 3 is -CHNHCHC(O)-. In some embodiments, L 3is -CHN(CH)CHC(O)-. In some embodiments, L 3 is -CH2CH2CH2CH2NHCH2C(O)-. In some embodiments, L 3 is -CH2CH2CH2CH2N(CH3)CH2C(O)-. In some embodiments, L 3 is -CHSCHCHC(O)NH-. In some embodiments, L 3 is -CH2OCH2CH2C(O)NH-. In some embodiments, L 3 is -CH2CH2OCH2CH2C(O)NH-. In some embodiments, L 3 is -CHNHCHCHC(O)NH-. In some embodiments, L 3 is -CHN(CH)CHCHC(O)NH-. In some embodiments, L 3 is -CH2CH2CH2CH2NHCH2CH2C(O)NH-. In some embodiments, L 3 is -CH2CH2CH2CH2N(CH3)CH2CH2C(O)NH-. In some embodiments, L 3 is -CHSCHCHC(O)-. In some embodiments, L 3 is -CH2OCH2CH2C(O)-. In some embodiments, L 3 is -CH2CH2OCH2CH2C(O)-. In some embodiments, L 3 is -CHNHCHCHC(O)-. In some embodiments, L 3 is -CHN(CH)CHCHC(O)-. In some embodiments, L 3 is -CH2CH2CH2CH2NHCH2CH2C(O)-. In some embodiments, L 3 is -CH2CH2CH2CH2N(CH3)CH2CH2C(O)-. In some embodiments, L 3 teeth, [ka] In some embodiments, L 3is selected from those illustrated in Table 1 below.

[0064] As defined herein above, L 4 is a covalent bond, -O-, -N(R)-, or -N(R)CHCHN(R)-.

[0065] In some embodiments, L 4 is a covalent bond. In some embodiments, L 4 In some embodiments, L 4 is -N(R)-, where R is as described herein. In some embodiments, L 4 is -N(R)CHCHN(R)-, where R is as defined herein.

[0066] In some embodiments, L 4 In some embodiments, L 4 is -NHCH2CH2NH-.

[0067] In some embodiments, L 4 is selected from those illustrated in Table 1 below.

[0068] As defined hereinabove, each R is independently hydrogen or C 1~4 It is aliphatic.

[0069] In some embodiments, R is H. In some embodiments, R is C 1~4 It is aliphatic.

[0070] In some embodiments, R is C 1~4 In some embodiments, R is alkyl. In some embodiments, R is methyl. In some embodiments, R is ethyl. In some embodiments, R is isopropyl. In some embodiments, R is propyl. In some embodiments, R is butyl. In some embodiments, R is isobutyl. In some embodiments, R is t-butyl. It's chill.

[0071] In some embodiments, R is selected from those depicted in Table 1 below.

[0072] As defined herein above, -Cy 1 - is each independently selected from phenylene, a 3- to 7-membered saturated or partially unsaturated carbocyclylene, a 4- to 7-membered saturated or partially unsaturated heterocyclylene having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 10- to 12-membered saturated or partially unsaturated bicyclic heterocyclylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 10- to 12-membered saturated or partially unsaturated tricyclic heterocyclylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 10- to 12-membered saturated or partially unsaturated tricyclic heterocyclylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an optionally substituted divalent ring selected from a 0-12 membered partially saturated bicyclic heteroarylene, a 10-12 membered partially saturated tricyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 9-12 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 19-20 membered partially unsaturated tetracyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0073] In some embodiments, -Cy 1 - is optionally substituted phenylene. In some embodiments, -Cy 1 - is an optionally substituted 3- to 7-membered saturated or partially unsaturated carbocyclylene. 1 - is an optionally substituted 4-7 membered saturated or partially unsaturated heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 1- is an optionally substituted 10-12 membered saturated or partially unsaturated bicyclic heterocyclylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 1 - is an optionally substituted 10-12 membered saturated or partially unsaturated tricyclic heterocyclylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 1 - is an optionally substituted 10-12 membered partially saturated bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 1 - is an optionally substituted 10-12 membered partially saturated tricyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 1 - is an optionally substituted 9-12 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 1 - is an optionally substituted 19-20 membered partially unsaturated tetracyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 1 - is an optionally substituted 5-6 membered heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0074] In some embodiments, -Cy 1 is selected from those depicted in Table 1 below.

[0075] As defined hereinabove, a scaffold is a trivalent group that attaches and orients a cyclic peptide.

[0076] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] It is.

[0077] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] It is.

[0078] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] It is.

[0079] In some embodiments, the scaffold is Ring A, said Ring A being selected from the group consisting of 18-crown-6, 1,7,13-triaza-18-crown-6, and a 3-12 membered optionally substituted, saturated, partially unsaturated, bridged bicyclic, bridged tricyclic, propellane, or aromatic ring having 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0080] In some embodiments, the scaffold is Ring B, wherein said Ring B is an optionally substituted 6-18 membered cyclophane having 0-9 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0081] In some embodiments, the scaffold is Ring B, said Ring B being an optionally substituted cyclophane having 1-5 aromatic or heteroaromatic ring units and an aliphatic chain bridging two ring units, wherein one, two, or three methylene units of each aliphatic chain are optionally independently replaced by -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -OC(O)N(R)-, -N(R)C(O)O-, -S(O)-, or -S(O)2-.

[0082] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] It is.

[0083] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] It is.

[0084] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] It is.

[0085] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] It is.

[0086] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] It is.

[0087] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] It is.

[0088] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] It is.

[0089] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] It is.

[0090] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] It is.

[0091] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] It is.

[0092] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] It is.

[0093] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] It is.

[0094] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] It is.

[0095] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] It is.

[0096] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] It is.

[0097] In some embodiments, the scaffold comprises: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] In some embodiments, the scaffold is: [ka] It is.

[0098] In some embodiments, the scaffold is selected from those depicted in Table 1 below.

[0099] As defined herein above, loop A is L 1 and the amino acid residue linked to L 2 In some embodiments, Loop A is a bivalent natural or non-natural amino acid residue or peptide bound to an amino acid residue linked to L 1 and the amino acid residue linked to L 2 In some embodiments, Loop A is a divalent naturally occurring amino acid residue linked to an amino acid residue linked to L 1 and the amino acid residue linked to L 2 In some embodiments, Loop A is a divalent non-natural amino acid residue attached to an amino acid residue linked to L 1 and the amino acid residue linked to L 2 is a divalent peptide bound to an amino acid residue linked to

[0100] In some embodiments, Loop A is [ka] where: R 3 are each independently hydrogen or C, as described herein. 1~4 It is aliphatic; R 4 Each independently represents hydrogen or C 1~6 an optionally substituted group selected from aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic carbocyclic aromatic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or R 4group and its adjacent R 3 groups, optionally together with their intervening atoms, form a 4-8 membered saturated or partially unsaturated monocyclic heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; p is 1 to 15.

[0101] In some embodiments, Loop A is [ka] In some embodiments, Loop A is: [ka] In some embodiments, Loop A is: [ka] It is.

[0102] In some embodiments, Loop A is [ka] In some embodiments, Loop A is: [ka] In some embodiments, Loop A is: [ka] It is.

[0103] As defined herein above, loop B is L 1 and the amino acid residue linked to L 3 In some embodiments, Loop B is a bivalent natural or non-natural amino acid residue or peptide bound to an amino acid residue linked to L 1and the amino acid residue linked to L 3 In some embodiments, Loop B is a divalent naturally occurring amino acid residue linked to an amino acid residue linked to L 1 and the amino acid residue linked to L 3 In some embodiments, Loop B is a divalent non-natural amino acid residue attached to an amino acid residue linked to L 1 and the amino acid residue linked to L 3 is a divalent peptide bound to an amino acid residue linked to

[0104] In some embodiments, Loop B is [ka] where R 3 are each independently hydrogen or C, as described herein. 1~4 It is aliphatic; R 4 Each independently represents hydrogen or C 1~6 an optionally substituted group selected from aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic carbocyclic aromatic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or R 4 group and its adjacent R 3 groups, optionally together with their intervening atoms, form a 4-8 membered saturated or partially unsaturated monocyclic heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; q is 1 to 15.

[0105] In some embodiments, Loop B is [ka] In some embodiments, Loop B is: [ka] In some embodiments, Loop B is: [ka] It is.

[0106] In some embodiments, Loop B is [ka] In some embodiments, Loop B is: [ka] In some embodiments, Loop B is: [ka] It is.

[0107] In some embodiments, loop A comprises 1-15 amino acid residues and loop B comprises 1-15 amino acid residues.

[0108] In some embodiments, loop A comprises 5 amino acid residues and loop B comprises 5 amino acid residues. In some embodiments, loop A comprises 6 amino acid residues and loop B comprises 5 amino acid residues. In some embodiments, loop A comprises 2 amino acid residues and loop B comprises 7 amino acid residues. In some embodiments, loop A comprises 3 amino acid residues and loop B comprises 7 amino acid residues. In some embodiments, loop A comprises 3 amino acid residues and loop B comprises 9 amino acid residues. In some embodiments, loop A comprises 3 amino acid residues and loop B comprises 6 amino acid residues. In some embodiments, loop A comprises 2 amino acid residues and loop B comprises 6 amino acid residues. In some embodiments, loop A comprises 6 amino acid residues and loop B comprises 5 amino acid residues.

[0109] In some embodiments, Loop A is [ka] and loop B is [ka] and R 3 , R 4 , p, and q are each, independently, as described herein. In some embodiments, p is 5 and q is 5. In some embodiments, p is 6 and q is 5. In some embodiments, p is 2 and q is 7. In some embodiments, p is 3 and q is 7. In some embodiments, p is 3 and q is 9. In some embodiments, p is 3 and q is 6. In some embodiments, p is 2 and q is 6. In some embodiments, p is 6 and q is 5.

[0110] In some embodiments, Loop A is selected from those depicted in Table 1 below. In some embodiments, Loop B is selected from those depicted in Table 1 below.

[0111] As defined herein above, Spacer 1 is a covalent bond, a natural or unnatural amino acid (wherein the amino group is attached to the C-terminus of the bicycle via an amide bond), or a peptide (wherein the N-terminal amino group of said peptide is attached to the C-terminus of the bicycle via an amide bond).

[0112] In some embodiments, Spacer 1 is a covalent bond. In some embodiments, Spacer 1 is a natural amino acid, and the amino group is attached to the C-terminus of the bicycle via an amide bond. In some embodiments, Spacer 1 is a non-natural amino acid, and the amino group is attached to the C-terminus of the bicycle via an amide bond. In some embodiments, Spacer 1 is a peptide, and the N-terminal amino group of said peptide is attached to the C-terminus of the bicycle via an amide bond.

[0113] In some embodiments, a spacer 1 is L-alanine. In some embodiments, spacer 1 is D-alanine.

[0114] In some embodiments, a spacer 1 teeth [ka] where: R 3 are each independently hydrogen or C, as described herein. 1~4 It is aliphatic; R 4 Each independently represents hydrogen or C 1~6an optionally substituted group selected from aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic carbocyclic aromatic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or R 4 group and its adjacent R 3 groups, optionally together with their intervening atoms, form a 4-8 membered saturated or partially unsaturated monocyclic heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; r is 0 to 4.

[0115] In some embodiments, a spacer 1 is selected from those illustrated in Table 1 below.

[0116] Spacer, as defined herein above 2 is a covalent bond, a natural or unnatural amino acid (wherein said acid is attached to the N-terminus of the bicycle via an amide bond), or a peptide (wherein the C-terminal acid of said peptide is attached to the N-terminus of the bicycle via an amide bond).

[0117] In some embodiments, a spacer 2 is a covalent bond. In some embodiments, spacer 2 is a natural amino acid, said acid being linked to the N-terminus of the bicycle via an amide bond. 2 is an unnatural amino acid, said acid being linked to the N-terminus of the bicycle via an amide bond. In some embodiments, spacer 2 is a peptide, said peptide's C-terminal acid being linked to the N-terminus of the bicycle via an amide bond.

[0118] In some embodiments, a spacer 2 is L-alanine. 2 is D-alanine.

[0119] In some embodiments, a spacer 2 teeth, [ka] It is.

[0120] In some embodiments, a spacer 2 teeth [ka] where: R 3 are each independently hydrogen or C, as described herein. 1~4 It is aliphatic; R 4 Each independently represents hydrogen or C 1~6 an optionally substituted group selected from aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic carbocyclic aromatic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or R 4 group and its adjacent R 3 groups, optionally together with their intervening atoms, form a 4-8 membered saturated or partially unsaturated monocyclic heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; s is 0 to 4.

[0121] In some embodiments, a spacer 2is selected from those illustrated in Table 1 below.

[0122] As defined hereinabove, R 1 and R 2 are each independently R, [ka] [ka] , or -linker-conjugate.

[0123] In some embodiments, R 1 is R. In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 is a -linker-conjugate, where the linker and conjugate are each independently as described herein.

[0124] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] It is.

[0125] In some embodiments, R 1 is selected from those illustrated in Table 1 below.

[0126] In some embodiments, R 2 is R. In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 is a -linker-conjugate, where the linker and conjugate are each independently as described herein.

[0127] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] In some embodiments, R 2 teeth, [ka] It is.

[0128] In some embodiments, R 2 is selected from those illustrated in Table 1 below.

[0129] As defined herein above, each linker is independently a covalent bond or a C 1~8 A divalent hydrocarbon chain, in which one, two or three methylene units are -Cy 1-, -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -OC(O)N(R)-, -N( R)C(O)O-, -S(O)-, -S(O)2-, -C(CH3)=NN(R)-, -N(R)N=C(CH3)-, -N(R)CH2C(O)-, -(CH2CH2O) 1~10 -, [ka] are independently replaced as necessary.

[0130] In some embodiments, the linker is a covalent bond. In some embodiments, the linker is a C 1~8 A divalent hydrocarbon chain, in which one, two or three methylene units are -Cy 1 -, -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -OC(O)N(R)-, -N( R)C(O)O-, -S(O)-, -S(O)2-, -C(CH3)=NN(R)-, -N(R)N=C(CH3)-, -N(R)CH2C(O)-, -(CH2CH2O) 1~10 -, [ka] are independently replaced as necessary.

[0131] In some embodiments, the linker is C 1~8 A divalent hydrocarbon chain, in which one, two or three methylene units are -Cy 1 -, optionally independently replaced by -. In some embodiments, the linker is 1~8 A divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are optionally and independently replaced with -S-. In some embodiments, the linker is C 1~8A divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are optionally and independently replaced by -N(R)-. In some embodiments, the linker is 1~8 A divalent hydrocarbon chain, in which one, two, or three methylene units are optionally and independently replaced with -O-. 1~8 A divalent hydrocarbon chain, in which one, two, or three methylene units are optionally and independently replaced with -C(O)-. In some embodiments, the linker is 1~8 A divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are optionally and independently replaced with -OC(O)-. In some embodiments, the linker is 1~8 A divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are optionally and independently replaced by -C(O)O-. In some embodiments, the linker is 1~8 A divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are optionally and independently replaced by -C(O)N(R)-. In some embodiments, the linker is 1~8 A divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are optionally and independently replaced with -N(R)C(O)-. In some embodiments, the linker is 1~8 A divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are optionally and independently replaced with -OC(O)N(R)-. In some embodiments, the linker is 1~8 A divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are optionally and independently replaced by -N(R)C(O)O-. In some embodiments, the linker is 1~8 A divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are optionally and independently replaced with -S(O)-. In some embodiments, the linker is 1~8 a divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are optionally independently replaced by -S(O)2-; In some embodiments, the linker is C 1~8 A divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are optionally and independently replaced with -C(CH3)=NN(R)-. In some embodiments, the linker is 1~8 A divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are optionally and independently replaced with -N(R)N=C(CH3)-. In some embodiments, the linker is 1~8 A divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are optionally and independently replaced with -N(R)CHC(O)-. In some embodiments, the linker is 1~8 A divalent hydrocarbon chain, in which one, two or three methylene units are -(CH2CH2O) 1~10 -, optionally independently replaced by -. In some embodiments, the linker is 1~8 A divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are [ka] In some embodiments, the linker is optionally independently replaced by C 1~8 A divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are [ka] are independently replaced as necessary.

[0132] In some embodiments, the linker is selected from those depicted in Table 1 below.

[0133] As defined herein above, each conjugate is independently a half-life extending motif, a solubilizing group, a transporter recognition motif, a cell permeability motif, a drug payload, or a detectable moiety.

[0134] In some embodiments, the conjugate is a half-life extending motif. In some embodiments, the half-life extending motif comprises or is a lipid. In some embodiments, the half-life extending motif comprises or is a fatty acid. In some embodiments, the fatty acid is a dietary fatty acid, such as myristic acid or palmitic acid. In some embodiments, the lipid is selected from the following: [ka] [ka]

[0135] In some embodiments, the half-life extending motif is selected from those described in Bech et al., ACS Med. Chem. Lett. 2018, 9, 577-580, the entire contents of which are incorporated herein by reference.

[0136] In some embodiments, the conjugate is a solubilizing group. In some embodiments, the solubilizing group is a polar chain. In some embodiments, the polar chain is polysarcosine. In some embodiments, the polar chain is polyethylene glycol (PEG). In some embodiments, the solubilizing group comprises an ionizable group, including but not limited to, a carboxylic acid, a sulfonic acid, an amine, or a quaternary ammonium group (such as guanidine).

[0137] In some embodiments, the conjugate is a transporter recognition motif. In some embodiments, the transporter recognition motif is selected from those described in Diaz-Perlas et al., Chem.Sci., 2018, (DOI:10.1039 / C8SC02415D), the entire contents of which are incorporated herein by reference.

[0138] In some embodiments, the transporter recognition motif is a blood-brain barrier (BBB) ​​shuttle peptide. In some embodiments, the BBB shuttle peptide is selected from the following: [ka] .

[0139] In some embodiments, the conjugate is a cell-penetrating motif. In some embodiments, the cell-penetrating motif is a cell-penetrating peptide. In some embodiments, the cell-penetrating motif is TAT ​​(sequence: GRKKRRQRRRPPQC). In some embodiments, the cell-penetrating motif is a cell-penetrating peptide (SEQ ID NO: 114). 2018, 23, 295 (the entire contents of which are incorporated herein by reference).

[0140] In some embodiments, the conjugate is a drug payload. In some embodiments, the drug payload is a toxin. As used herein, toxin refers to a chemotherapeutic agent. In some embodiments, the toxin is linked to any available position. In some embodiments, the toxin is linked to any available -OH, -C(O)OH, -SH, -NH2, or -NHCH3.

[0141] In some embodiments, the toxin is monomethylauristatin E (MMAE): [ka] In some embodiments, the toxin is monomethylauristatin F (MMAF): [ka] In some embodiments, the toxin is DM1: [ka] In some embodiments, the toxin is DM4: [ka] In some embodiments, the toxin is SN38: [ka] In some embodiments, the toxin is doxorubicin: [ka] In some embodiments, the toxin is a duocarmycin analog: [ka] .

[0142] In some embodiments, the conjugate is a detectable moiety. In some embodiments, the detectable moiety is any moiety that can be detected.

[0143] Those of skill in the art will appreciate that a variety of detectable moieties are suitable for achieving the imaging effects of the present invention.

[0144] As used herein, "M" is a metal.

[0145] In some embodiments, the detectable moiety is linked to any available position, hi some embodiments, the detectable moiety is linked to any available -OH, -C(O)OH, -SH, -NH2, or -NHCH3.

[0146] In some embodiments, the detectable moiety is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (also known as DOTA, DotA, or tetraxetane): [ka] In some embodiments, the detectable moiety is Bn-DOTA: [ka] In some embodiments, the detectable moiety is Bn-oxo-DOTA: [ka] In some embodiments, the detectable moiety is Bn-PCTA: [ka] In some embodiments, the detectable moiety is TETA: [ka] In some embodiments, the detectable moiety is Bn-NOTA: [ka] In some embodiments, the detectable moiety is CHX-A″-DTPA: [ka] In some embodiments, the detectable moiety is Bn-DTPA: [ka] In some embodiments, the detectable moiety is 2B3M-DTPA: [ka] .

[0147] In some embodiments, the detectable moiety is desferrioxamine (DFO): [ka] .

[0148] In some embodiments, the detectable moiety is a heptamethine dye: [ka] In some embodiments, the detectable moiety is fluorescein: [ka] In some embodiments, the detectable moiety is Alexa Fluor 488: [ka] .

[0149] In some embodiments, the detectable moiety is a DOTA complex with a metal: [ka] In some embodiments, the detectable moiety is a Bn-DOTA complex with a metal: [ka] In some embodiments, the detectable moiety is a Bn-oxo-DOTA complex with a metal: [ka] In some embodiments, the detectable moiety is a Bn-PCTA complex with a metal: [ka] In some embodiments, the detectable moiety is a TETA complex with a metal: [ka] In some embodiments, the detectable moiety is a Bn-NOTA complex with a metal: [ka] In some embodiments, the detectable moiety is a CHX-A″-DTPA complex with a metal: [ka] In some embodiments, the detectable moiety is a Bn-DTPA complex with a metal: [ka] In some embodiments, the detectable moiety is a 2B3M-DTPA complex with a metal: [ka] .

[0150] In some embodiments, the detectable moiety is a desferrioxamine (DFO) complex with a metal: [ka] .

[0151] In some embodiments, the detectable moiety is complexed with a metal.

[0152] In some embodiments, the detectable moiety is a scorpionate. [ka] In some embodiments, the detectable moiety is a nanomaterial. In some embodiments, the detectable moiety is a quantum dot.

[0153] In some embodiments, the conjugate is selected from those depicted in Table 1 below.

[0154] As defined herein above, Ring A is selected from the group consisting of 18-crown-6, 1,7,13-triaza-18-crown-6, and a 3-12 membered optionally substituted, saturated, partially unsaturated, bridged bicyclic, bridged tricyclic, propellane, or aromatic ring having 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0155] In some embodiments, Ring A is 18-crown-6. In some embodiments, Ring A is 1,7,13-triaza-18-crown-6. In some embodiments, Ring A is a 3-12 membered optionally substituted, saturated, partially unsaturated, bridged bicyclic, bridged tricyclic, propellane, or aromatic ring having 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0156] In some embodiments, ring A is a 7-membered optionally substituted, saturated, partially unsaturated, bridged bicyclic, bridged tricyclic, propellane, or aromatic ring having 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, ring A is a 7-membered optionally substituted saturated ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, ring A is a 7-membered optionally substituted saturated ring having 1-3 heteroatoms independently selected from nitrogen or oxygen.

[0157] In some embodiments, Ring A is optionally substituted with 0-3 oxo, methyl, ethyl, or spiroethylene groups. In some embodiments, Ring A is optionally substituted with 0-3 -OR, -N(R)2, or -COOR, where R is as described herein. In some embodiments, Ring A is optionally substituted with 0-3 -OH, -OCH3, -NHCH3, or -COOH.

[0158] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] It is.

[0159] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] It is.

[0160] In some embodiments, ring A is [ka] In some embodiments, ring A is: [ka] In some embodiments, ring A is: [ka] In some embodiments, ring A is: [ka] In some embodiments, ring A is: [ka] It is.

[0161] In some embodiments, ring A is [ka] In some embodiments, ring A is: [ka] It is.

[0162] In some embodiments, ring A is [ka] In some embodiments, ring A is: [ka] In some embodiments, ring A is: [ka] It is.

[0163] In some embodiments, ring A is [ka] In some embodiments, ring A is: [ka] It is.

[0164] In some embodiments, ring A is [ka] It is.

[0165] In some embodiments, ring A is selected from those depicted in Table 1 below.

[0166] As defined hereinabove, in some embodiments, Ring B is an optionally substituted 6-18 membered cyclophane having 0-9 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0167] In some embodiments, Ring B is a 6-18 membered cyclophane having 0-9 heteroatoms independently selected from nitrogen, oxygen, or sulfur, optionally substituted with 0-6 -OR, -N(R)2, or -COOR, where R is as described herein. In some embodiments, Ring B is optionally substituted with 0-3 -OR, -N(R)2, or -COOR, where R is as described herein. In some embodiments, Ring B is optionally substituted with 0-3 -OCH3, -NHCH3, or -COOH.

[0168] As defined herein above, in some embodiments, Ring B is an optionally substituted cyclophane having 1-5 aromatic or heteroaromatic ring units and an aliphatic chain bridging two ring units, wherein one, two, or three methylene units of each aliphatic chain are optionally and independently replaced by -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -OC(O)N(R)-, -N(R)C(O)O-, -S(O)-, or -S(O)2-.

[0169] In some embodiments, ring B is an optionally substituted cyclophane having 2, 3, or 4 aromatic or heteroaromatic ring units. In some embodiments, ring B is an optionally substituted cyclophane having 3 aromatic or heteroaromatic ring units. In some embodiments, the aromatic or heteroaromatic ring units of the cyclophane are independently 5- or 6-membered rings. In some embodiments, the aromatic or heteroaromatic ring units of the cyclophane are phenyl rings. In some embodiments, the aromatic or heteroaromatic ring units of the cyclophane are pyridine rings. In some embodiments, one, two, or three methylene units of the aliphatic chain of the cyclophane are optionally replaced with -N(R)-, -O-, or -C(O)-. In some embodiments, one, two, or three methylene units of the aliphatic chain of the cyclophane are optionally replaced with -N(R)-.

[0170]

[0171] In some embodiments, Ring B is [ka] In some embodiments, Ring B is: [ka] In some embodiments, Ring B is: [ka] In some embodiments, Ring B is: [ka] In some embodiments, Ring B is: [ka] In some embodiments, Ring B is: [ka] It is.

[0172] In some embodiments, Ring B is selected from those depicted in Table 1 below.

[0173] As defined hereinabove, in some embodiments, R 4 Each independently represents hydrogen or C 1~6 an optionally substituted group selected from aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic carbocyclic aromatic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0174] In some embodiments, R 4 is hydrogen. In some embodiments, R 4 is replaced as necessary 1~6 In some embodiments, R 4is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R 4 is optionally substituted phenyl. In some embodiments, R 4 is an optionally substituted 8-10 membered bicyclic carbocyclic aromatic ring. In some embodiments, R 4 is an optionally substituted 4-8 membered saturated or partially unsaturated monocyclic heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R 4 is independently selected from nitrogen, oxygen, or sulfur In some embodiments, R is an optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms. 4 is an optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0175] In some embodiments, R 4 is methyl. In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] It is.

[0176] In some embodiments, R 4 teeth [ka] and the binding site has the (S) configuration. In some embodiments, R 4 teeth [ka] and the binding site has the (R) configuration.

[0177] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] It is.

[0178] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] It is.

[0179] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] In some embodiments, R 4 teeth, [ka] It is.

[0180] In some embodiments, R 4 is selected from those illustrated in Table 1 below.

[0181] As defined hereinabove, in some embodiments, R 3 Each independently represents hydrogen or C 1~4 It is aliphatic.

[0182] In some embodiments, R 3 is hydrogen. In some embodiments, R 3 is C 1~4 In some embodiments, R 3 is C 1~4 In some embodiments, R 3 is methyl. In some embodiments, R 3 is ethyl. In some embodiments, R 3 is propyl. In some embodiments, R 3 is isopropyl. In some embodiments, R 3 is butyl. In some embodiments, R 3 is isobutyl. In some embodiments, R 3 is t-butyl. In some embodiments, R 3 is selected from those illustrated in Table 1 below.

[0183] As defined hereinabove, in some embodiments, R3 group and its adjacent R 4 The groups, optionally together with their intervening atoms, form a 4-8 membered saturated or partially unsaturated monocyclic heterocycle having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0184] In some embodiments, R 3 group and its adjacent R 4 A group, together with its intervening atoms, [ka] In some embodiments, R 3 group and its adjacent R 4 A group, together with its intervening atoms, [ka] Form.

[0185] In some embodiments, R 3 group and its adjacent R 4 The groups, together with their intervening atoms, form the groups depicted in Table 1 below.

[0186] As defined hereinabove, m is 0 or 1.

[0187] In some embodiments, m is 0. In some embodiments, m is 1.

[0188] In some embodiments, m is selected from those depicted in Table 1 below.

[0189] As defined hereinabove, n is 0 or 1.

[0190] In some embodiments, n is 0. In some embodiments, n is 1.

[0191] In some embodiments, n is selected from those depicted in Table 1 below.

[0192] In certain embodiments, the invention provides a compound of formula Ia, wherein the scaffold is ring A, thereby providing a compound of formula Ia: [ka] or a pharma- ceutically acceptable salt thereof, 1 , L 2 , L 3 , L 4 , spacer 1 , spacer 2 , R, R 1 , R 2 , R 3 , R 4 , m, n, r, and s, both alone and in combination, are as defined above and described in embodiments herein.

[0193] In certain embodiments, the invention provides a compound of formula Ib, wherein the scaffold is ring B, such that the compound of formula Ib: [ka] or a pharma- ceutically acceptable salt thereof, 1 , L 2 , L 3 , L 4 , spacer 1 , spacer 2 , R, R 1 , R 2 , R 3 , m, and n are each defined above, both alone and in combination, and may be any of the embodiments herein. As described.

[0194] In certain embodiments, the invention provides compounds of formula Ic, wherein Loop A is [ka] and loop B is [ka] and the spacer 1 teeth [ka] and the peptide 2 teeth [ka] whereby a compound of formula Ic: [ka] or a pharma- ceutically acceptable salt thereof is formed, and the scaffold, L 1 , L 2 , L 3 , R, R 1 , R 2 , R 3 , R 4 , p, q, r, and s, both alone and in combination, are as defined above and described in embodiments herein.

[0195] In certain embodiments, the compounds of the invention have formula Id: [ka] or a pharma- ceutically acceptable salt thereof, 1 , L 2 , L 3 , R, R 1 , R 2 , R 3 , R 4 , p, q, r, and s, both alone and in combination, are as defined above and described in embodiments herein.

[0196] In certain embodiments, the compounds of the invention have formula Ie: [ka] or a pharma- ceutically acceptable salt thereof, 1 , L 2 , L 3 , R, R 1 , R 2 , R 3 , R 4 , p, q, r, and s, both alone and in combination, are as defined above and described in embodiments herein.

[0197] In certain embodiments, the present invention provides a compound of formula II: [ka] or a pharma- ceutically acceptable salt thereof, wherein Scaffolding, L 2 , L 3 , L 4 , spacer 1 , spacer 2 , R, R 1 , R 2 , R 3 , m, and n, each alone and in combination, are as defined above and described in embodiments herein; Loop C is L 2 and the amino acid residue linked to L 3 a bivalent natural or non-natural peptide bound to an amino acid residue linked to R 5 is R 5 together with the atom to which it is attached form a moiety that includes a hydrogen bond acceptor (HBA) and / or a hydrogen bond donor (HBD), 2 and L 3 It forms hydrogen bonds with the amino acid residues of the peptide.

[0198] As defined herein above, loop C is L 2 and the amino acid residue linked to L 3 The peptide is a bivalent natural or non-natural peptide bound to an amino acid residue linked to

[0199] In some embodiments, Loop C is [ka] and loop A, loop B, R 3 , and R 4 are each as defined above and described in embodiments herein, both alone and in combination.

[0200] In some embodiments, Loop C is [ka] In some embodiments, loop C is [ka] It is.

[0201] In some embodiments, Loop C is selected from those depicted in Table 2 below.

[0202] As defined hereinabove, R 5 is R 5 together with the atom to which it is attached form a moiety that includes a hydrogen bond acceptor (HBA) and / or a hydrogen bond donor (HBD), 2 and L 3 It forms hydrogen bonds with the amino acid residues of the peptide.

[0203] In some embodiments, R 5 is a hydrogen atom, and the hydrogen atom forms a hydrogen bond with an amino acid residue in loop C.

[0204] In some embodiments, R 5 is hydrogen, and R 5 The atom to which is attached forms a hydrogen bond with an amino acid residue in loop C.

[0205] In some embodiments, R 5 contains a hydrogen bond acceptor (HBA), which forms hydrogen bonds with amino acid residues in loop C.

[0206] In some embodiments, R 5 contains a hydrogen bond donor (HBD), which forms hydrogen bonds with amino acid residues in loop C.

[0207] In some embodiments, R 5 is R 5 Together with the atom to which it is attached, it forms a -C(O)- group, and O forms a hydrogen bond with an amino acid residue in loop C.

[0208] In some embodiments, R 5 is R 5 Together with the atom to which it is attached, it forms an -NH- group, and the N or H forms a hydrogen bond with an amino acid residue in loop C.

[0209] In some embodiments, R 5 contains or is an -OH group, H forms a hydrogen bond with an amino acid residue of Loop C, and R is as defined above and described in embodiments herein.

[0210] In some embodiments, R 5 contains or is an -N(R)H group, where H forms a hydrogen bond with an amino acid residue of Loop C, and R is as defined above and described in embodiments herein.

[0211] In some embodiments, R 5 contains a -C(O)- group, where O forms a hydrogen bond with an amino acid residue in loop C.

[0212] In some embodiments, R 5 is selected from those illustrated in Table 2 below.

[0213] In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] teeth, [ka] It is.

[0214] In some embodiments, [ka] teeth, [ka] It is.

[0215] In some embodiments, the present invention provides a compound represented by formula II-a: [ka] or a pharma- ceutically acceptable salt thereof, 2 , L 3 , L 4 , spacer 1 , spacer 2 , R, R 1 , R 2 , R 3 , R 4 , m, and n, both alone and in combination, are as defined above and described in embodiments herein.

[0216] In some embodiments, the present invention provides a compound represented by formula II-b: [ka] or a pharma- ceutically acceptable salt thereof, 2 , L 3 , L 4 , spacer 1 , spacer 2 , R, R 1 , R 2 , R 3 , R 4 , R 5 , m, and n, each alone and in combination, are as defined above and as described in embodiments herein; R 5 is defined above and includes a hydrogen bond donor (HBD) as described in the embodiments herein.

[0217] In some embodiments, the present invention provides a compound represented by formula II-c: [ka] or a pharma- ceutically acceptable salt thereof, 2 , L 3 , L 4 , spacer 1 , spacer 2 , R, R 1 , R 2 , R 3 , R 4 , m, and n, both alone and in combination, are as defined above and described in embodiments herein.

[0218] In some embodiments, the present invention provides a compound represented by formula II-d: [ka] or a pharma- ceutically acceptable salt thereof, 2 , L 3 , L 4 , spacer 1 , spacer 2 , R, R 1 , R 2 , R 3 , R 4 , R 5 , m, and n, each alone and in combination, are as defined above and as described in embodiments herein; R 5 is defined above and includes a hydrogen bond acceptor (HBA) as described in the embodiments herein.

[0219] In some embodiments, the present invention provides a compound represented by formula II-e: [ka] or a pharma- ceutically acceptable salt thereof, 2 , L 3 , L 4 , spacer 1 , spacer 2 , R, R 1 , R 2, R 3 , R 4 , m, and n, alone or in combination, are each as defined above and as described in embodiments herein; and as shown in formula II-e, R 5 The atom to which (H in formula II-e) is attached forms a hydrogen bond with the amino acid residue.

[0220] In some embodiments, the present invention provides a compound of formula II-f: [ka] or a pharma- ceutically acceptable salt thereof, 2 , L 3 , L 4 , spacer 1 , spacer 2 , R, R 1 , R 2 , R 3 , R 4 , m, and n, each alone or in combination, are as defined above and as described in embodiments herein; 4 independently comprises a hydrogen bond donor (HBD) as defined above and described in embodiments herein.

[0221] In some embodiments, the present invention provides a compound of formula II-g: [ka] or a pharma- ceutically acceptable salt thereof, 2 , L 3 , L 4 , spacer 1 , spacer 2 , R, R 1 , R 2 , R 3 , R 4, m, and n, each alone or in combination, are as defined above and as described in embodiments herein; 4 independently comprises a hydrogen bond acceptor (HBA) as defined above and described in embodiments herein.

[0222] In some embodiments, the present invention provides a compound of formula II-h: [ka] or a pharma- ceutically acceptable salt thereof, 2 , L 3 , L 4 , spacer 1 , spacer 2 , R, R 1 , R 2 , R 3 , R 4 , R 5 , m, and n, each alone and in combination, are as defined above and as described in embodiments herein; R 4 contains a hydrogen bond acceptor (HBA) or a hydrogen bond donor (HBD), and R 5 forms hydrogen bonds with

[0223] In some embodiments, the present invention provides a compound represented by formula II-i: [ka] or a pharma- ceutically acceptable salt thereof, 2 , L 3 , L 4 , spacer 1 , spacer 2 , R, R 1 , R 2 , R 3 , R 4 , m, and n, each alone and in combination, are as defined above and as described in embodiments herein; R4 contains a hydrogen bond donor (HBD), and R 5 It forms a hydrogen bond with the atom bonded to (H in formula II-i).

[0224] Exemplary compounds of the present invention are shown in Tables 1 and 2 below. Table 1. Exemplary compounds [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12]

Table 1-13

Table 1-14

Table 1-15

Table 1-16

Table 1-17

Table 1-18

Table 1-19

Table 1-20

Table 1-21

Table 1-22

Table 1-23

Table 1-24

Table 1-25

Table 1-26

Table 1-27

Table 1-28

Table 1-29

Table 1-30

Table 1-31

Table 1-32

Table 1-33

Table 1-34

Table 1-35

Table 1-36

Table 1-37

Table 1-38

Table 1-39

Table 1-40

Table 1-41

Table 1-42

Table 1-43

Table 1-44

Table 1-45

Table 1-46

Table 1-47

Table 1-48

Table 1-49

Table 1-50

Table 1-51

Table 1-52

Table 1-53

[0225] In some embodiments, the present invention provides compounds shown in Tables 1 and 2, or pharma- ceutically acceptable salts thereof. Table 2. Exemplary compounds [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] [Table 2-9] [Table 2-10] [Table 2-11] [Table 2-12] [Table 2-13] [Table 2-14] [Table 2-15] [Table 2-16] [Table 2-17] [Table 2-18] 4. General Methods for Providing Compounds of the Invention

[0226] The compounds of the invention may be prepared or isolated generally by synthetic and / or semi-synthetic methods known to those of skill in the art for analogous compounds, as well as by methods detailed in the Examples herein.

[0227] The compounds of the invention can be prepared by treating a peptide with a molecular scaffolding reagent. A molecular scaffolding reagent comprises a scaffold and a reactive functional group (a leaving group ("LG") or a Michael acceptor). --("MA")), which covalently attaches peptides to molecular scaffolds via displacement of a leaving group or addition of a Michael acceptor group, followed by protonation of the adduct complex.

[0228] The exemplary compounds in Tables 1 and 2 are formed by treating the peptides with various molecular scaffolding reagents.

[0229] One such peptide is peptide 1 (17-69-07-N241), which has the following amino acid sequence: βAla-Sar10-AC(D-Ala)NE(1Nal)(D-Ala)CEDFYD(tBuGLy)C (SEQ ID NO: 1)

[0230] The bicyclic peptide formed by treating 17-69-07-N241 with the molecular scaffolding reagent 1,3,5-tris(bromomethyl)benzene ("TBMB") as described in WO2016 / 067035 yields an MT1-MMP binder with a Kd of 1.2 nM.

[0231] Another such peptide is Peptide 2, which has the following amino acid sequence: βAla-Sar10-A-CTECWVDGWVPC (sequence number 2).

[0232] The bicyclic peptide formed by treating 2 with the molecular scaffolding reagent 1,3,5-tris(bromomethyl)benzene ("TBMB") as described in UK Provisional Application P2120 yields a CAIX binder with a Kd of 10 nM.

[0233] One such peptide is peptide 3, which has the following amino acid sequence: AC(D-Ala)NE(1Nal)(D-Ala)CEDFYD(tBuGLy)C (SEQ ID NO: 3)

[0234] In the following schemes illustrating specific Michael acceptors ("MA"), leaving groups ("LG"), or transformation conditions, one of skill in the art will understand that other Michael acceptors, leaving groups, and transformation conditions are also suitable and contemplated. Such acceptors, groups, and transformations are described in detail in March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, M.B. Smith, M.D. and J. March, 5 th Edition, John Wiley&Sons, 2001, Comprehensive Organic Transformations, RC Larock, 2 nd Edition, John Wiley & Sons, 1999, and Protecting Groups in Organic Synthesis, T.W. Greene and P.G. M. Huts, 3 rd edition, John Wiley & Sons, 1999, each of which is incorporated herein by reference in its entirety.

[0235] As used herein, the phrase "leaving group" (LG) includes, but is not limited to, halogen (e.g., fluoride, chloride, bromide, iodide), sulfonate (e.g., mesylate, tosylate, benzenesulfonate, brosylate, nosylate, triflate), diazonium, and the like.

[0236] In certain embodiments, the present invention provides methods for preparing compounds of formula I according to the steps illustrated in Scheme I, shown below: Scheme I [ka]

[0237] In Scheme I above, L 1 , L 2 , L 3 , L 4, scaffold, loop A, loop B, R, spacer 1 , spacer 2 , R 1 , R 2 , R 3 , m, and n are each as defined above and below and in the classes and subclasses described herein; Y 1 and Z 1 L 1 Forming; Y 2 and Z 2 L 2 Forming; Y 3 and Z 3 L 3 Form.

[0238] In certain embodiments, the present invention provides a method for preparing a compound of formula II according to the steps illustrated in Scheme II shown below: Scheme II [ka]

[0239] In Scheme II above, L 2 , L 3 , L 4 , scaffold, loop C, R, spacer 1 , spacer 2 , R 1 , R 2 , R 3 , R 5 , m, and n are each as defined above and below and in the classes and subclasses described herein; Y 2 and Z 2 L 2 Forming; Y 3 and Z 3 L 3 Form.

[0240] L 1 (Y 1 and Z 1 reaction between L 2 (Y 2 and Z 2), and L 3 (Y 3 and Z 3 The reaction between can be effected by several synthetic methods known to those skilled in the art.

[0241] For example, in some embodiments, L 1 , L 2 , and L 3 One or more of Y are formed by a leaving group (LG) elimination reaction. 1 , Y 2 , and Y 3 Each is LG. In some embodiments, LG is a halogen. In some embodiments, LG is chlorine. In some embodiments, LG is a sulfonate. In some embodiments, a base is added to facilitate the detachment. In some embodiments, the base is ammonium carbonate. In some embodiments, the base is an amine. In some embodiments, the reactants further comprise a solvent. In some embodiments, the solvent is acetonitrile. In some embodiments, the solvent is a mixture of water and acetonitrile. In some embodiments, a catalyst is added to facilitate the detachment. In some embodiments, the catalyst is generated from a third generation XPhos pre-catalyst. In some embodiments, the solvent is tert-butanol. In some embodiments, the solvent is a mixture of water and tert-butanol.

[0242] In some embodiments, L 1 , L 2 , and L 3 In some embodiments, one or more of Y 1 , Y 2 , and Y 3are each a Michael acceptor (MA). In some embodiments, MA is an α,β-unsaturated amide. In some embodiments, MA is an α,β-unsaturated ketone. In some embodiments, MA is an α,β-unsaturated ester. In some embodiments, MA is an α,β-unsaturated sulfone. In some embodiments, MA is an α,β-unsaturated nitrile. In some embodiments, a base is added to facilitate the Michael addition. In some embodiments, the base is ammonium carbonate. In some embodiments, the base is an amine. In some embodiments, the reactants further comprise a solvent. In some embodiments, the solvent is acetonitrile. In some embodiments, the solvent is a mixture of water and acetonitrile.

[0243] In some embodiments, L 1 , L 2 , and L 3 In some embodiments, one or more of Y 1 contains an alkyne group, Z 1 In some embodiments, Y comprises an azide group. 1 contains an azide group, Z 1 In some embodiments, Y comprises an alkyne group. 2 contains an alkyne group, Z 2 In some embodiments, Y comprises an azide group. 2 contains an azide group, Z 2 In some embodiments, Y comprises an alkyne group. 3 contains an alkyne group, Z 3 In some embodiments, Y comprises an azide group. 3 contains an azide group, Z 3 In some embodiments, Y comprises an alkyne group. 1 , Y 2 , and Y 3 each contains an alkyne group, and Z 1 , Z 2 , and Z 3 Each Y comprises an azide group. 1 , Y 2 , and Y 3 each contains an azide group, and Z 1 , Z2 , and Z 3 each contains an alkyne group.

[0244] In some embodiments, L 1 , L 2 , and L 3 In some embodiments, one or more of Y 1 contains a carbonyl group, Z 1 In some embodiments, Y 2 contains a carbonyl group, Z 2 In some embodiments, Y 3 contains a carbonyl group, Z 3 In some embodiments, Y 1 , Y 2 , and Y 3 each contains a carbonyl group, and Z 1 , Z 2 , and Z 3 each contains a -N(R) group.

[0245] In some embodiments, L 1 , L 2 , and L 3 In some embodiments, one or more of Y 1 contains a carbonyl group, Z 1 In some embodiments, Y 2 contains a carbonyl group, Z 2 In some embodiments, Y 3 contains a carbonyl group, Z 3 In some embodiments, Y 1 , Y 2 , and Y 3 each contains a carbonyl group, and Z 1 , Z 2 , and Z 3 Each contains an -OH group.

[0246] In certain embodiments, R-1 is of the formula [ka] and Y 1 , Y 2 , Y 3 , Ring A, and Ring B are each as defined above and below and in the classes and subclasses described herein.

[0247] In certain embodiments, R-2 is of the formula [ka] and Y 2 , Y 3 , R 5 , Ring A, and Ring B are each as defined above and below and in the classes and subclasses described herein.

[0248] Those skilled in the art will appreciate that the compounds of the present invention may contain one or more stereocenters and may exist as racemic or diastereomeric mixtures. Additionally, those skilled in the art will appreciate that there are numerous methods of isomer separation known to those skilled in the art to obtain stereoenriched or stereopure isomers of the aforementioned compounds, including, but not limited to, HPLC of diastereomeric salts, chiral HPLC, fractional crystallization, kinetic enzymatic resolution (e.g., by lipases or esterases from fungi, bacteria, or animals), and formation of covalent diastereomeric derivatives using enantiomerically enriched reagents.

[0249] Those skilled in the art will appreciate that the various functional groups present in the compounds of the present invention, such as aliphatic groups, alcohols, carboxylic acids, esters, amides, aldehydes, halogens, and nitriles, can be interchanged by techniques well known in the art, including, but not limited to, reduction, oxidation, esterification, hydrolysis, partial oxidation, partial reduction, halogenation, dehydration, partial dehydration, and hydration. "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001, which is incorporated by reference in its entirety. Such interconversions may require one or more of the techniques described above, and certain methods for the synthesis of the compounds of the invention are described in the Examples below. 5. Use, Formulation, and Administration: Pharmaceutically acceptable compositions

[0250] According to another embodiment, the present invention provides a composition comprising a compound of the present invention or a pharma- ceutically acceptable derivative thereof, and a pharma- ceutically acceptable carrier, adjuvant, or vehicle. The amount of compound in the composition of the present invention is effective to measurably inhibit CAIX, MT1-MMP, CD38, EphA2, or PBP1A, or a variant thereof, in a biological sample or in a patient. In certain embodiments, the composition of the present invention contains The amount of compound is effective to measurably inhibit CAIX, MT1-MMP, CD38, EphA2 or PBP1A or variants thereof in a biological sample or in a patient. In certain embodiments, the compositions of the invention are formulated for administration to a patient in need of such compositions. In some embodiments, the compositions of the invention are formulated for oral administration to a patient.

[0251] The term "patient", as used herein, means an animal, preferably a mammal, and most preferably a human.

[0252] The term "pharmaceutically acceptable carrier, adjuvant or vehicle" refers to a non-toxic carrier, adjuvant or vehicle that does not destroy the pharmacological activity of the compound that is formulated together.The pharmaceutically acceptable carrier, adjuvant or vehicle that can be used in the composition of the present invention includes, but is not limited to, ion exchanger, alumina, aluminum stearate, lecithin, serum protein such as human serum albumin, buffer substances such as phosphate, glycine, sorbic acid, potassium sorbate, partial glyceride mixture of saturated vegetable fatty acid, water, salt or electrolyte (protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salt, etc.), colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylate, wax, polyethylene-polyoxypropylene-block polymer, polyethylene glycol and wool fat.

[0253] "Pharmaceutically acceptable derivative" means any non-toxic salt, ester, salt of an ester, or other derivative of a compound of the invention that is capable of providing, either directly or indirectly, the compound of the invention, or an inhibitory active metabolite or residue thereof, upon administration to a recipient.

[0254] As used herein, the term "inhibitorily active metabolite or residue thereof" means that the metabolite or residue thereof is also an inhibitor of CAIX, MT1-MMP, CD38, EphA2 or PBP1A or a mutant thereof.

[0255] The compositions of the present invention can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, bucally, vaginally, or via an implanted reservoir. The term "parenterally" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally, or intravenously. Sterile injectable forms of the compositions of the present invention can be aqueous or oleaginous suspensions. These suspensions can be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. Sterile injectable preparations can also be sterile solutions or suspensions for injection in non-toxic parenterally acceptable diluents or solvents, for example as solutions in 1,3-butanediol. Among the acceptable vehicles and solvents that can be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.

[0256] For this purpose, any bland fixed oil may be used, including synthetic mono- or diglycerides. Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharma- ceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated form. These oily solutions or suspensions also contain carboxylic acids commonly used in formulating pharma- ceutically acceptable dosage forms, including emulsions and suspensions. Long chain alcohol diluents or dispersants, such as dimethylcellulose or similar dispersants, may also be included. Other commonly used surfactants, such as Tweens, Spans and other emulsifiers, or bioavailability enhancers, commonly used in the manufacture of pharma- ceutically acceptable solid, liquid or other dosage forms, may also be used for formulation purposes.

[0257] The pharmaceutically acceptable composition of the present invention can be orally administered in any orally acceptable dosage form, including but not limited to capsules, tablets, aqueous suspensions or solutions.For tablets intended for oral use, commonly used carriers include lactose and corn starch.Lubricants such as magnesium stearate are also usually added.For oral administration in capsule form, useful diluents include lactose and dried corn starch.When aqueous suspensions are required for oral use, active ingredient is combined with emulsifiers and suspending agents.If desired, certain sweeteners, flavorings or colorings can also be added.

[0258] Alternatively, the pharma- ceutically acceptable composition of the present invention may be administered in the form of suppositories for rectal administration.These can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature, and therefore melts in the rectum to release the drug.Such materials include cocoa butter, beeswax and polyethylene glycol.

[0259] The pharma- ceutically acceptable compositions of the present invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

[0260] Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topical transdermal patches may also be used.

[0261] For topical application, the provided pharma- ceutically acceptable composition may be formulated with a suitable ointment containing the active ingredient suspended or dissolved in one or more carriers.Carriers for topical administration of the compounds of the present invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax and water.Alternatively, the provided pharma-ceutically acceptable composition may be formulated with a suitable lotion or cream containing the active ingredient suspended or dissolved in one or more pharma-ceutically acceptable carriers.Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

[0262] For ophthalmic use, the provided pharma- ceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH-adjusted, sterile saline, or preferably as solutions in isotonic, pH-adjusted, sterile saline, with or without preservatives such as benzylalkonium chloride. Alternatively, for ophthalmic use, the pharma-ceutically acceptable compositions may be formulated in an ointment such as petrolatum.

[0263] The pharma- ceutically acceptable compositions of the present invention may also be administered by nasal aerosol or inhalation.Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation, and may be prepared as solutions in saline using benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.

[0264] Most preferably, the pharmaceutically acceptable composition of the present invention is formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, the pharmaceutically acceptable composition of the present invention is administered without food. In other embodiments, the pharmaceutically acceptable composition of the present invention is administered with food.

[0265] The amount of the compounds of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration. Preferably, the provided compositions should be formulated so that a dosage of between 0.01-100 mg / kg body weight / day of the inhibitor can be administered to a patient receiving these compositions.

[0266] It should also be understood that the specific dosage and treatment regimen for any particular patient will depend on a variety of factors, including the activity of the specific compound used, age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, as well as the judgment of the treating physician and the severity of the particular disease being treated. The amount of a compound of the present invention in a composition will also depend on the particular compound in the composition. Uses of the Compounds and Pharmaceutically Acceptable Compositions

[0267] Certain bicyclic peptides of the invention are particularly useful as CAIX binding agents.

[0268] Various forms of the enzyme carbonic anhydrase (CA) catalyze the hydration of carbon dioxide to produce bicarbonate anion (HCO3-) and protons. Substrates of the reaction catalyzed by CA control several physiological processes, including the formation and transport of CO2, protons, and bicarbonate anions, such as respiration, maintenance of pH levels, bone development, and other processes. In the human body, 12 catalytically active CA isoenzymes have been identified that differ in cellular localization and expression in various tissues.

[0269] Clinical control of human carbonic anhydrase (hCA) activity by small molecule inhibitors has already proven to be a reliable method of treatment for several human diseases for several decades and remains a main component in the treatment of hypertension, glaucoma, hyperthyroidism, and hypoglycemia (Supuran (2008) Nat. Rev. Drug Discov. 7, 168). Classical inhibitors of carbonic anhydrase that bind to the active site of CA are aromatic or heteroaromatic sulfonamides.

[0270] Human carbonic anhydrase IX (hCAIX) is an isoform bound to the outer cell membrane (its catalytic domain is present in the extracellular space). Under physiological conditions, hCAIX is expressed only in specific tissues of the gastrointestinal tract. Its overexpression was observed during hypoxia in cancer cells both in vitro and in vivo. hCAIX expression was detected in cervical, ovarian, renal, esophageal, lung, breast, and brain carcinomas. In tumors, hCAIX is a key molecule in maintaining normal levels of intracellular pH, and its expression generates hypoxic tumor cells that have a growth advantage in acidic conditions (Chiche et al. (2009) Cancer Res 69, 358). Thus, the hCAIX enzyme is a favorable target for the development of specific inhibitors to be used as anticancer therapeutics with novel mechanisms of action (Neri and Supuran (2011) Nature Reviews 10, 767).

[0271] Polypeptide ligands selected according to the methods of the invention may be used in in vivo therapeutic and prophylactic applications, in vitro and in vivo diagnostic applications, and in vitro assay and reagent applications. Ligands with a selected level of specificity may be useful in a variety of applications, including testing in non-human animals where cross-reactivity is desirable. These are useful in applications involving the development of novel antibodies, or in diagnostic applications where cross-reactivity with homologs or paralogs must be carefully controlled. In some applications, such as vaccine applications, the ability to elicit an immune response against a range of antigens can be exploited to tailor vaccines to specific diseases and pathogens.

[0272] Substantially pure peptide ligands of at least 90-95% homogeneity are preferred for administration to mammals, with 98-99% or greater homogeneity being most preferred for pharmaceutical uses, particularly where the mammal is a human. Once purified, partially or to homogeneity as appropriate, the selected polypeptides may be used in the development and implementation of diagnostic or therapeutic (including in vitro) or assay procedures, immunofluorescence staining, and the like (Lefkovite et al., 2003). and Pernis,(1979 and 1981)Immunological Methods, Volumes I and II, Academic Press, NY).

[0273] According to a further aspect of the present invention there is provided a peptide ligand or drug conjugate as defined above for use in the prevention, inhibition or treatment of a disease or disorder mediated by CAIX.

[0274] According to a further aspect of the present invention, there is provided a method for preventing, inhibiting or treating a disease or disorder mediated by CAIX, comprising administering to a patient in need thereof an effector group and a drug conjugate of a peptide ligand as defined above.

[0275] In one embodiment, the CAIX is a mammalian CAIX. In a further embodiment, the mammalian CAIX is human CAIX (hCAIX).

[0276] In one embodiment, the disease or disorder mediated by CAIX is selected from cancer.

[0277] In another aspect, certain bicyclic peptides of the invention are particularly useful as high affinity binders of membrane type 1 metalloprotease (MT1-MMP, also known as MMP14). MT1-MMP is a transmembrane metalloprotease that plays an important role in extracellular matrix remodeling, directly by degrading several components of the extracellular matrix, and indirectly by activating pro-MMP2. Because MT1-MMP is important in tumor angiogenesis (Sounni et al (2002) FASEB J. 16(6), 555-564) and is overexpressed in various solid tumors, the MT1-MMP-binding bicyclic peptides of the invention are particularly useful in targeted treatment of cancer, particularly solid tumors, such as non-small cell lung cancer. In one embodiment, the bicyclic peptides of the invention are specific for human MT1-MMP. In a further embodiment, the bicyclic peptides of the invention are specific for mouse MT1-MMP. In yet a further embodiment, the bicyclic peptides of the invention are specific for human and mouse MT1-MMP. In yet a further embodiment, the bicyclic peptides of the invention are specific for human, mouse, and canine MT1-MMP.

[0278] The compounds and compositions described herein are generally useful for inhibiting carbonic anhydrase or metalloprotease activity of one or more enzymes.

[0279] The activity of the compounds utilized in the present invention as inhibitors of CAIX, MT1-MMP, CD38, EphA2, or PBP1A, or variants thereof, may be assayed in vitro, in vivo, or in cell lines. Another in vitro assay quantifies the ability of the inhibitor to bind to CAIX, MT1-MMP, CD38, EphA2, or PBP1A. Inhibitor binding is determined by the binding of the inhibitor / CAIX complex or inhibitor / MT1-MMP to the inhibitor / CAIX complex. P complex binding, radiolabeling of the inhibitor prior to isolation, and quantification of bound radiolabel. Alternatively, inhibitor binding can be determined by performing competition experiments in which new inhibitors are incubated with CAIX, MT1-MMP, CD38, EphA2, or PBP1A bound to known radioligands. Representative in vitro and in vivo assays useful in assaying for MT1-MMP inhibitors include those described and disclosed in: Pietraszek et al., (2014) FEBS Letters 588(23), 4319-4324; Cheltsov et al., (2014) FEBS Letters 588(23), 4319-4324; et al., (2012) Cancer Res. 72(9), 2339-49; and WO2009 / 098450, each of which is incorporated herein by reference in its entirety. Representative in vitro and in vivo assays useful for assaying CAIX inhibitors include those described and disclosed in: Wind et al., (2011) Ann Clin Biochem. 48(2), 112-120; Gandhi et al., (2015) J. Urology 193(4), e870-e871; and WO2004 / 005348, each of which is incorporated herein by reference in its entirety. Detailed conditions for assaying the compounds utilized in the present invention as inhibitors of CAIX, MT1-MMP, CD38, EphA2, or PBP1A, or mutants thereof, are provided in the Examples below.

[0280] As used herein, the terms "treatment", "treat" and "treating" refer to reversing, alleviating, delaying the onset of, or inhibiting the progression of a disease or disorder as described herein, or one or more symptoms thereof. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to susceptible individuals prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have been cured, e.g., to prevent or delay their recurrence.

[0281] The compounds provided are inhibitors of CAIX, MT1-MMP, CD38, EphA2 or PBP1A and are therefore useful for treating one or more disorders associated with CAIX, MT1-MMP, CD38, EphA2 or PBP1A activity. Thus, in certain embodiments, the present invention provides a method for treating a CAIX-, MT1-MMP-, CD38-, EphA2- or PBP1A-mediated disorder, comprising administering to a patient in need thereof a compound of the present invention or a pharma- ceutically acceptable composition thereof.

[0282] As used herein, the terms "CAIX-mediated," "MT1-MMP-mediated," "CD38-mediated," "EphA2-mediated," or "PBP1A-mediated" disorders, diseases, and / or conditions, as used herein, refer to any disease or other exacerbating condition in which CAIX, MT1-MMP, CD38, EphA2, or PBP1A, or variants thereof, are known to play a role. Accordingly, another embodiment of the present invention relates to treating or lessening the severity of one or more diseases in which CAIX, MT1-MMP, CD38, EphA2, or PBP1A, or variants thereof, are known to play a role.

[0283] Examples of cancers that may be treated (or inhibited) include tumors of epithelial origin (various types of adenomas and carcinomas, including adenocarcinoma, squamous cell carcinoma, transitional cell carcinoma and other carcinomas), e.g., carcinoma of the bladder and urinary tract, carcinoma of the breast, carcinoma of the digestive tract (including the esophagus, stomach, small intestine, colon, rectum and anus), carcinoma of the liver (hepatocellular carcinoma), carcinoma of the gallbladder and biliary system, carcinoma of the exocrine pancreas, carcinoma of the kidney, carcinoma of the lung (e.g., adenocarcinoma, small cell lung carcinoma, non-small cell lung carcinoma, and ovarian carcinoma), and carcinoma of the lung (e.g., adenocarcinoma, small cell lung carcinoma, non-small cell lung carcinoma, and ovarian carcinoma). lung cancer, bronchioloalveolar carcinoma and mesothelioma), carcinoma of the head and neck (e.g., carcinoma of the tongue, oral cavity, larynx, pharynx, nasopharynx, tonsils, salivary glands, nasal cavity and paranasal sinuses), carcinoma of the ovary, carcinoma of the fallopian tubes, carcinoma of the peritoneum, carcinoma of the vagina, carcinoma of the vulva, carcinoma of the penis, carcinoma of the cervix, carcinoma of the myometrium, carcinoma of the endometrium, carcinoma of the thyroid gland (e.g., thyroid follicular carcinoma), carcinoma of the adrenal gland, carcinoma of the prostate, carcinoma of the skin and carcinoma of the adnexa (e.g., melanoma, basal cell carcinoma, squamous cell carcinoma, keratoacanthoma, dysplastic nevi); hematological malignancies and related conditions of the lymphoid system (e.g., acute lymphoblastic leukemia [ALL], B-cell lymphomas such as chronic lymphocytic leukemia [CLL], diffuse large B-cell lymphoma [DLBCL], follicular lymphoma, Burkitt lymphoma, mantle cell lymphoma, T-cell lymphoma and leukemia, natural killer [NK] cell lymphoma, Hodgkin lymphoma, hairy cell leukemia, monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and post-transplant lymphoproliferative disorder) and hematological malignancies and related conditions of the myeloid lineage (e.g., acute myeloid leukemia [AML], chronic myelogenous leukemia [CML], chronic myelomonocytic leukemia [CMML]) hematological malignancies (i.e., leukemias, lymphomas) and premalignant hematological disorders and borderline malignant disorders, including hypereosinophilic syndromes, myeloproliferative disorders, such as polycythemia vera, essential thrombocythemia and primary myelofibrosis, myeloproliferative syndromes, myelodysplastic syndromes and promyelocytic leukemia; tumors of mesenchymal origin, such as osteosarcoma, fibrosarcoma, chondrosarcoma, rhabdomyosarcoma, leiomyosarcoma, liposarcoma, angiosarcoma, Kaposi's sarcoma, Ewing's sarcoma, synovial sarcoma, epithelioid sarcoma, gastrointestinal stromal tumors, benign and malignant histiocytoma and dermatofibrosarcoma protuberans; tumors of the central or peripheral nervous system (e.g., astrocytoma, glioma and glioblastoma, meningioma, ependymoma, pineal tumor and Schwannoma); endocrine tumors (e.g., pituitary tumor, adrenal tumor, islet cell tumor, parathyroid tumor, carcinoid tumor and medullary carcinoma of the thyroid); eye and adnexal tumors (e.g., retinoblastoma); germ cell and trophoblastic tumors (e.g., teratoma, seminoma, dysgerminoma, hydatidiform mole and choriocarcinoma); and pediatric and embryonal tumors (e.g., medulloblastoma, neuroblastoma, Wilms tumor and primitive neuroectodermal tumor);Alternatively, they may include, but are not limited to, congenital or otherwise related syndromes that leave patients susceptible to malignancies (e.g., xeroderma pigmentosum);

[0284] In further embodiments, the cancer is selected from cervical, ovarian, kidney, esophageal, lung, breast, and brain cancer.

[0285] Reference herein to the term "prevention" includes administration of the protective composition prior to the induction of disease. "Suppression" refers to administration of the composition after an inductive event but prior to the clinical appearance of disease. "Treatment" includes administration of the protective composition after disease symptoms become evident.

[0286] Animal model systems are available that can be used to screen the effectiveness of peptide ligands in protecting against or treating disease. The present invention facilitates the use of animal model systems, which can be used to develop polypeptide ligands that can cross-react with human and animal targets.

[0287] Furthermore, the present invention provides the use of a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, for the preparation of a medicament for the treatment of a proliferative disease. Combination therapy

[0288] Depending on the particular condition or disease to be treated, additional therapeutic agents that are normally administered to treat such conditions may be administered in combination with the compounds and compositions of the invention. As used herein, additional therapeutic agents that are normally administered to treat a particular disease or condition are known as "appropriate for the disease or condition being treated."

[0289] In certain embodiments, the provided combinations or compositions thereof are administered in combination with another therapeutic agent.

[0290] In certain embodiments, the combination therapy of the invention, or a pharma- ceutically acceptable composition thereof, is administered in combination with a monoclonal antibody or siRNA therapeutic.

[0291] These additional agents may be administered separately from the combination therapy provided as part of a multiple dose regimen. Alternatively, these agents may be part of a single dosage form, mixed together with the compound of the present invention in a single composition. When administered as part of a multiple dose regimen, the two active agents may be provided simultaneously, sequentially, or within a period of each other, usually within 5 hours of each other.

[0292] As used herein, the terms "combination," "in combination," and related terms refer to simultaneous or sequential administration of therapeutic agents according to the invention. For example, the combination of the invention may be administered simultaneously or sequentially with another therapeutic agent in separate unit dosage forms, or may be administered together in a single dosage form.

[0293] The amount of additional therapeutic agent present in the compositions of the present invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably, the amount of additional therapeutic agent in the compositions of the present disclosure will be in the range of about 50% to 100% of the amount that would normally be present in a composition comprising that agent as the only therapeutically active agent.

[0294] In one embodiment, the present invention provides a composition comprising a compound of the present invention and one or more additional therapeutic agents. The therapeutic agent may be administered together with the compound of the present invention, or before or after the compound of the present invention. Suitable therapeutic agents are described in further detail below. In certain embodiments, the compound of the present invention may be administered up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours before the therapeutic agent. In other embodiments, the compound of the present invention may be administered up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours after the therapeutic agent.

[0295] In another embodiment, the present invention provides a method of treating a hematological malignancy comprising administering to a patient in need thereof a compound of the present invention and one or more additional therapeutic agents selected from rituximab (Rituxan®), cyclophosphamide (Cytoxan®), doxorubicin (Hydrodaunorubicin®), vincristine (Oncovin®), prednisone, a hedgehog signaling inhibitor, a BTK inhibitor, a JAK / pan-JAK inhibitor, a TYK2 inhibitor, a PI3K inhibitor, a SYK inhibitor, and combinations thereof.

[0296] In another embodiment, the present invention provides a method of treating a solid tumor comprising administering to a patient in need thereof a compound of the present invention and one or more additional therapeutic agents selected from rituximab (Rituxan®), cyclophosphamide (Cytoxan®), doxorubicin (Hydrodaunorubicin®), vincristine (Oncovin®), prednisone, a hedgehog signaling inhibitor, a BTK inhibitor, a JAK / pan-JAK inhibitor, a TYK2 inhibitor, a PI3K inhibitor, a SYK inhibitor, and combinations thereof.

[0297] In another embodiment, the present invention relates to a method for the treatment of hedgehog (Hh) signaling disorders using a compound of the present invention. In some embodiments, the hematological malignancy is DLBCL (Ramirez et al. "Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphoma" Leuk. Res. (2012), published online July 17, and incorporated herein by reference in its entirety).

[0298] In another embodiment, the present invention provides a method of treating diffuse large B-cell lymphoma (DLBCL), comprising administering to a patient in need thereof a compound of the present invention and one or more additional therapeutic agents selected from rituximab (Rituxan®), cyclophosphamide (Cytoxan®), doxorubicin (Hydrodaunorubicin®), vincristine (Oncovin®), prednisone, a hedgehog signaling inhibitor, and combinations thereof.

[0299] In another embodiment, the present invention provides a method of treating multiple myeloma comprising administering to a patient in need thereof a compound of the present invention and one or more additional therapeutic agents selected from bortezomib (Velcade®), and dexamethasone (Decadron®), a hedgehog signaling inhibitor, a BTK inhibitor, a JAK / pan-JAK inhibitor, a TYK2 inhibitor, a PI3K inhibitor, a SYK inhibitor, in combination with lenalidomide (Revlimid®).

[0300] In another embodiment, the present invention provides a method of treating Waldenstrom's Macroglobulinemia comprising administering to a patient in need thereof a compound of the present invention and one or more additional therapeutic agents selected from chlorambucil (Leukeran®), cyclophosphamide (Cytoxan®, Neosar®), fludarabine (Fludara®), cladribine (Leustatin®), rituximab (Rituxan®), hedgehog signaling inhibitors, BTK inhibitors, JAK / pan-JAK inhibitors, TYK2 inhibitors, PI3K inhibitors, and SYK inhibitors.

[0301] In another embodiment, the present invention provides a method of treating or lessening the severity of a disease comprising administering to a patient in need thereof a compound of the present invention and a BTK inhibitor, wherein the aforementioned diseases include inflammatory bowel disease, arthritis, systemic lupus erythematosus (SLE), vasculitis, idiopathic thrombocytopenic purpura (ITP), rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, ordothyroiditis, Graves' disease, autoimmune thyroiditis, Sjogren's syndrome, multiple sclerosis, systemic sclerosis, Lyme neuroborreliosis, Guillain-Barré syndrome, acute disseminated encephalomyelitis, Addison's disease, opsoclonus-myoclonus syndrome, ankylosing spondylosis, antiphospholipid syndrome, aplastic anemia, autoimmune hepatitis, autoimmune gastritis, pernicious anemia, celiac disease, Goodpasture's syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma, primary biliary Hepatic cirrhosis, Reiter's syndrome, Takayasu's arteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis, alopecia universalis, Behçet's disease, chronic fatigue, autonomic neuropathy, membranous glomerular nephropathy, endometrial cancer, interstitial cystitis, pemphigus vulgaris, bullous pemphigoid, neuromyotonia, scleroderma, vulvodynia, hyperproliferative disorders, rejection of transplanted organs or tissues, acquired immune deficiency syndrome (AIDS, also known as HIV), type 1 diabetes, graft-versus-graft syndrome, Host disease, transplantation, blood transfusion, anaphylaxis, allergy (e.g., allergy to pollen, latex, drugs, food, insect venom, animal hair, animal dander, dust mites, or cockroach calix), type I hypersensitivity, allergic conjunctivitis, allergic rhinitis, and atopic dermatitis, asthma, appendicitis, atopic dermatitis, asthma, allergy, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic graft rejection, Colitis, conjunctivitis, Crohn's disease, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, small intestine colitis, epicondylitis, epididymitis, fasciitis, fibromyalgia, gastritis, gastroenteritis, Henoch-Schönlein purpura, hepatitis, sweat gland abscess, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, ulcerative colitis, uveitis, vaginitis, vasculitis, or vulvitis, B cell proliferative disorders, e.g., diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, acute lymphocytic leukemia, B cell prolymphocytic leukemia , lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, multiple myeloma (also known as plasma cell myeloma), non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmacytoma, extranodal marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma / leukemia, or lymphomatoid granulomatosis, breast cancer, prostate cancer, or or mast cell cancer (e.g., mastocytoma, mast cell leukemia, mast cell sarcoma, systemic mastocytosis), bone cancer, colorectal cancer, pancreatic cancer, bone and joint diseases including, but not limited to: rheumatoid arthritis, seronegative spondyloarthropathy (including ankylosing spondylitis, psoriatic arthritis, and Reiter's disease), Behcet's disease, Sjogren's syndrome, systemic sclerosis, osteoporosis, bone cancer, bone metastases, thromboembolic disorders, (e.g., myocardial infarction, angina pectoris, reocclusion after angioplasty, restenosis after angioplasty , reocclusion after aortocoronary artery bypass, restenosis after aortocoronary artery bypass, stroke, transient ischemia, peripheral arterial occlusive disorder, pulmonary embolism, deep vein thrombosis), inflammatory pelvic disease, urethritis, photodermatitis, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, gastritis, enteritis, dermatitis, gingivitis, appendicitis, pancreatitis, cholecystitis (cholocystitus), agammaglobulinemia, psoriasis, allergy, Crohn's disease, irritable bowel syndrome, ulcerative colitis, Sjogren's disease, tissue graft rejection,Hyperacute rejection of transplanted organs, asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome), autoimmune alopecia, pernicious anemia, glomerulonephritis, dermatomyositis, multiple sclerosis, scleroderma, vasculitis, autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome, atherosclerosis, Addison's disease, Parkinson's disease, Alzheimer's disease, diabetes, septic shock, systemic lupus erythematosus The disease is selected from systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, osteoarthritis, chronic idiopathic thrombocytopenic purpura, Waldenstrom's macroglobulinemia, myasthenia gravis, Hashimoto's thyroiditis, atopic dermatitis, degenerative joint disease, vitiligo, autoimmune hypopituitarism, Guillain-Barre syndrome, Behcet's disease, scleroderma, mycosis fungoides, acute inflammatory responses (such as acute respiratory distress syndrome and ischemia / reperfusion injury), and Graves' disease.

[0302] In another embodiment, the present invention provides a method of treating or lessening the severity of a disease comprising administering to a patient in need thereof a compound of the present invention and a PI3K inhibitor, wherein the disease is selected from cancer, a neurodegenerative disorder, an angiogenic disorder, a viral disease, an autoimmune disease, an inflammatory disorder, a hormone-related disease, a condition associated with organ transplantation, an immunodeficiency disorder, a destructive bone disorder, a proliferative disorder, an infectious disease, a condition associated with cell death, thrombin-induced platelet aggregation, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), a liver disease, a pathological immune condition involving T-cell activation, a cardiovascular disorder, a CNS disorder.

[0303] In another embodiment, the present invention provides a method of treating or lessening the severity of a disease comprising administering to a patient in need thereof a compound of the present invention and a PI3K inhibitor, wherein the disease is a benign or malignant tumor, carcinoma, or solid tumor of the brain, kidney (e.g., renal cell carcinoma (RCC)), liver, adrenal gland, bladder, breast, stomach, gastric tumor, ovary, colon, rectum, prostate, pancreas, lung, vagina, endometrium, cervix, testis, genitourinary tract, esophagus, larynx, skin, bone, or thyroid, sarcoma, glioblastoma, neuroblastoma, multiple myeloma, or gastrointestinal cancer, in particular colon cancer or or colorectal adenoma or tumors of the head and neck, epithelial hyperproliferation, psoriasis, prostatic hyperplasia, neoplasia, epithelial neoplasia, adenoma, adenocarcinoma, keratoacanthoma, epithelioid carcinoma, large cell carcinoma, non-small cell lung cancer, lymphoma (including, for example, non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (also called Hodgkin or Hodgkin's disease)), breast cancer, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, or leukemia, Cowden's syndrome, Lhermitte-Dudos disease disease), and diseases including Banayan-Zonana syndrome, or diseases in which the PI3K / PKB pathway is abnormally activated, asthma of any type or genesis (including both intrinsic (non-allergic) asthma and extrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, bronchitic asthma, exercise-induced asthma, occupational asthma, and asthma induced after bacterial infection), acute lung injury (ALI), adult / acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease, airway disease, or lung disease (COPD, COAD, or COLD) (including associated chronic bronchitis or dyspnea), emphysema, as well as exacerbations of airway hyperresponsiveness as a result of other medications, especially other inhaled medications, bronchitis of any type or genesis (acute, arachidonic, catarrhal, creeping, bronchitis, chronic or tuberculous), pneumoconiosis of any type or origin (an inflammatory, generally occupational, lung disease, whether chronic or acute, frequently accompanied by obstruction of the airways and caused by repeated inhalation of dust) (e.g., aluminum lung disease, anthracosis, asbestosis, lithotripsy, trichiasis, siderosis, silicosis, tobacconosis, and byssinosis), Löffler's syndrome, eosinophilic pneumonia, parasitic (especially metazoan) infestations (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), eosinophil-related disorders affecting the airways caused by eosinophilic granulomas and drug reactions, psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivityVasculitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphigus, epidermolysis bullosa acquisita, conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis, diseases affecting the nose, including allergic rhinitis, and inflammatory diseases involving an autoimmune response or with an autoimmune component or etiology, including autoimmune blood disorders (e.g., hemolytic anemia, aplastic anemia, vera erythrocytic anemia, and idiopathic thrombocytopenia), systemic lupus erythematosus, rheumatoid arthritis, polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Stevens-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease), endocrine eye disorders, opthalmopathy, Graves' disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary cirrhosis, uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial pulmonary fibrosis, psoriatic arthritis and glomerulonephritis with or without nephrotic syndrome (including, for example, idiopathic nephrotic syndrome or minimal change nephropathy), restenosis, cardiac hypertrophy, atherosclerosis, myocardial infarction, ischemic stroke and congestive heart failure, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and cerebral ischemia, as well as neurodegenerative diseases caused by trauma, glutamate neurotoxicity, and hypoxia.

[0304] The compounds and compositions according to the method of the present invention can be administered in any amount and using any route of administration effective for treating or reducing the severity of cancer, autoimmune disorders, proliferative disorders, inflammatory disorders, neurodegenerative or psychiatric disorders, schizophrenia, bone-related disorders, liver disease or cardiac disorders. The exact amount required will vary from subject to subject, depending on the subject's race, age and general condition, the severity of the infection, the specific drug, its mode of administration, and the like. The compounds of the present invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression "dosage unit form" as used herein refers to a physically discrete unit of drug appropriate for the patient to be treated. However, it will be understood that the total daily usage of the compounds and compositions of the present invention will be determined by the attending physician within the scope of sound medical judgment. The specific effective amount for any particular patient or organism will be determined by the attending physician within the scope of sound medical judgment. The appropriate dose level will depend on a variety of factors, including the disorder being treated and the severity of the disorder, the activity of the specific compound used, the specific composition used, the age, weight, general health, sex and diet of the patient, the time of administration, the route of administration, and the rate of excretion of the specific compound used, the duration of treatment, drugs used in combination or concomitantly with the specific compound used, and similar factors well known in the medical art. The term "patient", as used herein, means an animal, preferably a mammal, and most preferably a human.

[0305] The pharma- ceutically acceptable compositions of the invention can be administered to humans and other animals orally, rectally, parenterally, intravesically, intravaginally, intraperitoneally, topically (such as by powders, ointments or drops), buccally, as oral sprays or nasal drops, etc., depending on the severity of the infection being treated. In certain embodiments, the compounds of the invention can be administered orally or parenterally at dosage levels of about 0.01 mg / kg to about 50 mg / kg of subject's body weight per day, and preferably about 1 mg / kg to about 25 mg / kg of subject's body weight per day, one or more times per day to obtain the desired therapeutic effect.

[0306] Liquid dosage forms for oral administration include, but are not limited to, pharma- ceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.In addition to active compounds, liquid dosage forms can contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof.In addition to inert diluents, oral compositions can also contain adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavorings and aromatics.

[0307] According to known techniques, suitable dispersing or wetting agents and suspending agents can be used to formulate injection preparations, for example, injectable sterile aqueous or oleaginous suspensions. Sterile injection preparations can also be injectable sterile solutions, suspensions or emulsions in non-toxic parenterally acceptable diluents or solvents, for example, as solutions in 1,3-butanediol. Among the acceptable vehicles and solvents that can be used are water, Ringer's solution, USP, and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally used as a solvent or suspending medium. For this purpose, any non-irritating fixed oil can be used, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injections.

[0308] Injectable preparations can be sterilized prior to use, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other injectable sterile medium.

[0309] In order to prolong the effect of the compounds of the present invention, it is often desirable to slow down the absorption of the compounds from subcutaneous or intramuscular injection. This can be accomplished by using a liquid suspension of crystalline or amorphous material with poor water solubility. The absorption rate of the compound then depends on its dissolution rate, which in turn may depend on the crystal size and crystalline form. Alternatively, the absorption of parenterally administered compound forms is delayed by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsulated matrices of the compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of compound to polymer and the particular polymer used, the absorption rate can be adjusted to suit the individual needs. Depending on the nature of the polymer, the release rate of the compound can be controlled.Other examples of biodegradable polymers include poly(orthoesters) and poly(anhydrides).Injectable depot preparations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.

[0310] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing a compound of the invention with a suitable non-irritating excipient or carrier such as cocoa butter, polyethylene glycol or a suppository wax which is solid at ambient temperature but liquid at body temperature and therefore will melt in the rectum or vaginal cavity and release the active compound.

[0311] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert pharma- ceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate, and / or a) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants, such as glycerol, d) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents, such as paraffin, f) absorption accelerators, such as quaternary ammonium compounds, g) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents, such as kaolin and bentonite clay, and i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

[0312] Solid compositions of a similar type may also be used as fillers in soft and hard filled gelatin capsules using excipients such as lactose or milk sugar, and high molecular weight polyethylene glycols. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical compounding art. They may also optionally contain opacifying agents, which may be of a composition that releases the active ingredient(s) solely or preferentially in a certain part of the intestinal tract, optionally with a delayed release. Examples of embedding compositions that may be used include polymeric substances and waxes. Solid compositions of a similar type may also be used as fillers in soft and hard filled gelatin capsules using excipients such as lactose or milk sugar, and high molecular weight polyethylene glycols.

[0313] The active compound can also be in microencapsulated form with one or more excipients as described above. The solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical compounding art. In such solid dosage forms, the active compound can be mixed with at least one inert diluent, such as sucrose, lactose or starch. Such dosage forms can also contain, as is normal practice, additional substances other than the inert diluent, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, these dosage forms can also contain buffering agents. They can also optionally contain opacifying agents, which can be of such composition that they release the active ingredient(s) alone or preferentially in a certain part of the intestinal tract, optionally with a delay. Examples of embedding compositions that can be used include polymeric substances and waxes.

[0314] Dosage forms for topical or transdermal administration of the compounds of the present invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active ingredient is mixed under sterile conditions with a pharma- ceutically acceptable carrier and any necessary preservatives or buffers that may be required. Ophthalmic formulations, ear drops and eye drops are also contemplated to be within the scope of the present invention. In addition, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of the compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in a suitable medium. Absorption enhancers can also be used to increase the flux of the compound through the skin. The rate can be controlled by either providing a rate-controlling membrane or by dispersing the compound in a polymer matrix or gel.

[0315] According to one embodiment, the present invention relates to a method for inhibiting carbonic anhydrase activity in a biological sample, comprising the step of contacting said biological sample with a compound of the present invention, or a composition comprising said compound.

[0316] According to another embodiment, the present invention relates to a method of inhibiting metalloprotease activity in a biological sample, comprising the step of contacting said biological sample with a compound of the present invention, or a composition comprising said compound.

[0317]

[0318] According to another embodiment, the present invention relates to a method for irreversibly inhibiting the activity of CAIX, MT1-MMP, CD38, EphA2 or PBP1A or a mutant thereof in a biological sample, comprising the step of contacting said biological sample with a compound of the present invention or a composition comprising said compound.

[0319] The term "biological sample" as used herein includes, but is not limited to, cell cultures or extracts thereof; biopsy material obtained from a mammal or extracts thereof; and blood, saliva, urine, stool, semen, tears or other bodily fluids or extracts thereof.

[0320] Inhibition of the activity of CAIX, MT1-MMP, CD38, EphA2, or PBP1A, or variants thereof, in a biological sample is useful for a variety of purposes known to those of skill in the art, including, but not limited to, biological assays.

[0321] Another embodiment of the invention relates to a method of inhibiting carbonic anhydrase or metalloprotease activity in a patient, comprising the step of administering to said patient a compound of the invention or a composition comprising said compound.

[0322] According to another embodiment, the present invention provides a method for inhibiting the activity of CAIX, MT1-MMP, CD38, EphA2 or PBP1A or a mutant thereof in a patient, comprising administering to said patient a compound of the present invention or a composition comprising said compound.In another embodiment, the present invention provides a method for treating a disorder mediated by CAIX, MT1-MMP, CD38, EphA2 or PBP1A or a mutant thereof in a patient in need of such treatment, comprising administering to said patient a compound according to the present invention or a pharma- ceutically acceptable composition thereof.Such disorders are described in detail herein.

[0323] Depending on the particular condition, or disease, being treated, additional therapeutic agents, which are normally administered to treat that condition, may also be present in the compositions of this invention. As used herein, additional therapeutic agents that are normally administered to treat a particular disease or condition are known as "appropriate for the disease or condition being treated."

[0324] The compounds of the present invention can also be used to advantage in combination with other antiproliferative compounds. Such antiproliferative compounds include, but are not limited to, aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule active compounds; alkylating compounds; histone deacetylase inhibitors; compounds that induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; antineoplastic antimetabolites; platinum compounds; compounds that target / reduce protein or lipid kinase activity, and even antiangiogenic compounds; compounds that target, reduce or inhibit protein or lipid phosphatases; gonadorelin agonists; antiandrogens; methionine aminopeptides. idase inhibitors;matrix metalloproteinase inhibitors;bisphosphonates;biological response modifiers;antiproliferative antibodies;heparanase inhibitors;inhibitors of Ras oncogenic isoforms;telomerase inhibitors;proteasome inhibitors;compounds used in the treatment of hematological malignancies;compounds that target Flt-3 and reduce or inhibit its activity;Hsp90 inhibitors (17-AAG (17-allylaminogeldanamycin, NSC330507), 17-DMAG (17-dimethylaminoethylamino-17-demethoxy-geldanamycin, NSC707545), IPI-504, CNF1010, CNF2024, CNF1010 (Conforma Therapeutics); temozolomide (Temodal®); kinesin spindle protein inhibitors (such as SB715992 or SB743921 from GlaxoSmithKline, or pentamidine / chlorpromazine from CombinatoRx); MEK inhibitors (such as ARRY142886 from Array BioPharma, AZd6244 from AstraZeneca, PD181461 and leucovorin from Pfizer). The term "aromatase inhibitor", as used herein, relates to a compound that inhibits estrogen production, for example the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively.The term includes, but is not limited to, steroids, especially atamestane, exemestane and formestane, and nonsteroids, especially aminoglutethimide, rogletimide, pyridoglutethimide, trilostane, testolactone, ketoconazole, vorozole, fadrozole, anastrozole and letrozole. Exemestane is marketed under the trade name Aromasin™. Formestane is marketed under the trade name Lentaron™. Fadrozole is marketed under the trade name Afema™. Anastrozole is marketed under the trade name Arimidex™. Letrozole is marketed under the trade name Femara™ or Femar™. Aminoglutethimide is marketed under the trade name Orimeten™. The combinations of the present invention that include a chemotherapeutic agent that is an aromatase inhibitor are particularly useful for the treatment of hormone receptor positive tumors, such as breast tumors.

[0325] The term "anti-estrogen" as used herein refers to a compound that antagonizes the action of estrogen at the estrogen receptor level. This term includes, but is not limited to, tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride. Tamoxifen is marketed under the trade name Nolvadex™. Raloxifene hydrochloride is marketed under the trade name Evista™. Fulvestrant can be administered under the trade name Faslodex™. The combination of the present invention that includes a chemotherapeutic agent that is an anti-estrogen is particularly useful for treating estrogen receptor positive tumors, such as breast tumors.

[0326] The term "antiandrogen" as used herein refers to any substance capable of inhibiting the biological action of androgenic hormones, including, but not limited to, bicalutamide (Casodex™). The term "gonadorelin agonist" as used herein includes, but is not limited to, abarelix, goserelin and goserelin acetate. Goserelin can be administered under the brand name Zoladex™.

[0327] The term "topoisomerase I inhibitors" as used herein includes, but is not limited to, topotecan, gimatecan, irinotecan, camptothecin and its analog 9-nitrocamptothecin, and the macromolecule camptothecin conjugate PNU-166148. Irinotecan can be administered, for example, in the form marketed, for example, under the trademark Camptosar™. Topotecan is marketed under the trademark Hycamptin™.

[0328] The term "topoisomerase II inhibitors" as used herein includes, but is not limited to, doxorubicin (including liposomal formulations such as Caelyx™), daunorubicin, epirubicin, anthracyclines such as idarubicin and nemorubicin, the anthraquinones mitoxantrone and rosoxantrone, and the podophyllotoxins etoposide and teniposide. Etoposide is marketed under the trade name Etopophos™. Teniposide is marketed under the trade name VM26-Bristol. Doxorubicin is marketed under the trade names Acriblastin™ or Adriamycin™. Epirubicin is marketed under the trade name Farmorubicin™. Idarubicin is marketed under the trade name Zavedos™. Mitoxantrone is marketed under the trade name Novantron.

[0329] The term "microtubule activator" refers to microtubule stabilizing compounds, microtubule destabilizing compounds and microtubule polymerization inhibitors, including, but not limited to, taxanes such as paclitaxel and docetaxel; vinca alkaloids such as vinblastine or vinblastine sulfate, vincristine or vincristine sulfate and vinorelbine; discodermolides; colchicine and epothilones and their derivatives. Paclitaxel is marketed under the trade name Taxol™. Docetaxel is marketed under the trade name Taxotere™. Vinblastine sulfate is marketed under the trade name Vinblastin RP™. Vincristine sulfate is marketed under the trade name Farmistin™.

[0330] The term "alkylating agent" as used herein includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan, or nitrosourea (BCNU or Gliadel). Cyclophosphamide is marketed under the trade name Cyclostin™. Ifosfamide is marketed under the trade name Holoxan™.

[0331] The term "histone deacetylase inhibitors" or "HDAC inhibitors" relates to compounds which inhibit histone deacetylase and which possess antiproliferative activity, including but not limited to suberoylanilide hydroxamic acid (SAHA).

[0332] The term "antineoplastic antimetabolites" includes, but is not limited to, 5-fluorouracil or 5-FU, capecitabine, gemcitabine, DNA demethylating compounds (such as 5-azacytidine and decitabine), methotrexate and edatrexate, and folate antagonists (such as pemetrexed). Capecitabine is marketed under the trade name Xeloda™. Gemcitabine is marketed under the trade name Gemzar™.

[0333] The term "platin compound" as used herein includes, but is not limited to, carboplatin, cisplatin, cisplatinum and oxaliplatin. Carboplatin can be administered, e.g., in the form as it is marketed, e.g., under the trademark Carboplat™. Oxaliplatin can be administered, e.g., in the form as it is marketed, e.g., under the trademark Eloxatin™.

[0334] The term "compounds that target / increase protein or lipid kinase activity; or protein or lipid phosphatase activity; or even anti-angiogenic compounds" as used herein includes, but is not limited to, a) compounds that target platelet derived growth factor receptor (PDGFR) and reduce or inhibit its activity, such as compounds that inhibit the PDGF receptor, such as N-phenyl-2-pyrimidine-amine derivatives, such as imatinib, SU101, SU6668 and GFB-111, b) compounds that target fibroblast growth factor receptor (FGFR) and reduce or inhibit its activity, c) compounds that target insulin-like growth factor receptor I (IGF-IR) and reduce or inhibit its activity, such as compounds that inhibit the kinase activity of the IGF-I receptor, or antibodies that target the extracellular domain of the IGF-I receptor or its growth factors. d) compounds that target the Trk receptor tyrosine kinase family and reduce or inhibit their activity or ephrin B4 inhibitors; e) compounds that target the Axl receptor tyrosine kinase family and reduce or inhibit their activity; f) compounds that target the Ret receptor tyrosine kinase and reduce or inhibit its activity; g) compounds that target the Kit / SCFR receptor tyrosine kinase such as imatinib and reduce or inhibit its activity; h) compounds that target the c-Kit receptor tyrosine kinase such as imatinib and reduce or inhibit its activity; Compounds that target and decrease or inhibit the activity of the tyrosine kinase family, in particular compounds that target and decrease or inhibit the activity of the C-kit receptor tyrosine kinase, which is part of the PDGFR family, such as compounds that inhibit the c-Kit receptor, such as imatinib: i) N-phenyl-2-pyrimidine-amine derivatives, such as imatinib or nilotinib (AMN107); PD180970; AG957; NSC680410; PD173955 from ParkeDavis;or dasatinib (BMS-354825), j) compounds that target and reduce or inhibit the activity of members of the c-Abl family, their gene fusion products (e.g. BCR-Abl kinase) and mutants, including compounds that target and reduce or inhibit the activity of c-Abl family members and their gene fusion products, such as dasatinib (BMS-354825); j) compounds that target and reduce or inhibit the activity of members of the cyclin-dependent kinase family (CDK), including members of the protein kinase C (PKC) and Raf families of serine / threonine kinases, MEK, SRC, JAK / pan-JAK, FAK, PDK1, PKB / Akt, Ras / MAPK, PI3K, SYK, TYK2, BTK and TEC families, and / or staurosporine derivatives such as midostaurin (further examples of compounds include UCN-01, safingol, BAY43-9006, bryostatin 1, perifossin, Perifosine; llmofosine; RO318220 and RO320432; GO6976; lsis3521; LY333531 / LY379196; isoquinoline compounds; FTIs; PD184352 or QAN697 (P13K inhibitors) or AT7519 (CDK inhibitors); k) imatinib mesylate (Gleevec™) or tyrphostin (tyrphostin A23 / RG Targeted protein-tyrosine kinase inhibitors, including -50810;AG99;Tyrphostin AG213;Tyrphostin AG1748;Tyrphostin AG490;Tyrphostin B44;Tyrphostin B44 (+) enantiomer;Tyrphostin AG555;AG494;Tyrphostin AG556, AG957, etc.) and Adaphostin (4-{[(2,5-dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl ester;NSC680410, Adaphostin); l) compounds that target, reduce or inhibit the activity of protein tyrosine kinase inhibitors, such as compounds that target, reduce or inhibit the activity of protein tyrosine kinase inhibitors, l) compounds that target, reduce or inhibit the activity of epidermal growth factor receptor family, in particular compounds, proteins or antibodies that inhibit members of the EGF receptor tyrosine kinase family such as EGF receptor, ErbB2, ErbB3 and ErbB4, or that bind to EGF or EGF related ligands, CP358774, ZD1839, ZM105180; trastuzumab (Herceptin™), cetuximab (Erbitux™), Iressa, Tarceva, OSI-774, Cl-1033, EKB-569, GW-2016, E1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 or E7.6.Compounds which target, reduce or inhibit the activity of the epidermal growth factor family of receptor tyrosine kinases (EGFR1, ErbB2, ErbB3, ErbB4 as homodimers or heterodimers) and their mutants, such as 3 and 7H-pyrrolo-[2,3-d]pyrimidine derivatives, m) compounds which target, reduce or inhibit the activity of c-Met, in particular compounds which inhibit the kinase activity of the c-Met receptor or the extracellular domain of c-Met. n) compounds that target, decrease or inhibit the activity of the c-Met receptor, such as antibodies that target c-Met receptor or bind to HGF, n) compounds that inhibit one or more JAK family members (JAK1 / JAK2 / JAK3 / TYK2 and / or TYK3), including but not limited to PRT-062070, SB-1578, baricitinib, pacritinib, momelotinib, VX-509, AZD-1480, TG-101348, tofacitinib and ruxolitinib o) compounds that target PI3 kinase (PI3K) and decrease or inhibit its kinase activity, including, but not limited to, ATU-027, SF-1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparlisib, pictorelisib, PF-4691502, BYL-719, dactolisib, XL-147, XL-765, and idelalisib. and q) protein tyrosine kinase and / or serine and / or threonine kinase inhibitors or lipid kinase inhibitors, such as compounds that target, reduce or inhibit the signaling action of the Hedgehog protein (Hh) or Smoothened receptor (SMO) pathways, including, but not limited to, cyclopamine, vismodegib, itraconazole, erysmodegib and IPI-926 (salidegib).

[0335] The term "PI3K inhibitor" as used herein includes, but is not limited to, compounds that have inhibitory activity against one or more enzymes in the phosphatidylinositol-3-kinase family, including, but not limited to, PI3K α, PI3K γ, PI3K δ, PI3K β, PI3K-C2 α, PI3K-C2 β, PI3K-C2 γ, Vps34, p110-α, p110-β, p110-γ, p110-δ, p85-α, p85-β, p55-γ, p150, p101 and p87. Examples of PI3K inhibitors useful in the present invention include, but are not limited to, ATU-027, SF-1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparlisib, pictorelisib, PF-4691502, BYL-719, dactolisib, XL-147, XL-765, and idelalisib.

[0336] The term "BTK inhibitor" as used herein includes, but is not limited to, compounds that have inhibitory activity against Bruton's tyrosine kinase (BTK), including, but not limited to, AVL-292 and ibrutinib.

[0337] The term "SYK inhibitor" as used herein refers to an agent that has inhibitory activity against spleen tyrosine kinase (SYK), including, but not limited to, PRT-062070, R-343, R-333, Excellair, PRT-062607, and fostamatinib. Compounds having the formula:

[0338] Further examples of BTK inhibitory compounds, and conditions treatable by such compounds in combination with the compounds of the present invention, can be found in WO2008039218 and WO2011090760, which are incorporated by reference in their entireties.

[0339] Further examples of SYK inhibitory compounds, and conditions treatable by such compounds in combination with the compounds of the present invention, can be found in WO2003063794, WO2005007623, and WO2006078846, which are incorporated by reference in their entireties.

[0340] Further examples of PI3K inhibitory compounds, and conditions treatable by such compounds in combination with the compounds of the present invention, can be found in WO2004019973, WO2004089925, WO2007016176, US8138347, WO2002088112, WO2007084786, WO2007129161, WO2006122806, WO2005113554 and WO2007044729, which are incorporated by reference in their entireties.

[0341] Further examples of JAK inhibitory compounds, and conditions treatable by such compounds in combination with the compounds of the present invention, can be found in WO2009114512, WO2008109943, WO2007053452, WO2000142246, and WO2007070514, which are incorporated by reference in their entireties.

[0342] Additional anti-angiogenic compounds include compounds that have another mechanism for their activity unrelated to, for example, protein or lipid kinase inhibition, such as thalidomide (Thalomid™) and TNP-470.

[0343] Examples of proteasome inhibitors useful for use in combination with the compounds of the invention include, but are not limited to, bortezomib, disulfiram, epigallocatechin-3-gallate (EGCG), salinosporamide A, carfilzomib, ONX-0912, CEP-18770, and MLN9708.

[0344] Compounds which target protein or lipid phosphatases, decreasing or inhibiting their activity are, for example, inhibitors of phosphatase 1, phosphatase 2A or CDC25, such as okadaic acid or a derivative thereof.

[0345] Compounds that induce cell differentiation processes include, but are not limited to, retinoic acid, α-, γ-, or δ-tocopherol, or α-, γ-, or δ-tocotrienol.

[0346] The term cyclooxygenase inhibitors as used herein includes, but is not limited to, Cox-2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acids and derivatives (such as celecoxib (Celebrex™), rofecoxib (Vioxx™), etoricoxib, valdecoxib, or 5-alkyl-2-arylaminophenylacetic acids (such as 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, lumiracoxib, etc.).

[0347] The term "bisphosphonates" as used herein includes, but is not limited to, etridonic acid, clodronic acid, tiludronic acid, pamidronic acid, alendronic acid, ibandronic acid, risedronic acid, and zoledronic acid. Etridonic acid is sold under the trade name Didro nel™. Clodronic acid is marketed under the trade name Bonefos™. Tiludronic acid is marketed under the trade name Skelid™. Pamidronic acid is marketed under the trade name Aredia™. Alendronic acid is marketed under the trade name Fosamax™. Ibandronic acid is marketed under the trade name Bondranat™. Risedronic acid is marketed under the trade name Actonel™. Zoledronic acid is marketed under the trade name Zometa™. The term "mTOR inhibitors" relates to compounds that inhibit the mammalian target of rapamycin (mTOR) and have antiproliferative activity, such as sirolimus (Rapamune®), everolimus (Certican™), CCI-779 and ABT578.

[0348] The term "heparanase inhibitors" as used herein refers to compounds that target, reduce or inhibit heparin sulfate degradation. This term includes, but is not limited to, PI-88. The term "biological response modifiers" as used herein refers to lymphokines or interferons.

[0349] The term "inhibitor of Ras oncogenic isoforms", such as H-Ras, K-Ras or N-Ras, as used herein, refers to compounds that target Ras and reduce or inhibit its oncogenic activity, for example, "farnesyltransferase inhibitors", such as L-744832, DK8G557 or R115777 (Zarnestra™).The term "telomerase inhibitor", as used herein, refers to compounds that target telomerase and reduce or inhibit its activity.The compounds that target telomerase and reduce or inhibit its activity are especially compounds that inhibit telomerase receptors, such as telomestatin.

[0350] The term "methionine aminopeptidase inhibitor" as used herein refers to a compound that targets, reduces or inhibits the activity of methionine aminopeptidase. Compounds that target, reduces or inhibit the activity of methionine aminopeptidase include, but are not limited to, bengamide or its derivatives.

[0351] The term "proteasome inhibitor" as used herein refers to a compound that targets the proteasome and reduces or inhibits its activity. Compounds that target the proteasome and reduces or inhibits its activity include, but are not limited to, bortezomib (Velcade™) and MLN341.

[0352] The term "matrix metalloproteinase inhibitors" or ("MMP" inhibitors), as used herein, includes, but is not limited to, collagen peptidomimetic inhibitors and non-peptidomimetic inhibitors, tetracycline derivatives, such as the hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogs marimastat (BB-2516), prinomastat (AG3340), metastat (NSC683551), BMS-279251, BAY12-9566, TAA211, MMI270B or AAJ996.

[0353] The term "compounds used in the treatment of hematological malignancies" as used herein includes, but is not limited to, FMS-like tyrosine kinase inhibitors, which are compounds that target, decrease or inhibit the activity of FMS-like tyrosine kinase receptor (Flt-3R); interferon, 1-β-D-arabinofuransylcytosine (ara-c) and bisulfan; and ALK inhibitors, which are compounds that target, decrease or inhibit anaplastic lymphoma kinase.

[0354] Compounds that target the FMS-like tyrosine kinase receptor (Flt-3R) and reduce or inhibit its activity are, inter alia, compounds, proteins or antibodies that inhibit members of the Flt-3R receptor kinase family, such as PKC412, midostaurin, staurosporine derivatives, SU11248 and MLN518.

[0355] The term "HSP90 inhibitors" as used herein includes, but is not limited to, compounds that target, reduce or inhibit the intrinsic ATPase activity of HSP90; compounds that degrade, target, reduce or inhibit HSP90 client proteins via the ubiquitin proteasome pathway. Compounds that target, reduce or inhibit the intrinsic ATPase activity of HSP90 are, among others, compounds, proteins or antibodies that inhibit the ATPase activity of HSP90, such as 17-allylamino, 17-demethoxygeldanamycin (17AAG), geldanamycin derivatives, other geldanamycin-related compounds; radicicol and HDAC inhibitors.

[0356] The term "antiproliferative antibody" as used herein includes, but is not limited to, trastuzumab (Herceptin™), trastuzumab-DM1, erbitux, bevacizumab (Avastin™), rituximab (Rituxan®), PRO64553 (anti-CD40) and 2C4 antibodies. By antibody is meant intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least two intact antibodies, and antibody fragments, so long as they exhibit the desired biological activity.

[0357] For the treatment of acute myeloid leukemia (AML), the compound of the present invention can be used in combination with standard leukemia therapy, especially in combination with therapy used for the treatment of AML.In particular, the compound of the present invention can be administered in combination with other drugs useful for the treatment of AML, such as, for example, farnesyltransferase inhibitors, and / or daunorubicin, adriamycin, Ara-C, VP-16, teniposide, mitoxantrone, idarubicin, carboplatinum and PKC412.

[0358] Other anti-leukemia compounds include, for example, the pyrimidine analog Ara-C, which is a 2'-alpha-hydroxyribose (arabinoside) derivative of deoxycytidine.Similarly, the purine analog of hypoxanthine, 6-mercaptopurine (6-MP) and fludarabine phosphate are included.Compounds that target, reduce or inhibit the activity of histone deacetylase (HDAC) inhibitors, such as sodium butyrate and suberoylanilide hydroxamic acid (SAHA), inhibit the activity of enzymes known as histone deacetylases. Specific HDAC inhibitors include compounds disclosed in US6,552,065, including but not limited to MS275, SAHA, FK228 (formerly FR901228), trichostatin A, and N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propanamide or its pharmaceutically acceptable salt and N-hydroxy-3-[4-[(2-hydroxyethyl){2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide or its pharmaceutically acceptable salt, especially lactate. Somatostatin receptor antagonist, as used herein, refers to compounds that target, treat or inhibit somatostatin receptors, such as octreotide and SOM230. Methods that damage tumor cells refer to methods such as ionizing radiation. The term "ionizing radiation" referred to above and hereafter means ionizing radiation that occurs either as electromagnetic rays (such as X-rays and gamma rays) or particles (such as alpha and beta particles). Ionizing radiation is provided in, but not limited to, radiation therapy and is known in the art. Hellman, Principles of Radiation Therapy, Cancer, Principles and Practice of Oncology, Dev. See Ita et al. (eds.), 4th ed., Vol. 1, pp. 248-275 (1993).

[0359] Similarly, EDG binders and ribonucleotide reductase inhibitors are included. The term "EDG binders" as used herein refers to a class of immunosuppressants that modulate lymphocyte recirculation, such as FTY720. The term "ribonucleotide reductase inhibitors" refers to pyrimidine or purine nucleoside analogs, including but not limited to fludarabine and / or cytosine arabinoside (ara-C), 6-thioguanine, 5-fluorouracil, cladribine, 6-mercaptopurine (particularly in combination with ara-C agonists for ALL), and / or pentostatin. Ribonucleotide reductase inhibitors are especially hydroxyurea or 2-hydroxy-1H-isoindole-1,3-dione derivatives.

[0360] Also included are VEGF compounds, proteins or monoclonal antibodies such as 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a pharma- ceutically acceptable salt thereof, 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate; Angiostatin™; Endostatin™; anthranilamide; ZD4190; Zd6474; SU5416; SU6668; bevacizumab; or anti-VEGF antibodies or anti-VEGF receptor antibodies such as rhuMAb and RHUFab, VEGF aptamers such as Macugon; FLT-4 inhibitors, FLT-3 inhibitors, VEGFR-2 IgGI antibodies, Angiozyme (RPI4610) and bevacizumab (Avastin™), among others.

[0361] Photodynamic therapy, as used herein, refers to a treatment that uses certain chemicals known as photosensitive compounds to treat or prevent cancer. Examples of photodynamic therapy include treatment with compounds such as Visudyne™ and porfimer sodium.

[0362] Angiogenic antisteroids, as used herein, refer to compounds that block or inhibit angiogenesis, such as, for example, anecortave, triamcinolone, hydrocortisone, 11-α-epihydrocortisol, cortexolone, 17α-hydroxyprogesterone, corticosterone, desoxycorticosterone, testosterone, estrone and dexamethasone.

[0363] Implants containing corticosteroids refer to compounds such as fluocinolone and dexamethasone.

[0364] Other chemotherapeutic compounds include, but are not limited to, plant alkaloids, hormonal compounds and antagonists; biological response modifiers, preferably lymphokines or interferons; antisense oligonucleotides or oligonucleotide derivatives; shRNA or siRNA; or miscellaneous compounds or compounds with other or unknown mechanisms of action.

[0365] The structures of the active compounds identified by code numbers, generic names or trade names can be taken from the actual edition of the standard abstract "The Merck Index" or from databases such as Patents International (eg IMS World Publications).

[0366] The compounds of the present invention may also be used in combination with known therapeutic processes, such as the administration of hormones or radiation. In certain embodiments, provided compounds are used as radiosensitizers, particularly to treat tumors that are poorly sensitive to radiation therapy. do.

[0367] The compounds of the present invention can be administered alone or in combination with one or more other therapeutic compounds, and possible combination therapy can be in the form of a fixed combination, or the compounds of the present invention and one or more other therapeutic compounds are administered at different times or independently of each other, or a fixed combination can be administered in combination with one or more other therapeutic compounds.The compounds of the present invention can be administered for tumor treatment in combination with other or additional, inter alia, chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical intervention or a combination thereof.Long-term treatment is equally possible in the context of other treatment strategies, as described above, as well as adjuvant therapy.Other possible treatments are, for example, treatments to maintain the patient's condition after tumor regression or even after chemopreventive treatment in patients at risk.

[0368] These additional agents may be administered separately from the composition containing the compound of the present invention as part of a multiple dose regimen. Alternatively, these agents may be part of a single dosage form, mixed together with the compound of the present invention in a single composition. When administered as part of a multiple dose regimen, the two active agents may be provided simultaneously, sequentially, or within a period of each other, usually within 5 hours of each other.

[0369] As used herein, the term "combination," "combined," and related terms refer to simultaneous or sequential administration of a therapeutic agent according to the present invention. For example, a compound of the present invention may be administered simultaneously or sequentially with another therapeutic agent in separate unit dosage forms, or may be administered together in a single dosage form. Thus, the present invention provides a single dosage form that includes a compound of the present invention, an additional therapeutic agent, and a pharma-ceutically acceptable carrier, adjuvant, or vehicle.

[0370] The amount of both the compounds of the present invention and additional therapeutic agents (in compositions containing additional therapeutic agents as described above) that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Preferably, the compositions of the present invention should be formulated so that a dosage of the compound of the present invention that is between 0.01-100 mg / kg body weight / day can be administered.

[0371] In compositions containing an additional therapeutic agent, such additional therapeutic agent and the compound of the present invention can act synergistically. Thus, the amount of additional therapeutic agent in such compositions will be less than that required in a monotherapy utilizing only that therapeutic agent. In such compositions, a dosage of the additional therapeutic agent between 0.01 and 1,000 μg / kg body weight / day can be administered.

[0372] The amount of additional therapeutic agent present in the compositions of the present invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably, the amount of additional therapeutic agent in the compositions of the present disclosure will be in the range of about 50% to 100% of the amount that would normally be present in a composition comprising that agent as the only therapeutically active agent. EXAMPLES

[0373] As illustrated in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures: While the general methods illustrate the synthesis of certain compounds of the invention, it will be understood that the following general methods, as well as other methods known to those of skill in the art, can be applied to all compounds as described herein, and each subclass and species of these compounds. Example 1: Scaffold Synthesis - Molecular Scaffold Reagents A and A' (MSR-A and MSR-A') [ka] 1.1.Process 1 [ka]

[0374] 3-(Bromomethyl)benzonitrile (5 g, 24.2 mmol) was added to a suspension of 4-toluenesulfonamide (2.2 g, 12 mmol) and potassium carbonate (5.2 g, 37.7 mmol) in dimethylacetamide (30 ml) and the reaction heated to 60° C. for 16 h. After cooling the mixture was filtered and the mother liquor diluted with ethyl acetate and water. The phases were separated, the organic layer dried (MgSO4) and the solvent evaporated to give the desired product as a brown solid (5.06 g). 1 H NMR(300 MHz,CDCl3)2.50(3H,s),4.30(4H,s),7.15(2H,s),7.35(6H,m),7.45(2H,m),7.75(2H,d).LCMS M+H + =402,C 23 H 19 N3O2S requires 401;RT=3.00 min. 1.2.Process 2 [ka]

[0375] Borane tetrahydrofuran (48 ml, 48 mmol, 1.0 M in tetrahydrofuran) was added dropwise to a solution of [2] (4.8 g, 12 mmol) in tetrahydrofuran (50 ml) under N2 and the reaction was stirred for 3 h. The reaction was quenched by the addition of saturated aqueous ammonium chloride and stirred for 1 h. The solvent was evaporated and dioxane (120 ml) was added. This was treated with 5 M HCl (100 ml) and the mixture was stirred for 20 h. The solvent was evaporated and the mixture was treated with dichloromethane to form a solid. The solvent was evaporated and the remaining aqueous layer was separated by decantation. The solid was washed with diethyl ether and dried in vacuo to give the desired product as the dihydrochloride salt (6.45 g). 1H NMR(300 MHz,DMSO)2.45(3H,s),3.90(4H,m),4.30(4H,s),7.10(2H,s),7.15-7.45(6H,m),7.50(2H,d),7.25(2H,d)8.50(6H,br s).LCMS M+H + =410,C 23 H 27 N3O2S requires 409;RT=1.05 min. 1.3.Process 3 [ka]

[0376] Potassium carbonate (2.9 g, 20.98 mmol) in water (20 ml) was added to a suspension of [3] (2 g, 4.15 mmol) in tetrahydrofuran (60 ml) and the mixture was stirred for 2 minutes. p-Toluenesulfonyl chloride (1.58 g, 8.29 mmol) in tetrahydrofuran (20 ml) was added and the mixture was stirred for 30 minutes. The reaction was heated to 65° C. under N2 for 16 hours. The reaction mixture was cooled to room temperature and the solvent was evaporated to give a crude oil. This was dissolved in ethyl acetate and water was added. The organic layer was collected and 2M Further washing with HCl, saturated brine, drying (MgSO4) and evaporation of the solvent gave a crude solid which was purified by chromatography (200 g silica, 30-40% ethyl acetate / iso-hexane) to give the desired product as a colourless solid (1.39 g). 1 H NMR(300 MHz, CDCl3)2.45(6H,s),2.50(3H,s),3.95(4H,d),4.20(4H,s),5.15(2H, t),6.90(2H,s),7.00(4H,m),7.15(2H,m),7.30(6H,m),7.75(6H,d).LCMS M+H + =718,C 37 H 39 N3O6S3 requires 717;RT=3.26 min. 1.4.Process 4 [ka]

[0377] A solution of α,α',dibromo-m-xylene (1.06 g, 4.01 mmol) in dimethylacetamide (40 ml) was added via syringe pump to a mixture of [4] (2.23 g, 3.11 mmol) and potassium carbonate (0.57 g, 4.13 mmol) in dimethylacetamide (310 ml) at 80° C. under nitrogen over 6 h, and the reaction was stirred for a further 90 min and then at room temperature for 18 h. The solvent was evaporated and the crude material was purified by chromatography (100 g, silica, 30-50% ethyl acetate / iso-hexane) to give the desired product as a white solid (2.28 g). 1 H NMR(300 MHz,DMSO)2.50(9H,s),4.05(12H,s),6.45(3H,s),6.95(6H,d),7.10(3H,t),7.45(6H,d),7.75(6H,d).LCMS M+H + =820,C 45 H 45 N3O6S3 requires 819; RT = 3.84 min 1.5.Process 5 [ka]

[0378] A solution of lithium aluminium hydride (12ml, 12mmol, 1.0M in tetrahydrofuran) was added to a solution of [5] (1g, 1.2mmol) in dry tetrahydrofuran (20ml) at room temperature. The reaction was heated to reflux for 4 hours and then cooled to room temperature. Diethyl ether (50ml) was added followed by water (1ml), sodium hydroxide (2M, 2ml) and water (1ml). The mixture was stirred vigorously for 1 hour. The resulting solid was filtered off and washed with tetrahydrofuran. The combined solvents were evaporated to give a crude gum. This was purified by SCX (20g cartridge) eluting with methanol followed by methanol containing 1% ammonium hydroxide and the desired fractions were collected and evaporated to give the product as a waxy solid (0.426g). 1H NMR(300 MHz,DMSO)3.65(12H,s),7.20(9H,m),7.60(3H,s).LCMS M+H + =358,C 24 H 27 N3 requires 357; RT=0.29 min 1.6.Process 6 [ka]

[0379] Chloroacetyl chloride (0.137 ml, 1.74 mmol) was added to a solution of [6] (0.2 g, 0.56 mmol) and triethylamine (0.312 ml, 2.24 mmol) in acetonitrile (10 ml) under N2 and the reaction was stirred for 1 h. The solvent was evaporated and the crude material was suspended in ethyl acetate and washed with water. The organic layer was dried (MgSO4) and the solvent was evaporated. The product (MSR-A) was isolated by trituration from diethyl ether as a light brown solid (280 mg). 1 H NMR(300 MHz,CDCl3)4.25(6H,s),4.50(12H,br s),6.75(3H,br s),7.30(9H,br m).LCMS M+H + =586,C 30 H 30 35 Cl3N3O3 requires 585; RT = 2.63 min 1.7.Process 7 [ka]

[0380] Acryloyl chloride (0.178 ml, 2.2 mmol) was added to a solution of [6] (0.253 g, 0.71 mmol) and triethylamine (0.395 ml, 2.83 mmol) in acetonitrile (10 ml) under N2 and the reaction was stirred for 1 h. The solvent was evaporated and the crude material was suspended in ethyl acetate and washed with water. The organic layer was dried (MgSO4) and the solvent was evaporated. The product (MSR-A') was isolated by trituration from diethyl ether as a light brown solid (182 mg). 1 LCMS M+H + =520,C 33 H 33 N3O3 requires 519;RT=2.28 min. Example 2: Peptide synthesis Molecular scaffolding reagents with leaving groups

[0381] Peptide synthesis was performed using the Symphony peptide synthesis kit manufactured by Peptide Instruments. The synthesis was based on Fmoc chemistry using a Tide synthesizer and a SyroII synthesizer from MultiSynTech. Standard Fmoc-amino acids with appropriate side chain protecting groups were used (Sigma, Merck): standard coupling conditions applicable in each case were used, followed by deprotection using standard methods. The peptides were purified using HPLC and after isolation, the peptides were modified with a molecular scaffolding reagent with a leaving group. For this, the linear peptide was diluted to about 35 mL with H2O, about 500 μL of 100 mM molecular scaffolding reagent in acetonitrile was added and the reaction was started with 5 mL of 1 M NH4HCO3 in water. The reaction was allowed to proceed for about 30-60 min at room temperature and, once the reaction was complete (as judged by MALDI), it was lyophilized. After lyophilization, the reaction mixture was loaded onto a Gemini C18 column (Phenomenex). The solvents (H2O, acetonitrile) were acidified with 0.1% trifluoroacetic acid. The gradient range was 30-70% acetonitrile for 15 min at a flow rate of 15-20 mL / min using a Gilson preparative HPLC system. Pure fractions containing the desired product were pooled, lyophilized, and kept at -20 °C for storage. Molecular scaffolding reagents containing Michael acceptors

[0382] Alternatively, the peptides were purified using HPLC and after isolation, the peptides were modified with a molecular scaffolding reagent containing a Michael acceptor. For this, the linear peptide was diluted to approximately 35 mL with 50:50 MeCN:H2O, approximately 500 μL of 100 mM Michael acceptor-containing molecular scaffolding reagent in acetonitrile was added, and the reaction was initiated with 5 mL of 1 M aqueous NH4HCO3. The reaction was allowed to proceed at room temperature for approximately 30-60 minutes, and upon completion (as determined by MALDI) the reaction was lyophilized. Upon completion, 1 mL of 1 M aqueous L-cysteine ​​hydrochloride monohydrate (Sigma) was added to the reaction at room temperature for approximately 60 minutes to quench any excess Michael acceptor-containing molecular scaffolding reagent.

[0383] After lyophilization, the modified peptide was purified as above, except that the Luna C8 was replaced with a Gemini C18 column (Phenomenex) and the acid was exchanged for 0.1% trifluoroacetic acid. Pure fractions containing the exact desired product were pooled, lyophilized, and kept at -20°C for storage.

[0384] All amino acids were used in the L-configuration unless otherwise stated.

[0385] The following linear peptides were prepared based on Fmoc chemistry using a Symphony peptide synthesizer from Peptide Instruments and a SyroII synthesizer from MultiSynTech. βAla-Sar10-AC(D-Ala)NE(1Nal)(D-Ala)CEDFYD(tBuGLy)C (SEQ ID NO: 1) βAla-Sar10-A-CTECWVDGWVPC (sequence number 2). AC(D-Ala)NE(1Nal)(D-Ala)CEDFYD(tBuGLy)C (SEQ ID NO: 3) Peptide 4: [ka] Ac-CTECWVDGWVPC (sequence number 4). Peptide 5: [ka] ACFWLDGECFDWHNHECA (SEQ ID NO:5) Peptide 6: [ka] ADVHCPWGPFWCPVNRPGCA (SEQ ID NO:6) Peptide 7: [ka] ACRYTSCPPYTVCA (SEQ ID NO: 7) Peptide 8: AC(D-Ala)NE(1Nal)(D-Ala)AEDFYD(tBuGLy)C (SEQ ID NO: 8) Peptide 9: [ka] Ac-CTEYWVDGWVPC (SEQ ID NO: 9) Peptide 10: [ka] Ac-YTECWVDGWVPY (SEQ ID NO: 10) Example 3. Preparation of cyclic peptides Cyclization Protocol

[0386] Linear peptides and all scaffolds were dissolved in acetonitrile / water 50 / 50 at a concentration of 5 mM. The peptide solutions were further diluted with 1 M ammonium bicarbonate (AMBIC) to a final concentration of 1 mM.

[0387] 3 ml of 1 mM linear peptide solution was mixed with 1 ml of 5 mM scaffold solution (linear peptide / scaffold molar ratio 1 / 1.6). The reaction mixture was kept at room temperature overnight and the completion of cyclization was confirmed by LC-MS (Acquity UPLC CSH C18 column, 1.7 μm, 2.1×30 mm; elution with acetonitrile / water / HCOOH-containing buffer and acetonitrile gradient from 15 to 60% over 10 min). The cyclic peptide was purified using RP-HPLC (Gemini C18-semi-preparative column, 5 μm, 110A, 250×10 mm; elution with acetonitrile / water / TFA-containing buffer and acetonitrile gradient from 20 to 80% over 20 min). The results of the cyclization protocol are provided in Table 3 below. Table 3. Results of the cyclization protocol. [Table 3-1] [Table 3-2] Example 4: CAIX Assay

[0388] CAIX competitive binding assay. The affinity (Ki) of the peptides of the invention for human CAIX is determined using a competitive fluorescence polarization assay similar to that described in Dubois et al. (2011) Radiotherapy and Oncology 99(3), 424-43, using A-(CAECWIDGWVPC)-A-Sar6-K(Fl), (SEQ ID NO: 11) as the fluorescent ligand.

[0389] The results of the CAIX competitive binding assay are reported in Table 4. Compounds designated as "A" have a Ki of less than 0.5 μM. Compounds designated as "B" have a Ki of 0.5 μM or greater and less than 1 μM. Compounds designated as "C" have a Ki of 1 μM or greater and less than 10 μM. Compounds designated as "D" have a Ki of 10 μM or greater. Table 4. CAIX competitive binding assay results (n=2). [Table 4] Example 5: Determination of dissociation rate constants of bicyclic binding agents to MT1-MMP Direct-binding fluorescence polarization (anisotropy) assay

[0390] Direct binding fluorescence polarization assays or anisotropy assays are performed by titrating a fixed concentration of a fluorescent tracer (here, the fluorescently labeled bicyclic peptide under study) with its binding partner (here, the MT1-MMP hemopexin domain). As the concentration of the binding partner increases during the titration, the polarization signal changes proportionally to the proportion of bound and unbound material. This allows the dissociation rate (K d ) is quantitatively determined. The assay data can be fitted using a standard ligand binding equation.

[0391] Typically, the concentration of the tracer is ideally well below the Kd of the tracer:titrant pair, with the concentration chosen usually being around 1 nM or less. The titrant (binding partner) concentration varies from 0.1 nM, typically up to 5 μM. The range is chosen so that the maximum fluorescence polarization change can be observed. The buffer used is phosphate buffered saline with 0.01% Tween. Experiments were performed in black 384-well low binding / low volume plates (Corning 3820) and the fluorescence polarization signal was measured using a BMG Pherastar FS plate reader. The fluorescent tracers mentioned in the text are bicyclic peptides that are fluorescently labeled using 5,6-carboxyfluorescein. The N-terminal amino group of the peptide, which is separated from the bicyclic core sequence by a sarcosine spacer (usually Sar5), may be fluorescently labeled. If the N-terminal amino group is unique to the peptide, this can be done during Fmoc solid phase synthesis or post-synthesis (after cyclization with a molecular scaffolding reagent and purification). Alternatively, the C-terminus can be fluorescently labeled, usually a lysine introduced as the first C-terminal residue, which is then separated from the Bicycle Core Sequence by a sarcosine spacer (usually Sar6). Thus, the N-terminal tracer can have the molecular format described as Fluo-Gly-Sar5-A(BicycleCoreSequence), and for C-terminally fluorescently labeled constructs, it can have the molecular format described as (BicycleCoreSequence)-A-Sar6-K(Fluo).

[0392] MT1-MMP direct binding fluorescence polarization results are reported in Table 5. Compounds designated as "A" have a K of less than 0.5 μM. i Compounds designated as "B" have a K of 0.5 μM or greater and less than 1 μM. i Compounds designated as "C" have a K of 1 μM or greater and less than 10 μM. i Compounds designated as "D" have a K of 10 μM or greater. i has. Table 5. MT1-MMP direct binding fluorescence polarization results (n=2). [Table 5] Example 6: Competitive assay using fluorescence polarization (anisotropy)

[0393] Due to their high affinity for the MT1-MMP hemopexin domain (PEX), fluorescently labeled derivatives of certain MT1-MMP-binding bivalent peptides can be used for competition experiments (using FP for detection). Here, a preformed complex of PEX with a fluorescent PEX-binding tracer is titrated using a free non-fluorescently labeled bicyclic peptide. Since the MT1-MMP-binding bicyclic peptide is expected to bind to the same site, the titrant will disassociate the fluorescent tracer from PEX. The dissociation of the complex can be quantitatively measured, as the K of the competitor (titrant) for the target protein. d The advantage of the competitive method is that the affinity of a non-fluorescently labeled bicyclic peptide can be determined accurately and quickly.

[0394] The concentration of the tracer is typically at or below the Kd (here, 1 nM) and the binding protein (here, hemopexin for MT1-MMP) is in 15-fold excess such that greater than 90% of the tracer is bound. Subsequently, a non-fluorescently labeled competitor bicyclic peptide (usually just the bicyclic core sequence) is titrated to displace the fluorescent tracer from the target protein. Displacement of the tracer is measured and correlated with a decrease in fluorescence polarization. The decrease in fluorescence polarization is proportional to the fraction of the target protein bound to the non-fluorescent titrant, and thus this decrease is a measure of the affinity of the titrant for the target protein.

[0395] The raw data are fitted to an analytical solution of a cubic equation that describes the equilibrium between the fluorescent tracer, the titrant, and the bound protein. The fit requires a value for the affinity of the fluorescent tracer for the target protein, which can be determined independently by direct binding FP experiments (see previous section). Curve fitting is performed using Sigmaplot 12.0, using an adapted version of the equation described by Zhi-Xin Wang (FEBS Letters 360 (1995) 1 11-1 14). Example 7: Preparation of Molecular Scaffold Reagent B (MSR-B) [ka]

[0396] 4-Cyanobenzyl bromide [9] (2.5 g, 12.8 mmol) was added portionwise to trifluoromethanesulfonic acid (3 ml, 33.9 mmol) under N2 at 0°C and the resulting mixture was stirred at room temperature for 18 h. It was poured onto a stirring ice / water mixture and basified with saturated aqueous sodium bicarbonate. The resulting solid was collected by filtration, washed with water and dried under reduced pressure to give the title compound (MSR-B) as a white solid (2.35 g, 94%). 1 H NMR(300 MHz,CDCl3)4.60(6H,s),7.60(6H,d),8.75(6H,d). 13 C NMR(75 MHz,CDCl3)32.7,129.3,129.4,136.1,142.3,171.1.LCMS M+H + =589,C 24 H 18 Br3N3 requires 588; RT=4.21 min. Example 8: Preparation of Molecular Scaffold Reagent C (MSR-C) [ka]

[0397] Step A: tert-Butyl 4-[4-[4,6-bis[4-(1-tert-butoxycarbonyl-4-piperidyl)piperazin-1-yl]-1,3,5-triazin-2-yl]piperazin-1-yl]piperidine-1-carboxylate

[0398] tert-Butyl 4-piperazin-1-ylpiperidine-1-carboxylate (650 mg, 2.41 mmol), cyanuric chloride (144 mg, 0.78 mmol), and diisopropylethylamine (1.35 mL, 7.75 mmol) were dissolved in dimethylacetamide (12 mL) and the reaction was stirred at 80° C. for 3 days. The reaction was added dropwise to stirring water (200 mL) and the resulting solid was isolated by filtration and dried under vacuum at 50° C. overnight. This was purified by chromatography (80 g cartridge, 0 to 10% MeOH / DCM) and the desired fractions were collected and evaporated to give the title compound as a tan solid (570 mg, 83%). 1 LCMS M+H + =884,C 45 H 78 N 12 O6 requires 883; RT=2.29 min.

[0399] Step B: 2,4,6-tris[4-(4-piperidyl)piperazin-1-yl]-1,3,5-triazine hydrochloride

[0400] 4M HCl in dioxane (5 mL) was added to a solution of tert-butyl 4-[4-[4,6-bis[4-(1-tert-butoxycarbonyl-4-piperidyl)piperazin-1-yl]-1,3,5-triazin-2-yl]piperazin-1-yl]piperidine-1-carboxylate (570 mg, 0.65 mmol) in dioxane (10 mL) and the reaction was stirred at room temperature for 18 hours. The reaction mixture was evaporated to give the title compound as a tan solid (440 mg, 98%).1 H NMR(300 MHz,DMSO)1.99(6H,m),2.30(6H,d),2.95(12H,m),3.48(21H,m),4.69(6H,d).LCMS M+H + =583,C 30 H 54 N 12 requires 582; RT=0.19 min.

[0401] Step C: 1-[4-[4-[4,6-bis[4-[1-(2-chloroacetyl)-4-piperidyl]piperazin-1-yl]-1,3,5-triazin-2-yl]piperazin-1-yl]-1-piperidyl]-2-chloro-ethanone

[0402] A solution of chloroacetic anhydride (428 mg, 2.51 mmol) in dichloromethane (10 mL) was added dropwise to a suspension of 2,4,6-tris[4-(4-piperidyl)piperazin-1-yl]-1,3,5-triazine hydrochloride (525 mg, 0.76 mmol) and diisopropylethylamine (812 μL, 4.55 mmol) in dichloromethane (30 mL) cooled to 0° C. and the reaction was stirred at 0° C. for 2 h. Diisopropylethylamine (812 μL, 4.55 mmol) and chloroacetic anhydride (428 mg, 2.51 mmol) in dichloromethane (10 mL) were added repeatedly and the reaction was stirred at 0° C. for an additional 1 h to obtain complete solution. The reaction was diluted with saturated aqueous sodium bicarbonate and dichloromethane and the phases were separated. The organic layer was dried (MgSO4) and the solvent was evaporated to give a crude oil. This was triturated with diethyl ether and then pentane to give the title compound (MSR-C) as a tan solid (401 mg, 68%). NMR (300 MHz, CDCl3) 1.52 (9H,m), 1.90 (6H,m), 2.55 (12H,m), 2.66 (3H,m), 3.12 (3H,m), 3.76 (12H,m), 3.92 (3H,d), 4.06 (6H,q), 4.59 (3H,d). LCMS M+H + =811,C 36 H 57 Cl3N 12O3 requires 810; RT=0.33 min. Example 9: Preparation of Molecular Scaffold Reagent D (MSR-D) [ka]

[0403] Step A: tert-Butyl 4-[[4,6-bis[(1-tert-butoxycarbonyl-4-piperidyl)amino]-1,3,5-triazin-2-yl]amino]piperidine-1-carboxylate

[0404] tert-Butyl 4-aminopiperidine-1-carboxylate (1.33 g, 6.70 mmol), cyanuric chloride (400 mg, 2.15 mmol), and diisopropylethylamine (3.76 mL, 21.58 mmol) were suspended in dioxane (30 mL) and the reaction was stirred at 80° C. overnight. An additional portion of tert-butyl 4-aminopiperidine-1-carboxylate (1.33 g, 6.70 mmol) was added and the mixture was stirred for 3 days. An additional portion of tert-butyl 4-aminopiperidine-1-carboxylate (1.33 g, 6.70 mmol) was added and the mixture was stirred for an additional 2 days. The reaction was diluted with ethyl acetate and washed with saturated aqueous sodium bicarbonate and then with brine. The organics were dried (MgSO4), filtered, and the solvent was evaporated to give a crude oil. This was purified by chromatography (80 g cartridge, 5 to 100% EtOAc / iso-hexane) and the desired fractions were collected and evaporated to give the title compound as a tan solid (1.202 g, 83%). 1 H NMR(300 MHz,CDCl3)1.35(6H,m),1.45(27H,s),1.95(6H,d),2.89(6H,t),3.95(6H,m),4.66(3H,bs).LCMS M+H + =676,C 33 H 57 N9O6 requires 675;RT=2.29 min.

[0405] Step B: N2,N4,N6-Tris(4-piperidyl)-1,3,5-triazine-2,4,6-triamine hydrochloride

[0406] 4M HCl in dioxane (10 mL) was dissolved in tert-butyl 4-[[4,6-bis[(1-tert-butoxycarbonyl-4-piperidyl)amino]-1,3,5-triazin-2-yl]amino]piperidine-1-carboxylate (695 mg, 1.0 mL). To a solution of 1,3-dichlorophenyl ether (3 mmol) in dioxane (10 mL) was added and the reaction was stirred at room temperature for 18 h. The reaction mixture was filtered and the filter cake was washed with diethyl ether and pentane and dried under vacuum to give the title compound as a tan solid (484 mg, 97%). 1 H NMR(300 MHz,DMSO)1.74(6H,m),1.99(6H,m),3.00(6H,m),3.28(6H,m),4.00(3H,m).LCMS M+H + =376,C 18 H 33 N9 requires 375; RT=0.19 min.

[0407] Step C: 2-chloro-1-[4-[[4-[[1-(2-chloroacetyl)-4-piperidyl]amino]-6-[[1-[1-(chloromethyl)vinyl]-4-piperidyl]amino]-1,3,5-triazin-2-yl]amino]-1-piperidyl]ethanone

[0408] A solution of chloroacetic anhydride (620 mg, 3.63 mmol) in dichloromethane (10 mL) was added dropwise to a 0° C. cooled suspension of N2,N4,N6-tris(4-piperidyl)-1,3,5-triazine-2,4,6-triamine hydrochloride (532 mg, 1.10 mmol) and diisopropylethylamine (1.15 mL, 6.60 mmol) in dichloromethane (30 mL) and the reaction was stirred at 0° C. for 2 h. The reaction was diluted with saturated aqueous sodium bicarbonate and dichloromethane and the phases were separated. The organic layer was dried (MgSO4) and the solvent evaporated to give a tan solid. This was trituated with diethyl ether then pentane to give the title compound (MSR-D) as a tan solid (540 mg, 81%). NMR(300 MHz,CDCl3)1.45(6H,m),2.07(6H,m),2.91(3H,t),3.25(3H,t),3.85(3H,d),4.07(9H,m),4.42(3H,d),4.69(3H,bs).LCMS M+H + =604,C 24 H 36 Cl3N9O3 requires 603;RT=1.25 min. Example 10: Preparation of Molecular Scaffold Reagent E (MSR-E) [ka]

[0409] Sulfuric acid (2 drops) was added to a solution of 4-cyanobenzyl bromide (1.64 g, 8.3 mmol) in dichloroethane (10 mL) and the reaction was heated to 90° C. To this was added a suspension of paraformaldehyde (500 mg, 5.55 mmol) and 4-cyanobenzyl bromide (1.64 g, 8.3 mmol) in dichloroethane (10 mL) dropwise and the resulting mixture was stirred at 90° C. for 5 hours. The reaction was cooled and the solid was filtered off and washed with methanol (3×). The combined organics were evaporated to give a crude solid. The solid was washed with ethyl acetate (3×) to give the title compound (MSR-E) as a white solid (963 mg, 26%). 1H NMR(300 MHz,CDCl3)4.65(6H,br s),5.35(6H,br s),7.40(12H,br s). 13 C NMR(75 MHz,CDCl3)33.9,62.8,126.5,128.2,129.7,140.9,169.2.LCMS M+H + =679,C 27 H 24 Br3N3O3 requires 678;RT=2.90 min. Example 11: Preparation of Molecular Scaffolding Reagent F (MSR-F) [ka]

[0410] Step A: tert-Butyl 4-[4-[4,6-bis[4-(4-tert-butoxycarbonylpiperazin-1-yl)phenyl]-1,3,5-triazin-2-yl]phenyl]piperazine-1-carboxylate

[0411] n-Butyllithium (1.6M in THF, 2.58 mL, 6.46 mmol) was added dropwise to a solution of tert-butyl 4-(4-bromophenyl)piperazine-1-carboxylate (2.02 g, 5.92 mmol) in THF (40 mL) at -78°C under N2 and the reaction was stirred for 90 min. Cyanuric chloride (331 mg, 1.79 mmol) in THF (8 mL) was added dropwise to the reaction mixture and stirring was continued at -78°C for 3 h. The reaction was quenched by addition of saturated aqueous sodium bicarbonate followed by warming to room temperature. After addition of water and ethyl acetate, the phases were separated. The organic layer was dried (MgSO4) and evaporated to give a crude oil. This was purified by chromatography (80 g cartridge, 0 to 50% EtOAc / i-Hexane) and the desired fractions were collected and evaporated, followed by trituration from Et2O to give the title compound as a pale yellow solid (448 mg, 30%). 1 H NMR(300 MHz,CDCl3)1.00(27H,s),3.35(12H,m),3.60(12H,m),7.00(6H,d),8.65(6H,d).LCMS M+H+ =862,C 48 H 63 N9O6 requires 861;RT=4.81 min.

[0412] Step B: 2,4,6-tris(4-piperazin-1-ylphenyl)-1,3,5-triazine trihydrochloride

[0413] 4M HCl in dioxane (10 mL) was added to a suspension of tert-butyl 4-[4-[4,6-bis[4-(4-tert-butoxycarbonylpiperazin-1-yl)phenyl]-1,3,5-triazin-2-yl]phenyl]piperazine-1-carboxylate (448 mg, 0.52 mmol) in dioxane (20 mL) to give the reaction mixture. The mixture was stirred at room temperature for 18 hours. The reaction mixture was evaporated to give the title compound as an orange solid (332 mg, 96%). 1 H NMR(300 MHz,DMSO)3.35(12H,br s),3.60(12H,br s),7.15(6H,d),8.55(6H,d),9.25(6H,br s).LCMS M+H + =562,C 33 H 39 N9 requires 561; RT=0.82 min.

[0414] Step C: 1-[4-[4-[4,6-bis[4-[4-(2-chloroacetyl)piperazin-1-yl]phenyl]-1,3,5-triazin-2-yl]phenyl]piperazin-1-yl]-2-chloro-ethanone

[0415] Chloroacetyl chloride (101 μL, 1.28 mmol) was added dropwise to a solution of 2,4,6-tris(4-piperazin-1-ylphenyl)-1,3,5-triazine trihydrochloride (245 mg, 0.365 mmol) and diisopropylethylamine (635 μL, 3.65 mmol) in dichloromethane (15 mL) and the reaction was stirred at room temperature for 1 h. The reaction was diluted with water and dichloromethane and the phases were separated. The organic layer was dried (MgSO4) and the solvent was evaporated to give a crude oil. This was trituated with diethyl ether to give the title compound (MSR-F) as a light brown solid (221 mg, 77%). NMR(300 MHz,CDCl3)3.40(12H,m),3.70(6H,m),3.80(6H,m),4.10(6H,s),7.00(6H,d),8.65(6H,d).LCMS M+H + =790,C 39 H 42 Cl3N9O3 requires 789;RT=3.09 min. Example 12: Preparation of Molecular Scaffold Reagent G (MSR-G) [ka]

[0416] To a solution of vinylsulfonamide (200 mg, 1.87 mmol) and paraformaldehyde (56 mg, 1.87 mmol) in dichloroethane (2 mL) was added concentrated sulfuric acid (1 drop) and the reaction was sealed. It was heated to 90° C. for 5 h. After cooling, the reaction mixture was diluted with dichloromethane and water. The phases were separated and the organic layer was dried (MgSO4). The solvent was evaporated to give the title compound (MSR-G) as a waxy solid (200 mg, 89%). NMR (300 MHz, CDCl3) 4.90 (6H,s), 6.05 (3H,d), 6.35 (3H,d), 6.60 (3H,m). LCMS M+H + =358,C9H 15 N3O6S3 requires 357;RT=1.75 min. Example 13: Preparation of Molecular Scaffold Reagent H (MSR-H) [ka]

[0417] Step A: [4-[[bis[[4-(hydroxymethyl)phenyl]methyl]amino]methyl]phenyl]methanol

[0418] A mixture of 4-hydroxybenzaldehyde (509 mg, 3.74 mmol), 4-hydroxybenzylamine (256 mg, 1.87 mmol), and formic acid (71 μL, 1.87 mmol) was heated in a sealed tube at 70° C. for 18 h. After cooling, the reaction was suspended in dichloromethane and the mixture was stirred for 1 h. The solid was collected by filtration. This was purified by chromatography (40 g cartridge, 0 to 100% EtOAc / i-hexane) to give the title compound as a colorless solid (94 mg, 15%). NMR (300 MHz, MeOD) 3.50 (6H,s), 4.05 (6H,s), 7.30 (6H,d), 7.35 (6H,d). LCMS M+H + =378,C 24 H 27 NO3 requires 377;RT=0.78 min.

[0419] Step B: 1-[4-(bromomethyl)phenyl]-N,N-bis[[4-(bromomethyl)phenyl]methyl]methanamine

[0420] A mixture of [4-[[bis[[4-(hydroxymethyl)phenyl]methyl]amino]methyl]phenyl]methanol (90 mg, 0.24 mmol) in 48% HBr (2 mL) was stirred at room temperature for 72 h. The mixture was diluted with dichloromethane and water and the phases were separated. The organic layer was dried (MgSO4) and the solvent was evaporated to give the title compound (MSR-H) as a light brown solid (106 mg, 79%). NMR (300 MHz, CDCl3) 4.20 (6H, br s), 4.45 (6H, s), 7.50 (6H, m), 7.65 (6H, m). LCMS M+H + =567,C 24 H 24 Br3N requires 566; RT=3.35 min. Example 14: Preparation of Molecular Scaffolding Reagent I (MSR-I), 1,4-Bis(2-bromoacetyl)-1,4-diazepan-6-one [ka]

[0421] Step A: tert-Butyl N-[2-(tert-butoxycarbonylamino)ethyl]carbamate

[0422] To a stirred solution of ethane-1,2-diamine (1.8 g, 30 mmol) in THF (30 mL) at 0° C. was added a solution of di-tert-butyl dicarbonate (14.4 g, 66 mmol) in THF (12 mL) dropwise and the reaction was stirred at room temperature for 18 h. The solvent was evaporated and the residue was partitioned between water and DCM. The organic layer was collected and passed through a phase separator and the solvent was removed. It was dissolved in DCM and then concentrated to ½ the volume and the title compound was collected by filtration as a white solid (4.1 g, 52%). 1 H NMR(300 MHz, CDCl3)1.45(18H,s),3.25(4H,s),4.85(2H,br s).

[0423] Step B: Di-tert-butyl 6-methylene-1,4-diazepane-1,4-dicarboxylate

[0424] To a stirred suspension of sodium hydride (60% oil suspension) (1.74 g, 43.5 mmol) in N,N-dimethylformamide (36 mL) at 0° C. was added 2-chloro-2-(chloromethyl)prop-1-ene (1.54 mL, 14.5 mmol). To this was added tert-butyl N-[2-(tert-butoxycarbonylamino)ethyl]carbamate (3.78 g, 14.5 mmol) in THF (36 mL). After 15 min, the ice bath was removed and the reaction was allowed to stand at room temperature for 18 h. The reaction was quenched by the addition of saturated ammonium chloride (100 mL) and the mixture was concentrated to remove THF. The aqueous solution was extracted with EtOAc (3×) and the combined organics were dried (MgSO4) and the solvent was evaporated to give a crude solid. This was purified (silica, 0 to 20% EtOAc / i-hexane) to give the title compound as a white solid (2.24 g, 49%). 1 H NMR(300 MHz, CDCl3)1.45(18H,s),3.45(4H,m),3.90(2H,m),4.0(2H,m),4.95(2H,m).

[0425] Step C: Di-tert-butyl 6-oxo-1,4-diazepane-1,4-dicarboxylate

[0426] To a stirred solution of di-tert-butyl 6-methylene-1,4-diazepane-1,4-dicarboxylate (2.24 g, 7.17 mmol) in DCM (43 mL) and MeCN (43 mL) was added 2,6-lutidine (1.66 mL, 14.3 mmol) and sodium periodate (6.13 g, 28.7 mmol) in water (64 mL). Finally, ruthenium(III) hydrochloride hydrate (52 mg, 0.25 mmol) in water (7.2 mL) was added dropwise and the reaction was stirred for 1 h. The reaction was diluted with water (200 mL) and extracted with DCM (3×). The combined organics were passed through a phase separator and the solvent was evaporated. This was purified (silica 0 to 30% EtOAc / i-hexane) to give the title compound as a white solid (1.94 g, 86%). 1H NMR(300 MHz,CDCl3)1.50(18H,s),3.60(4H,br s),3.90(4H,m).

[0427] Step D: 1,4-Diazepan-6-one

[0428] To a stirred suspension of di-tert-butyl 6-oxo-1,4-diazepane-1,4-dicarboxylate (0.97 g, 3.1 mmol) in DCM (15.5 mL) was added 4M HCl in dioxane (15.5 mL) and the reaction was stirred for 4 h. The solvent was evaporated and the residue was passed through an SCX cartridge eluting with MeOH / water followed by 1M ammonia in MeOH to give the title compound which was used directly in the next step.

[0429] Step E: 1,4-Bis(2-bromoacetyl)-1,4-diazepan-6-one

[0430] Bromoacetic anhydride (1.77 g, 6.82 mmol) in DCM (11 mL) was added to a solution of 1,4-diazepan-6-one (ca. 3.1 mmol) in DCM (20 mL) at 0° C. and the mixture was stirred for 30 min. The solids were filtered off and the solvent was evaporated. This was purified (silica 0 to 3% MeOH / EtOAc) to give a yellow gum. This was trituated with diethyl ether to give the title compound (MSR- I) was obtained as a light brown solid (529 mg, 48%). 1 H NMR (300 MHz, CDCl3) 3.85 (5.5 H, m), 3.95 (2.7 H, m), 4.15 (1.1 H, m), 4.25 (2.7 H, m) mixture of rotamers. LCMS M+H + =355, C 12 H 12 The theoretical value for Br2N2O3 is 354;RT=1.16 min.

[0431] A similar procedure was used to prepare MSR-J: [ka] . Example 15. Preparation of cyclic peptides containing tyrosine bonds

[0432] Linear peptides and all scaffolds were dissolved in acetonitrile / water 50 / 50 at a concentration of 5 mM. The peptide solution was further diluted with 1 M potassium carbonate to a final concentration of 1 mM.

[0433] 3 ml of 1 mM linear peptide solution was mixed with 1 ml of 5 mM scaffold solution (linear peptide / scaffold molar ratio 1 / 1.6). The reaction mixture was kept at room temperature overnight and the completion of cyclization was confirmed by LC-MS (AcquityUPLC CSH C18 column, 1.7 μm, 2.1×30 mm; elution with acetonitrile / water / HCOOH containing buffer and acetonitrile gradient from 15 to 60% over 10 min). The cyclic peptide was purified using RP-HPLC (Gemini C18-semi-preparative column, 5 μm, 110A, 250×10 mm; elution with acetonitrile / water / TFA containing buffer and acetonitrile gradient from 20 to 80% over 20 min). The results of the cyclization protocol are provided in Table 6 below. Table 6. Results of the cyclization protocol for cyclic peptides containing tyrosine linkages. [Table 6] Example 16. EphA2 SPR assay

[0434] SPR measurements: Non-Fc fusion proteins were biotinylated with EZ-Link™ Sulfo-NHS-LC-Biotin using a 3-fold molar excess of biotin over protein in 4 mM sodium acetate, 100 mM NaCl (pH 5.4) for 1 h. The degree of labeling was determined using a fluorescent biotin quantification kit (Thermo) after dialysis of the reaction mixture in PBS. For analysis of peptide binding, a Biacore T200 10 instrument with a XanTec CMD500D chip was used. Streptavidin was immobilized on the chip using standard amine coupling chemistry at 25° C. with HBS-N (10 mM HEPES, 0.15 M NaCl, pH 7.4) as running buffer. Briefly, carboxymethyldextran surfaces were activated by a 7-min injection of 1:1 ratio of 0.4 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) / 0.1 M N-hydroxysuccinimide (NHS) at a flow rate of 10 μl / min. For streptavidin capture, proteins were diluted to 0.2 mg / ml in 10 mM sodium acetate (pH 4.5) and captured by injecting 120 μl over the activated chip surface. Remaining activated groups were blocked by a 7-min injection of 1 M ethanolamine (pH 8.5):HBS-N (1:1). The buffer was exchanged with PBS / 0.05% Tween 20, and biotinylated EphA2 was captured to a level of 500-1500 RU by diluting the protein to 0.2 μM in buffer. A dilution series of peptides was prepared in this buffer with a final DMSO concentration of 0.5%, with the highest concentration of peptide being 50 or 100 nM, and six further diluted 2-fold. SPR analysis was performed at 25 °C with a flow rate of 90 μl / min, using an association time of 60 s and a dissociation time of 900-1200 s. Data were corrected to account for the effect of DMSO excluded volume. All data were double-referenced against blank injections and a reference surface using standard processing procedures, and data processing and kinetic fitting were performed using Scrubber software version 2.0c (BioLogic Software).

[0435] Data were fitted using a simple 1:1 binding model that accounted for mass transport effects for binding of bicyclic drug conjugates where necessary, and a Biacore3000 instrument was used. For biotinylated proteins, immobilization levels were 1500 RU with a maximum concentration of 100 nM. The method was otherwise identical to that described above, using either a CMD500D chip or a CM5 chip (GE Healthcare). For Fc-tagged proteins, the CM5 chip was activated as described above, and then a goat anti-human IgG antibody (Thermo-Fisher H10500) was diluted to 20 μg / ml in 10 mM sodium acetate (pH 5.0) and captured to approximately 3000 RU. The surface was then blocked as described above. Subsequent capture of Fc-tagged proteins was performed to yield approximately 200-400 RU of target protein. All proteins were reconstituted in manufacturer's recommended buffers and concentrations and captured using PBS / 0.05% Tween 20 containing 5-10 μg / ml protein.

[0436] The results of the EphA2 SPR assay are reported in Table 7. Compounds designated as "A" have a K of less than 0.5 μM. d Compounds designated as "B" have a K of 0.5 μM or greater and less than 1 μM. d Compounds designated as "C" have a K of 1 μM or greater and less than 10 μM. d Compounds designated as "D" have a K of 10 μM or greater. d has. Table 7. EphA2 SPR assay results (n=2). [Table 7-1] [Table 7-2] Example 17. PBP1A Fluorescence Polarization Competitive Binding Assay.

[0437] Fluorescence polarization competition was performed using a BODIPY-labeled penicillin tracer and unlabeled peptide to compete with the unmodified PBP protein. Polarization was measured using a BMG Labtech PHERAstar FS equipped with a FP 485 520 520 optical module.

[0438] 5 mM fluorescent BODIPY-labeled penicillin in DMSO was diluted to 6.25 nM in binding buffer (10 mM HEPES, pH 8, 300 mM NaCl, 2% glycerol). Unlabeled PBP was diluted to 2 μM in binding buffer. Two-fold dilution series of unmodified peptide was prepared across 12 wells in binding buffer with the highest final well concentration of 60 μM and the lowest concentration of 50 nM. 5 μl of the dilution series of unmodified peptide or carbenicillin was added to 12 wells of a 384-well NBS™ low volume microplate (Fisher Scientific). Then 10 μl of diluted fluorescent BODIPY-labeled penicillin (6.25 nM) was added to the 12 wells containing the unmodified peptide dilutions. Then, 10 ul of unmodified PBP (2 μM) was added to the 12 wells containing unmodified peptide and fluorescent BODIPY-labeled penicillin to give a final volume of 25 μl and final concentrations of 2.5 nM for fluorescent BODIPY-labeled penicillin and 800 nM for unmodified PBP.

[0439] A control well lacking unmodified peptide was prepared using a final fluorescent BODIPY-labeled penicillin concentration of 2.5 nM and a final concentration of unmodified PBP of 800 nM for a final volume of 25 μl in binding buffer. A second control well lacking unmodified peptide and unmodified PBP was prepared using a final fluorescent BODIPY-labeled penicillin concentration of 2.5 nM for a final volume of 25 μl in binding buffer.

[0440] Fluorescence polarization was measured every 5 min for 1 h at room temperature. Gain and focal distance were optimized using control wells lacking unmodified peptide and unmodified PBP. Wells were excited at 485 nm and emission detection was set at 520 nm.

[0441] Data were analyzed with GraphPad software to derive values ​​of inhibition constants. Experiments were repeated at least three times. Example 18. CD38 competitive binding assay

[0442] The affinity (Ki) of the peptides of the invention for human CD38 was determined using a fluorescence polarization assay using the method reported by Lea et al. (Expert Opin Drug Discov. 2011 6(1):17-3).

[0443] Although the inventors have described several embodiments of the invention, it is apparent that the inventors' basic examples may be modified to provide other embodiments that utilize the compounds and methods of the invention. Accordingly, it is understood that the scope of the invention should be defined by the appended claims rather than by the specific embodiments that have been represented by way of example. will be understood.

Claims

1. Formula I: 【Chemical 348】 (In the formula, L 1 , L 2 , and L 3 Each independently represents a covalent bond or C 1~8 a divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are -Cy 1 -, -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -OC(O)N(R)-, -N(R)C(O)O-, -S(O)-, -S(O) 2 -, -C(CH 3 )=N-N(R)-, -N(R)N=C(CH 3 )-,-N(R)CH 2 C(O)-,-(CH 2 CH 2 O) 1~10 --, 【Chemical 349】 are independently replaced as necessary by; L 4 is a covalent bond, -O-, -N(R)-, or -N(R)CH 2 CH 2 N(R)-; Each R is independently hydrogen or C1-4 aliphatic; -Cy 1 - is each independently selected from phenylene, 3- to 7-membered saturated or partially unsaturated carbocyclylene, 4- to 7-membered saturated or partially unsaturated heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 10- to 12-membered saturated or partially unsaturated bicyclic heterocyclylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 10- to 12-membered saturated or partially unsaturated tricyclic heterocyclylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 10- to 12-membered saturated or partially unsaturated tricyclic heterocyclylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 10-12 membered partially saturated bicyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 10-12 membered partially saturated tricyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 9-12 membered bicyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 19-20 membered partially unsaturated tetracyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or a 5-6 membered heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. is a divalent ring; The scaffold is a trivalent group that attaches and orients the cyclic peptide; Loop A is L 1 and an amino acid residue linked to L 2 is a bivalent natural or non-natural amino acid residue or peptide bound to an amino acid residue linked to Loop B is L 1 and an amino acid residue linked to L 3 is a bivalent natural or non-natural amino acid residue or peptide bound to an amino acid residue linked to Spacer 1 is a covalent bond, a natural or unnatural amino acid (wherein the amino group is attached to the C-terminus of the bicycle via an amide bond), or a peptide (wherein the N-terminal amino group of said peptide is attached to the C-terminus of the bicycle via an amide bond); Spacer 2 is a covalent bond, a natural or unnatural amino acid (wherein the acid is attached to the N-terminus of the bicycle via an amide bond), or a peptide (wherein the C-terminal acid of said peptide is attached to the N-terminus of the bicycle via an amide bond); R 1 and R 2 are each independently R, 【Chemistry 350-1】 【Hua 350-2】 or -linker-conjugate; Each linker is independently a covalent bond or 1~8 a divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are -Cy 1 -, -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -OC(O)N(R)-, -N(R)C(O)O-, -S(O)-, -S(O) 2 -, -C(CH 3 )=N-N(R)-, -N(R)N=C(CH 3 )-,-N(R)CH 2 C(O)-,-(CH 2 CH 2O ) 1~10 --, 【Chemistry 351】 are independently replaced as necessary by; Each conjugate is independently a half-life extending motif, a solubilizing group, a transporter recognition motif, a cell penetrating motif, a drug payload, or a detectable moiety; R 3 Each independently represents hydrogen or C 1~4 is aliphatic; m is 0 or 1; n is 0 or 1. or a pharma- ceutically acceptable salt thereof.

2. 2. The compound of claim 1, wherein the scaffold is Ring A, said Ring A being selected from the group consisting of 18-crown-6, 1,7,13-triaza-18-crown-6, and a 3-12 membered optionally substituted, saturated, partially unsaturated, bridged bicyclic, bridged tricyclic, propellane, or aromatic ring having 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

3. 3. The compound of claim 1 or 2, wherein the scaffold is Ring A, said Ring A being a 3-12 membered optionally substituted, saturated, partially unsaturated, bridged bicyclic, bridged tricyclic, propellane, or aromatic ring having 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

4. 4. The compound of any one of claims 1 to 3, wherein the scaffold is Ring A, said Ring A being a 7-membered optionally substituted, saturated, partially unsaturated, bridged bicyclic, bridged tricyclic, propellane, or aromatic ring having 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

5. 5. The compound of any one of claims 1 to 4, wherein the scaffold is Ring A, said Ring A being a 7-membered optionally substituted saturated ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

6. The scaffold is Ring A, said Ring A comprising: 【Chemistry 352】 The compound according to any one of claims 1 to 5,

7. 2. The compound of claim 1, wherein the scaffold is Ring B, said Ring B being an optionally substituted 6-18 membered cyclophane having 0-9 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

8. The scaffold is Ring B, which is an optionally substituted cyclophane having 1 to 5 aromatic or heteroaromatic ring units and an aliphatic chain bridging two ring units, where one, two, or three methylene units of each aliphatic chain are -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -OC(O)N(R)-, -N(R)C(O)O-, -S(O)-, or -S(O). 2 The compound of claim 1, optionally independently replaced by -.

9. Ring B comprises three aromatic or heteroaromatic ring units and an aliphatic chain bridging two ring units. where one, two or three methylene units of each aliphatic chain are selected from -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -OC(O)N(R)-, -N(R)C(O)O-, -S(O)-, or -S(O). 2 The compound of claim 8, optionally independently replaced by -.

10. 10. The compound of claim 9, wherein Ring B is an optionally substituted cyclophane having three aromatic or heteroaromatic ring units and an aliphatic chain bridging two ring units, where one, two, or three methylene units of each aliphatic chain are optionally and independently replaced with -N(R)-.

11. Ring B is 【Chemical 353】 11. The compound of claim 10,

12. The scaffolding, 【Hua 354-1】 【Hua 354-2】 2. The compound of claim 1 selected from the group consisting of:

13. 2. The compound of claim 1, wherein the compound is selected from those depicted in Table 1.

14. Formula II: 【Chemistry 355】 (In the formula, L 2 , and L 3 Each independently represents a covalent bond or C 1~8 a divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are -Cy 1 -, -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -OC(O)N(R)-, -N(R)C(O)O-, -S(O)-, -S(O) 2 -, -C(CH 3 )=N-N(R)-, -N(R)N=C(CH 3 )-,-N(R)CH 2 C(O)-,-(CH 2 CH 2O ) 1~10 --, 【Chemical 356】 are independently replaced as necessary by; L 4 is a covalent bond, -O-, -N(R)-, or -N(R)CH 2 CH 2 N(R)-; Each R is independently hydrogen or C 1~4 is aliphatic; -Cy 1 - is each independently selected from phenylene, 3- to 7-membered saturated or partially unsaturated carbocyclylene, 4- to 7-membered saturated or partially unsaturated heterocyclylene having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 10- to 12-membered saturated or partially unsaturated bicyclic heterocyclylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 10- to 12-membered saturated or partially unsaturated tricyclic heterocyclylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 10- to 12-membered saturated or partially unsaturated tricyclic heterocyclylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an optionally substituted divalent ring selected from a 0-12 membered partially saturated bicyclic heteroarylene, a 10-12 membered partially saturated tricyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 9-12 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 19-20 membered partially unsaturated tetracyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; The scaffold is a trivalent group that attaches and orients the cyclic peptide; Loop C is L 2 and an amino acid residue linked to L3; Spacer 1 is a covalent bond, a natural or unnatural amino acid (where the amino group is an amide a peptide, wherein the N-terminal amino group of said peptide is attached to the C-terminus of the bicycle via an amide bond; Spacer 2 is a covalent bond, a natural or unnatural amino acid (wherein the acid is attached to the N-terminus of the bicycle via an amide bond), or a peptide (wherein the C-terminal acid of said peptide is attached to the N-terminus of the bicycle via an amide bond); R 1 and R 2 are each independently R, 【Hua 357-1】 【Hua 357-2】 or -linker-conjugate; Each linker is independently a covalent bond or 1~8 a divalent hydrocarbon chain, wherein one, two, or three methylene units of said chain are -Cy 1 -, -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -OC(O)N(R)-, -N(R)C(O)O-, -S(O)-, -S(O) 2 -, -C(CH 3 )=N-N(R)-, -N(R)N=C(CH 3 )-,-N(R)CH 2 C(O)-,-(CH 2 CH 2 O) 1~10 --, 【Chemical 358】 are independently replaced as necessary by; Each conjugate is independently a half-life extending motif, a solubilizing group, a transporter recognition motif, a cell penetrating motif, a drug payload, or a detectable moiety; R 3 Each of is independently hydrogen or C 1~4 is aliphatic; R 5 is R 5 Together with the atom to which it is bonded, L 2 and L 3 forming a moiety containing a hydrogen bond acceptor (HBA) and / or a hydrogen bond donor (HBD) that forms one or more hydrogen bonds with one or more amino acid residues of the peptide between the m is 0 or 1; n is 0 or 1. or a pharma- ceutically acceptable salt thereof.

15. R 5 is hydrogen, and said hydrogen forms a hydrogen bond with an amino acid residue of Loop C.

16. R 5 is hydrogen, R 5 The compound of claim 14 , wherein the atom to which is attached forms a hydrogen bond with an amino acid residue of Loop C.

17. R 5 is R 5 is taken together with the atom to which it is attached to form a -C(O)- group, said O forming a hydrogen bond with an amino acid residue of Loop C.

18. 【Chemical 359】 teeth, 【Hua360】 15. The compound of claim 14, wherein

19. The compound according to any one of claims 14 to 18, wherein the compound is selected from those depicted in Table 2.

20. A pharmaceutical composition comprising a compound according to any one of claims 1 to 19 or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier, adjuvant or vehicle.

21. 20. A method of inhibiting CAIX in a patient or a biological sample, comprising administering to said patient or contacting said biological sample with a compound according to any one of claims 1 to 19 or a pharma- ceutically acceptable salt thereof.

22. A method for inhibiting MT1-MMP in a patient or biological sample, comprising administering to said patient or contacting said biological sample with a compound according to any one of claims 1 to 19 or a pharma- ceutically acceptable salt thereof. A method, including a process.

23. 21. A method of treating a CAIX-mediated disorder, disease or condition in a patient, comprising administering to the patient a pharmaceutical composition according to claim 20.

24. 21. A method of treating an MT1-MMP mediated disorder, disease or condition in a patient, comprising administering to the patient a pharmaceutical composition according to claim 20.

25. 24. The method of claim 23, wherein the CAIX-mediated disorder, disease or condition is selected from the group consisting of cancer or a proliferative disorder.

26. 25. The method of claim 24, wherein the MT1-MMP mediated disorder, disease or condition is selected from the group consisting of cancer or a proliferative disorder.

27. The cancer or proliferative disorder may be selected from the group consisting of tumors of epithelial origin (various types of adenomas and carcinomas, including adenocarcinoma, squamous cell carcinoma, transitional cell carcinoma and other carcinomas), e.g., carcinoma of the bladder and urinary tract, carcinoma of the breast, carcinoma of the digestive tract (including the esophagus, stomach, small intestine, colon, rectum and anus), carcinoma of the liver (hepatocellular carcinoma), carcinoma of the gallbladder and biliary system, carcinoma of the exocrine pancreas, carcinoma of the kidney, carcinoma of the lung (e.g., adenocarcinoma, small cell lung carcinoma, non-small cell lung carcinoma, bronchioloalveolar carcinoma and mesothelioma), carcinoma of the head and neck (e.g., carcinoma of the tongue, oral cavity, larynx, pharynx, nasopharynx, tonsils, salivary glands, nasal cavity and parathyroid gland), and carcinoma of the bladder and urinary tract (including the esophagus, stomach, small intestine, colon, rectum and anus). cancer of the nasal cavity), ovarian carcinoma, fallopian tube carcinoma, peritoneal carcinoma, vaginal carcinoma, vulva carcinoma, penile carcinoma, cervical carcinoma, myometrial carcinoma, endometrial carcinoma, thyroid carcinoma (e.g., thyroid follicular carcinoma), adrenal carcinoma, prostate carcinoma, skin and adnexal carcinoma (e.g., melanoma, basal cell carcinoma, squamous cell carcinoma, keratoacanthoma, dysplastic nevi); hematological malignancies and related conditions of the lymphoid system (e.g., acute lymphocytic leukemia [ALL], chronic lymphocytic leukemia [CLL], B-cell lymphomas such as diffuse large B-cell lymphoma [DLBCL], follicular lymphoma, Burkitt's lymphoma, lymphoma, mantle cell lymphoma, T-cell lymphoma and leukemia, natural killer [NK] cell lymphoma, Hodgkin's lymphoma, hairy cell leukemia, monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and post-transplant lymphoproliferative disorder) and hematological malignancies and related conditions of the myeloid lineage (e.g., acute myeloid leukemia [AML], chronic myelogenous leukemia [CML], chronic myelomonocytic leukemia [CMML], eosinophilic syndromes, myeloproliferative disorders such as polycythemia vera, essential thrombocythemia and primary myelofibrosis, myeloproliferative syndromes, myelodysplastic syndromes and hematological malignancies (i.e., leukemias, lymphomas) and premalignant hematological disorders and borderline malignant disorders, including myeloid leukemia (myeloma, myeloma, and promyelocytic leukemia); tumors of mesenchymal origin, e.g., sarcomas of the soft tissue, bone or cartilage, such as osteosarcoma, fibrosarcoma, chondrosarcoma, rhabdomyosarcoma, leiomyosarcoma, liposarcoma, angiosarcoma, Kaposi's sarcoma, Ewing's sarcoma, synovial sarcoma, epithelioid sarcoma, gastrointestinal stromal tumors, benign and malignant histiocytoma and dermatofibrosarcoma protuberans; tumors of the central or peripheral nervous system (e.g., astrocytoma, glioma and glioblastoma, meningioma, ependymoma, pineal tumor and Schwannoma);27. The method of claim 25 or 26, wherein the tumor is selected from the group consisting of endocrine tumors (e.g., pituitary tumors, adrenal tumors, islet cell tumors, parathyroid tumors, carcinoid tumors and medullary carcinoma of the thyroid); eye and adnexal tumors (e.g., retinoblastoma); germ cell and trophoblastic tumors (e.g., teratomas, seminomas, dysgerminomas, hydatidiform moles and choriocarcinomas); and pediatric and embryonal tumors (e.g., medulloblastomas, neuroblastomas, Wilms' tumors and primitive neuroectodermal tumors); or congenital or otherwise syndromes that leave the patient susceptible to malignancies (e.g., xeroderma pigmentosum).

28. 20. A method of inhibiting CD38 in a patient or biological sample, comprising administering to the patient or contacting with the biological sample a compound according to any one of claims 1 to 19, or a pharma- ceutically acceptable salt thereof.

29. 20. A method of inhibiting EphA2 in a patient or biological sample comprising administering to the patient or contacting with the biological sample a compound of any one of claims 1-19, or a pharma- ceutically acceptable salt thereof.

30. 20. A method of inhibiting PBP1A in a patient or biological sample, comprising administering to the patient or contacting with the biological sample a compound according to any one of claims 1 to 19, or a pharma- ceutically acceptable salt thereof.

31. 21. A method of treating a CD38-mediated disorder, disease, or condition in a patient, comprising administering to the patient a pharmaceutical composition according to claim 20.

32. 21. A method of treating an EphA2-mediated disorder, disease, or condition in a patient, comprising administering to the patient a pharmaceutical composition of claim 20.

33. 21. A method of treating a PBP1A-mediated disorder, disease, or condition in a patient, comprising administering to the patient a pharmaceutical composition according to claim 20.

Citation Information

Patent Citations

  • Cytotoxic proteins containing a cell targeting binding domain and a Shiga toxin a subunit domain for selective killing of specific cell types

    JP2016512519A

  • Direct immunohistochemistry assay

    JP2017515121A

  • Compounds for treating cancer

    US20180200378A1

  • Method for selecting a candidate drug compound

    WO2004077062A2

  • Binding compounds, immunogenic compounds and peptidomimetics

    WO2006078161A1